Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
Confidentia l Page 1 of 163 CL
INICAL TRIAL PROTOCOL  
Trial Title:  A Phase 1, Open -Label, Multicenter Trial Investigating the Safety, 
Tolerability, and Preliminary Antineoplastic Activity of Sym022 
(Anti -LAG-3) in Patients with Advanced Solid Tumor 
Malignancies  or Lymphomas  
Short Title:  Sym022 in Patients with Advanced Solid Tumor  Malignancies  or 
Lymphomas 
Sponsor:  Symphogen A/S  
Pederstrupvej 93 DK-2750 Ballerup 
Denmark  
Sponsor’s Medical 
Expert:  Rita P. Dalal,  
Vice President, Global Oncology 
Coordinating 
Investigator: Lillian Siu, MD, FRCPC  
Princess Margaret Cancer Centre  
Toronto, Ontario , Canada  
Trial ID:  Sym022-01 
Trial Phase:  Phase 1  
EudraCT number:  Not Applicable  
IND Number:  136992  
Protocol Version/Date:  3.0 / 04-Apr-2019 (Amendment 2) 
Previous Protocol 
Versions/Dates:  2.0 / 13 -Mar-2018 (Amendment 1)  
1.0 / 17 -Jan-2018  
[STUDY_ID_REMOVED]
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 2 of 163 
 
 Sponsor Declarations  
This confidential document is the property of Symphogen A/S. No unpublished information 
contained herein may be passed on, reproduced, published or used without prior written approval from Symphogen A/S. Access to this document must be restricted to relevant parties. 
The trial will be conducted in compliance with this clinical trial protocol,  International Council 
for Harmonisation (ICH) of Technical Requireme nts for Pharmaceuticals for Human Use  
E6(R2): Guideline for Good Clinical Practice  (GCP ) (EMA/CHMP/ICH/135/1995) , the 
Declaration of Helsinki, and applicable regulations. 
The Sponsor has appoint ed a Coordinating Investigator for the trial. This Coordinating 
Investigator will provide input to the trial design and act as overall coordinator for Investigators 
across all sites. The Coordinating Investigator will furthermore sign off the Clinic al Trial Report 
on behalf of all Investigators. 
Lists of Investigator s responsible for conducting the trial, medically qualified physicians 
responsible for all site -related medical decisions (if other than the Investigators), monitors, 
clinical laboratorie s, and other medical and/or technical departments and/or institutions  involved 
in the trial are provided as separate documents.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 3 of 163 
 
 Principal Investigator  Signature Page  
 
I, the undersigned, am responsible for the conduct of the trial at this site and agree:  
• To assume responsibility for the proper conduct of the clinical tri al at this Investigational 
Site 
• Not to implement any changes to the clinical trial protocol without agreement from the 
Sponsor and prior review and written approval from the appropri ate Health Authority (as 
indicated) and the Institutional Review Board/ Ethics Committee, except where necessary 
to eliminate an immediate hazard to the patients  
• That I am aware of, and will comply with “Good Clinical Practice” (ICH E6(R2)  GCP ) 
(EMA/CHMP /ICH/135/ 1995) , the Declaration of Helsinki, and all applicable regulatory 
requirements  
• That all site staff to which I have delegated tasks for this clinical trial, are appropriately selected and adequately informed about the investigational product(s) and of their trial-related duties and functions as described in the clinical tr ial protocol  
 
 
________________________________  ____________________ 
Signature           Date of Signature  
 
Name: ______________________________________ 
 
Academic Degree: _____________________________ 
 
Function: ____________________________________ 
 
Institution:   ___________________________________ 
 
 
 
  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 4 of 163 
 
 TABLE OF CONTENTS  
LIST OF ABBREVIATIONS AND EXPANDED TERMS  .........................................................10  
1 SYNOPSIS  .............................................................................................................................17  
2 SCIENTIFIC BACKGROUND AND RATIONALE  ...........................................................30  
2.1 Background  ........................................................................................................................30  
2.1.1  Tumor Malignancies  ........................................................................................................30  
2.1.2  Overview of the Target: LAG -3 ......................................................................................30  
2.1.3  Overview of the Product: Sym022  ..................................................................................31  
2.2 Summa ry of Nonclinical Studies  .......................................................................................31  
2.2.1  Nonclinical Pharmacology Studies  ..................................................................................31  
2.2.2  Nonclinical Toxicology Studies  ......................................................................................32  
2.3 Clinical Experience  ............................................................................................................33  
2.3.1  Clinical Experience with Agents Related to Sym022 .....................................................33  
2.3.1.1  Clinical Evidence of Activity in M alignant Diseases  ...................................................33  
2.3.1.2  Safety and Tolerability of anti -LAG- 3 mAbs  ...............................................................33  
2.3.1.3  Patient Selection for Treatment w ith Sym022  ..............................................................34  
2.3.1.4  Potential Pharmacodynamic Biomarkers  ......................................................................34  
2.3.2  Clinical Experience with Sym022  ...................................................................................35  
2.4 Trial Rationale  ...................................................................................................................35  
2.5 Dose Rationale  ...................................................................................................................35  
2.6 Overall Benefits /Risk  .........................................................................................................36  
3 TRIAL OBJECTIVES AND DESIGN SUMMARY ............................................................38  
3.1 Objectives:  Sym022 (anti -LAG- 3) Dose -Escalation  ........................................................38  
3.1.1  Primary Objectiv e ............................................................................................................38  
3.1.2  Secondar y Objectives  ......................................................................................................38  
3.1.3  Exploratory Objectives  ....................................................................................................38  
3.2 Trial De sign Summary  .......................................................................................................39  
4 PATIENT SELECTION  ........................................................................................................44  
4.1 Number of Patients  ............................................................................................................44  
4.1.1  Investig ational Sites  .........................................................................................................44  
4.1.2  Number of Patients  ..........................................................................................................44  
4.2 Criteria for Inclusion  ..........................................................................................................44  
4.3 Criteria  for Exclusion .........................................................................................................45  
4.3.1  Patients to be Excluded  ...................................................................................................45  
4.3.2  Drugs and Other Treatments to be Excluded  ..................................................................49  
5 INVESTIGATIONAL MEDICINAL PRODUCT  ................................................................51  
5.1 Sym022  ..............................................................................................................................51  
5.1.1  Formulation Excipients  ...................................................................................................51  
5.2 Storage and Handling of IMP  ............................................................................................51  
5.3 Stability of IMP ..................................................................................................................51  
5.4 Labeling of IMP  .................................................................................................................52  
5.5 Packaging of IMP  ..............................................................................................................52  
5.6 Administration of IMP  .......................................................................................................52  
5.7 Dose Calculation  ................................................................................................................52  
5.8 Dose Preparati on ................................................................................................................52  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 5 of 163 
 
 5.9 Accountability  ....................................................................................................................53  
5.10  Disposition of Used IMP  ...................................................................................................53  
5.11  Unuse d IMP  .......................................................................................................................53  
5.12  Destruction of IMP  ............................................................................................................53  
6 EXPERIMENTAL PLAN  .....................................................................................................54  
6.1 Design Elements  ................................................................................................................54  
6.2 Projected Recr uitment Period and Duration of this Trial  ..................................................54  
6.3 Cohort Management ...........................................................................................................54  
6.3.1  Patient Screening and Dose Cohort Assignment  .............................................................54  
6.3.1.1  Screening of Potential Patients  .....................................................................................54  
6.3.1.2  Submission of Patient Enrollment Documentation .......................................................55  
6.3.1.3  Patient Identification Code Assignment ........................................................................55  
6.3.1.4  Screen Failures  ..............................................................................................................56  
6.3.2  Cohort Closure  .................................................................................................................56  
6.4 Requirements for Patient Observation  ...............................................................................56  
6.5 Drug Treatment Regimen  ..................................................................................................56  
6.5.1  Study Start Day ................................................................................................................56  
6.5.2  Patient Availability  ..........................................................................................................57  
6.5.3  Therapy with Study Drug ................................................................................................57  
6.5.3.1  Doses to be Administered .............................................................................................57  
6.5.3.1.1  Doses to be Evaluated  .................................................................................................57  
6.5.3.1.2  Changes in Dose to be Administered ..........................................................................57  
6.5.3.2  Route of Administration  ................................................................................................58  
6.5.3.3  Diluent and Delivery  .....................................................................................................58  
6.5.3.4  Volume of Infusion  .......................................................................................................58  
6.5.3.5  Duration of Infusion  ......................................................................................................58  
6.5.3.6  Schedule  ........................................................................................................................59  
6.5.4  Premedication  ..................................................................................................................59  
6.6 Cycle 1  ...............................................................................................................................59  
6.6.1  Rules for Dose -Escal ation and Cohort Expansion ..........................................................60  
6.6.2  Rules for Duration of Exposure Prior to Star t of Next Patient and Next Cohort  ............61  
6.6.3  Rules for Estab lishing the MTD and/or RP2D  ................................................................61  
6.6.4  Rules for Stopping the Study ...........................................................................................61  
6.7 Continued Treatment After Cycle 1  ...................................................................................61  
6.7.1  Retreatment Guidelines  ...................................................................................................62  
6.7.2  Doses and Regimens  ........................................................................................................62  
6.7.3  Evaluation Schedules  .......................................................................................................62  
6.7.4  Duration of Treatment  .....................................................................................................63  
6.7.5  Continued Treatment after Radiologic Disease Progression ...........................................63  
6.7.6  Retreatment Following an Objective Response  ..............................................................63  
6.8 Adverse Events and Dose -Limiting Toxicities  ..................................................................63  
6.8.1  Adverse Event Grading  ...................................................................................................63  
6.8.2  Management of Dose -Limiting Toxicities and Other Toxicities  ....................................64  
6.8.3  Definition of Dose -Limiting Toxicity  .............................................................................64  
6.9 Definition of Maximum Tolera ted Dose ............................................................................66  
6.10  Review of Safety Data During Study................................................................ .................66  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 6 of 163 
 
 6.11  Duration of Study Follow -Up ............................................................................................66  
6.12  Concurrent Treatments and Supportive Care  .....................................................................68  
7 STUDY ASSESSMENTS  .....................................................................................................70  
7.1 Consent and Medical History.............................................................................................70  
7.1.1  Signing of Informed Consent/Assessment of Eligibility  .................................................70  
7.1.2  Demography  ....................................................................................................................71  
7.1.3  Past Medical History  .......................................................................................................71  
7.1.4  History of the Primary Malignancy  .................................................................................71  
7.2 Safety As sessments (1)  ......................................................................................................71  
7.2.1  Medication and Procedure Surveys  .................................................................................71  
7.2.2  Adverse Event Reporting ................................................................................................71  
7.2.3  Dose -Limiting Toxicity Assessment ...............................................................................72  
7.2.4  Performance Status Evaluation  ........................................................................................72  
7.2.5  Vital Signs  .......................................................................................................................73  
7.2.6  Physical Examination  ......................................................................................................73  
7.2.7  Laboratory Assessments and Pregnancy Test  .................................................................74  
7.2.7.1  Hematology P anel .........................................................................................................74  
7.2.7.2  Bioche mistry Panel .......................................................................................................75  
7.2.7.3  Coagulation Panel  .........................................................................................................75  
7.2.7.4  Thyr oid Function Tests  .................................................................................................76  
7.2.7.5  Urinalysis  ......................................................................................................................76  
7.2.7.6  Pregnancy Testing .........................................................................................................77  
7.2.8  Electr ocardiogram  ...........................................................................................................77  
7.3 Safety Assessments (2)  ......................................................................................................78  
7.3.1  Multi- Gated Acquisition Scan or Echocardiogram  .........................................................78  
7.3.2  Ophthalmology Examination ...........................................................................................78  
7.3.3  Pulmonary Function Tests  ...............................................................................................78  
7.4 Disease Assessments  ..........................................................................................................78  
7.4.1  Tumor Marker Measurement  ...........................................................................................79  
7.4.2  Diagnostic Imaging for Assessment of Disease (and Pulmonary Status)  .......................79  
7.4.3  Response Assessment  ......................................................................................................80  
7.5 Immunogenicity Assessment  .............................................................................................80  
7.5.1  Peripheral Blood for Immunogenicity Assessment (Spec ialty Lab)  ...............................80  
7.6 Pharmacokinetic Assessments  ...........................................................................................80  
7.6.1  Peripheral Blood for Pharmacokinetic Assessment (Specialty Lab)  ...............................81  
7.7 Pharmacodynamic and Other Biomarker Assessments (Specialty Lab)  ............................81  
7.7.1  Pharmacodynamic Assessments  ......................................................................................82  
7.7.2  Biomarker Assessments  ...................................................................................................82  
7.7.2.1  Blood Samples for Biomarker Assessments  .................................................................82  
7.7.2.2  Tumor Samples for Biomarker Assessm ent (Biopsies Optional)  .................................83  
8 MANAGEMENT OF TOXICITY  .........................................................................................84  
8.1 Grading and Recording of Toxicity ...................................................................................84  
8.2 Evaluation and Treatment of Toxicity ...............................................................................84  
8.3 Determination of DLT versus Non- DLT  ...........................................................................84  
8.4 Premedication  ....................................................................................................................85  
8.4.1  Infusion- Related Reactions  .............................................................................................85  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 7 of 163 
 
 8.4.2  Premedication for IRRs (Prior to the First Dose)  ............................................................86  
8.4.3  Premedication for IRRs (Following an IRR)  ...................................................................86  
8.4.4  Premedication for other Study Drug- Related Toxicities  .................................................86  
8.5 Dose Modification Options  ................................................................................................87  
8.5.1  Prolongation of Infusion Duration ...................................................................................87  
8.5.1.1  Instructions for Infusion Prolongation for IRRs  ...........................................................87  
8.5.1.2  Treatment Following Infusion Prolongation  .................................................................88  
8.5.2  Dose Reduction  ...............................................................................................................88  
8.5.3  Dose Delay  ......................................................................................................................88  
8.5.4  Schedule Alterations  ........................................................................................................88  
9 DISCONTINUING PATIENTS FROM STUDY TREATMENT  ........................................89  
9.1 Criteria for Treatment Discontinuation  ..............................................................................89  
9.2 Replacements  .....................................................................................................................91  
10 ADVERSE EVENTS  .............................................................................................................92  
10.1  Definitions of Adverse Events  ...........................................................................................92  
10.1.1  Adverse Event  .................................................................................................................92  
10.1.2  Events Not to be Considered as Adverse Events  .............................................................92  
10.1.3  Adverse Events of Medical Interest  ................................................................................92  
10.1.4  Serious Adverse Events  ...................................................................................................93  
10.1.5  Events That D o Not Meet the Definition of Serious Adverse Events  .............................93  
10.2  Adverse Event Recording and Reporting ..........................................................................94  
10.2.1  Information to be Provided for  each AE  .........................................................................94  
10.2.2  Required Follow -up for AEs  ...........................................................................................95  
10.3  Serious Adverse Event Recording and Reporting .............................................................95  
10.3.1  Timeframes for Reporting to the Sponsor  .......................................................................95  
10.3.2  Safety Reporting to Health Authorities, Institutional Review Boards/Ethics Committees, 
and Investigators  ............................................................................................................................96  
10.4  Pregnancy  ...........................................................................................................................96  
11 PRECAUTIONS WHEN DOSI NG WITH STUDY DRUG  .................................................98  
11.1  Precautions Regard ing Procreation  ....................................................................................98  
11.2  Additional Precautions  .......................................................................................................98  
12 SAFETY SURVEILLANCE DURING STUDY  ................................................................100  
12.1  Safety Review  ..................................................................................................................100  
12.2  Other Safety Surveillance Activities  ................................................................................100  
13 REGULATORY AND ETHICAL CONSIDERATIONS  ...................................................102  
13.1  Conditions of Testing  .......................................................................................................102  
13.2  Institutional Review  .........................................................................................................102  
13.3  Informed Consent .............................................................................................................102  
13.4  Conditions for Modifying or Terminating the Study .......................................................103  
13.4.1  Modification of the Study Protocol  ...............................................................................103  
13.4.2  Modification of the Informed Consent Form  ................................................................104  
13.4.3  Conditions for Termination of the Study or a Study Site  ..............................................104  
13.5  Trial Registration  .............................................................................................................104  
13.6  Insurance and Liability  ....................................................................................................105  
14 INVESTIGATOR RESPONSIBILITIES  ............................................................................106  
14.1  Medical Supervision ........................................................................................................106  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 8 of 163 
 
 14.2  Confidentiality  .................................................................................................................106  
14.3  Use of Information  ...........................................................................................................106  
14.4  Publications  ......................................................................................................................107  
14.5  Patient Screening Log  ......................................................................................................107  
14.6  Drug Dispensing Inventory ..............................................................................................107  
14.7  Handling and Disposal of Study Drug .............................................................................108  
14.8  Recording of Data  ............................................................................................................108  
14.9  Source Do cument Requirement s ......................................................................................108  
14.10  Laboratory Reports  ..........................................................................................................109  
14.11  Record Retention  .............................................................................................................109  
14.12  Monitori ng of the Study ...................................................................................................109  
14.13  Patient Confidentiality  .....................................................................................................110  
14.14  Financing and Insurance  ..................................................................................................111  
15 HANDLING AND PROCESSING OF DATA  ...................................................................112  
15.1  Data Handling  ..................................................................................................................112  
15.2  Data Review During this Study  .......................................................................................112  
15.3  Data Processing  ................................................................................................................112  
15.4  Clinical Trial Report ........................................................................................................112  
16 STATIST ICAL ANALYSIS  ...............................................................................................114  
16.1  Statistical Considerations  .................................................................................................114  
16.2  Sample Size Considerations  .............................................................................................114  
16.3  Analysis Populations  ........................................................................................................114  
16.4  Trial E ndpoints .................................................................................................................114  
16.4.1  Primary Endpoints  .........................................................................................................114  
16.4.2  Secondary Endpoints  .....................................................................................................115  
16.5  Statistical Analysis  ...........................................................................................................115  
16.5.1  General Specifications  ...................................................................................................115  
16.5.2  Patie nt Disposition, Baseline and Treatment Characteristics  ........................................115  
16.5.3  Study Treatment  ............................................................................................................116  
16.5.4  Maximum Tolerated Dose  .............................................................................................116  
16.5.5  Adverse Events  ..............................................................................................................116  
16.5.6  Laboratory Determinations  ............................................................................................117  
16.5.7  Vital Signs, Body Weight, P hysical Exam Findings  .....................................................117  
16.5.8  ECG Findings  ................................................................................................................117  
16.5.9  Other Safet y Data  ..........................................................................................................117  
16.5.10  Antineoplastic Activity  ..................................................................................................117  
16.5.11  Pharmacokinetic Analysis  .............................................................................................118  
16.6  Additional Endpoints and Analyses  .................................................................................119  
16.6.1  Pharmacodynamic and other Biomarker Analyses  ........................................................119  
16.7  Modeling of Pharmacokinetic and Pharmacodynamic/Biomarker Data  .........................119  
16.8  Deviations from the Statistical Plan  .................................................................................119  
16.9  Interim Analysis  ...............................................................................................................120  
17 REFERENCES  ....................................................................................................................121  
18 APPENDICES  .....................................................................................................................123  
Appendix 1  Performance Status Evaluation ..............................................................................123  
Appendix 2  New York Heart Association  Functional Criteria  .................................................124  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 9 of 163 
 
 Appendix 3  Clinical Adverse Events: Grading Scale  ...............................................................125  
Appendix 4  Clinical Adverse Events: Determining Relationship t o Study Drug .....................126  
Appendix 5  Response Evaluation Criteria in Solid Tumors (RECIST v1.1)  ............................127  
Appendix 6  Immunotherapeutics RECIST (iRECIS T) .............................................................132  
Appendix 7  Response Evaluation Criteria in Lymphoma (RECIL 2017)  ................................139  
Appendix 8  Adverse Events Observed with Antibodies to PD -1 and PD -L1 ...........................140  
Appendix 9  Grading and Management of Infusion- Related Reactions  ....................................145  
Appendix 10  Management of Immune -Mediated Toxicities  ......................................................148  
Appendix 11  Maximum Total Blood Collection Volumes  .........................................................149  
Appendix 12  Schedule of Assessments  .......................................................................................150  
19 Summary of Changes  ...........................................................................................................154  
19.1  Protocol Amendment 1 dated 13- Mar-2018  ....................................................................154  
19.2  Protocol Amendment 2 dated 04- Apr-2019  .....................................................................161  
 
List of Figures  
 
Figure 1:  Dose -Escalation Schema  ...............................................................................................41  
 
List of Tables  
 
Table 1:  Overall  Trial Plan  ...........................................................................................................43  
Table 2:  Schedule of Safety Blood and Urine Sampling ..............................................................74  
Table 3:  ADA and PK Sampling Timepoints  ...............................................................................81  
Table 4:  Recommended Premedication Regimen  .........................................................................86  
Table 5:  PK Endpoint, Definitions, and Derivations  ..................................................................119  
Table 6:  Protocol Amendment 1 .................................................................................................155  
Table 7:  Protocol Amendment 2 .................................................................................................162  
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 10 of 163 
 
 LIST OF ABBREVIATIONS AND EXPANDED TERMS   
Abbreviation  Expanded Term  
1M FUP  1-Month F ollow -up 
Ab Antibody  
ADA  Anti-Drug A ntibody  
ADCC  Antibody -Dependent Cellular Cytotoxicity  
AE Adverse Event 
ALP  Alkaline Phosphatase  
ALT  Alanine Aminotransferase  
ANC  
aPTT Absolute Neutrophil Count 
Activated Partial Thromboplastin Time  
ARDS  Acute Respirat ory Distress Syndrome  
AST  Aspartate A minotransferase  
AUC  Area Under the Concentration -Time Curve 
AUC τ Area Under the Concentration -Time  Curve in a dosing interval  
AUC inf Area Under the Concentration -Time Curve from start of infusion to infinity  
AUC norm, τ  Dose -Normalized Area Under the Concentration -Time Curve in a dosing interval  
β-hCG  Beta-Human Chorionic Gonadotropin  
BM Bone Marrow  
BNP    Brain  Natriuretic Peptide  
BP Blood Pressure  
BPM  Beats Per Minute  
BUN  Blood Urea Nitrogen  
Bx Biopsy  
C Centigrade, Celsius  
C#/D# Cycle #/ Day #  
Ca Calcium  
CBC  Complete Blood Count  
CDC  Complement -Dependent Cytotoxicity  
CEOI Concentration at the End of Infusion  
CFR  Code of Federal Regulations  
CHF  Congestive Heart Failure  
CIOMS  Council for International Or ganizations of Medical Sciences  
CK Creatine Kinase  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 11 of 163 
 
 Abbreviation  Expanded Term  
Cl Chloride  
CL Clearance  
Cmax Maximum Concentration  
CPD  Confirmed Progressive Disease  
Ctrough Trough Concentration  
CNS  Central Nervous System  
CR Complete Response  
CRF  Case Report Form  
CS Clinical ly Significant  
CT Computed Tomography  
CTC  Common Toxicity Criteria  
CTCAE  v5.0 Common Terminology Criteria for Adverse Events (Version 5.0) 
ctDNA  Circulating Tumor Deoxyribonucleic Acid  
CTLA -4 Cytotoxic T -Lymphocyte -Associated Protein 4 
CV Curriculum Vitae  
D, d Day 
D5W  5% Dextrose in Water  
dL Deciliter  
DL CO Diffusing Capacity of Carbon Monoxide  
DLT  Dose -Limiting Toxicity  
DMP  Data Management Plan  
DNA  Deoxyribonucleic Acid  
DSUR  Development Safety Update Report  
DVT  Deep Vein Thrombosis  
EC Ethic s Committee  
ECG  Electrocardiogram  
ECHO  Echocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EDC  Electronic Data Capture  
EEA  European Economic Area  
EOC # End of Cycle # 
EOI End of Infusion  
EOS  End of Study  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 12 of 163 
 
 Abbreviation  Expanded Term  
EOT  End of Treatment  
F Fahrenheit  
FAS Full Analysis Set  
FDG  Fluorodeoxyglucose  
FEV 1 Forced Expiratory Volume in 1 Second  
FFPE  Formalin -Fixed, Paraffin Embedded  
FRC  Functional Residual Capacity  
FSH Follicle -Stimulating Hormone  
fT3 Free Triiodothyronine  
fT4 Free Thyroxine  
FUP Follow -up 
FVC Forced Vital Capacity  
GCP  Good Clinical Practice  
GI Gastrointestinal  
GLP  Good Laboratory Practice  
H, h  Hour  
HBV  Hepatitis B Virus  
hCG  Human Chorionic Gonadotropin  
HCV  Hepatitis C Virus  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human Immunodeficiency Virus  
HPF High Power Field  
HR Heart Rate  
HRT  Hormone Replacement Therapy  
HSCT  Hematopoietic Stem Cell Transplantation  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization  of Tech nical Requirements for 
Pharmaceuticals for Human Use  
ICMJE  International Committee of Medical Journal Editors  
Ig Immunoglobulin  
IHC Immunohistochemistry  
IL-2 Interleukin -2 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 13 of 163 
 
 Abbreviation  Expanded Term  
ILD Interstitial Lung Disease  
IMP Investigational Medicinal Product  
IND Inves tigational New Drug  
INR International Normalized Ratio  
IRB Institutional Review Board   
iRECIST  Immunotherapeutics Response Evaluation Criteria in Solid Tumors  
IRR Infusion -Related Reaction  
IU International Units  
IV Intravenous  
K Potassium  
KLH  Keyh ole Limpet Hemocyanin  
kg Kilogram  
LAG -3 Lymphocyte Activation G ene 3 
LSECtin  Liver Sinusoidal Endothelial Cell Lectin  
LLN  Lower Limit of Normal  
LVEF  Left Ventricular Ejection Fraction  
M, m  Month, Molar, Meter  
mAb  Monoclonal Antibody  
MABEL  Minimal A nticipated Biological Effect Level  
MAD  Maximum Administered Dose  
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Magnesium  
mg Milligram  
MHC  Major Histocompatibility Complex  
MI Myocardial Infarction  
min Minute  
mL Milliliter  
mm Millimeter  
MRI Magnetic Resonance Imaging  
MRSD  Maximum Recommended Starting Dose  
msec  Millisecond  
MTD  Maximum Tolerated Dose  
MUGA  Multi -Gated Acquisition  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 14 of 163 
 
 Abbreviation  Expanded Term  
Na Sodium  
NCS  Not Clinically Significant  
NE Not Evaluable  
NK Natural Killer (cell)  
NL New Lesion  
NLNT  New Lesion -Non-Target  
NLT  New Lesion -Target  
NOAEL  No Observed Adverse Effect Level  
NT Non-Target  
NYHA  New York Heart Association  
OR Objective Response  
PBMC  Peripheral Blood Mononuclear Cell  
PD Progressive Disease , Disease Progression  
PDF Portable Doc ument Format  
PD-1 Programmed Cell Death Protein  1 
PD-L1 Programmed Death -Ligand 1  
PE Pulmonary Embolism  
PET Positron Emission Tomography  
PFT Pulmonary Function Test  
PK Pharmacokinetic  
PO Per Os (orally, by mouth)  
PR Partial Response  
PR Interval  ECG interval between beginning of the P -wave to beginning of the QRS complex  
PS Performance Status  
PSA Prostate Specific Antigen  
PSPD  Pseudoprogression  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
Q2M  Every 2 Months  
Q2W  Every 2 Weeks  
QT Interv al ECG interval between onset of QRS complex to end of the T -wave  
QTc Interval  Heart R ate-corrected QT interval  
RBC  Red Blood Cell  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 15 of 163 
 
 Abbreviation  Expanded Term  
RECIL  2017  Response Evaluation Criteria in Lymphoma  (2017)  
RECIST  v1.1 Response Evaluation Criteria in Solid Tumors  (Vers ion 1.1)  
RNA  Ribonucleic Acid  
RNA -seq Ribonucleic Acid Sequencing  
RSI Reference Safety Information  
RP2D  Recommended Phase 2 Dose  
RV Residual Volume  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SAR  Suspected Adverse Reaction  
SAS Statisti cal Analysis System  
SD Stable Disease  
SEB Staphylococcal Enterotoxin B  
SOC  System Organ Class  
SOI Start of Infusion  
SOM  Sum of Measurements  
SOP Standard Operating Procedure  
SSA Somatostatin Analog  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T Target  
T1/2  Terminal Elimination Half-life 
TBD  To Be Determined  
TCR  T-cell Receptor  
TDAR  T-cell Dependent Antibody Response  
TEAE  Treatment Emergent Adverse Event  
TK Toxicokinetic  
TLC  Total Lung Capacity  
Tmax Time to Maximum Concentration  
TP Timepoint  
TRAE  Treatment Related Adverse Event  
TSH  Thyroid Stimulating Hormone  
TTP Time to Progression  
ULN  Upper Limit of Normal  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 16 of 163 
 
 Abbreviation  Expanded Term  
µg Microgram  
µM Micromolar  
UPD  Unconfirmed Progressive Disease  
U.S. United States  
U/S Ultrasound  
UV Ultraviolet  
V, v, Vol  Volume  
Vd Volume of Distribution  
VS Vital Signs  
W, w  Week  
w/v Weight to Volume  
WBC  White Blood Cell  
WES  Whole -exome Sequencing  
WHO  World Health Organization  
WOCBP  Woman of Childbearing Potential  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 17 of 163 
 
 1 SYNOPSIS  
CLINICAL TRIAL PROTOCOL  
Trial Title  A Phase 1, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary 
Antineoplastic Activity of Sym 022 (Anti -LAG -3) in Patients with Advanced Solid Tumor 
Malignancies or Lymphoma s 
Trial ID  Sym022-01 
Trial Phase  Phase 1 
INVE STIGATIONAL MEDICINAL PRODUCT  
Investigational 
Medicinal Product  The Investigational Medicinal Product (IMP) is Sym 022 (also referred to as study drug).   
Sym022 is a recombinant anti -lymphocyte activation gene  3 (anti-LAG -3) human monoclonal 
antibody (mAb) with silenced effector functions  
Supplies  
Labeled supplies of study drug will be provided  by the Sponsor .  Each single-use glass vial 
contains Sym 022: 
• As a liquid formulation for intravenous (IV) infusion  
• With a nominal fill volume of 8.0 milliliter (mL)  
• At a concentration of 20 mg/mL for a total vial content of 160 milligrams (mg)  
Formulati on Excipients  
Provided herein  
Storage  
Refrigerate (2ºC to 8ºC); store in an access -controlled, secure location; protect from direct sunlight  
Combination Agent  None  
TRIAL OBJECTIVES  
Sym 022 Dose -
Escalation  
 Primary  
Evaluation of the safety, tolerability, and dose -limiting toxicities (DLTs) to establish the maximum 
tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of 
Sym022 when administered once every 2 weeks (Q2W) by IV infus ion to patient cohorts with 
locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas  that are 
refractory to available therapy  or for which no standard therapy is available   
Note :   Q2W dosing; 4 weeks equals 1 dosing cycle.  Goal is identification of the MTD or determination of a 
RP2D based on clinical data, including safety, pharmacokinetic (PK), and pharmacodynamic  outcomes .  
The MTD , if identified , and the RP2D may not be the same as the RP2D may be lower .  If an MTD is 
not identified , a maximum administered dose (MAD) will be determined and will not exceed 10 mg/kg . 
Secondary  
• Evaluation of the immunogenicity of Sym 022  
• Characterization of  the PK profile  of Sym022 
• Evaluation of  the preliminary antineoplastic effects of Sym 022, including: 
o Evidence of objective response (OR) or stable disease (SD)*  
o Duration of OR or SD*  
o Time to progression (TTP) of disease* 
*As assessed by Response Evaluation Criteria in Solid Tumors  (Version 1.1)  (RECIST v1.1), 
Immunotherapeutics Response Evaluation Criteria in Solid Tumors (i RECIST ), and Response Evaluation 
Criteria in Lymphoma (2017) (RECIL 2017)   
Exploratory  
• Evaluation of potential pharmacodynamic markers , e.g. receptor occupancy in peripheral  
blood mononuclear cells (PBMCs) (peripheral blood to be collected)  
• Evaluation of potential biomarkers including but not limited to assessment of:  
o In peripheral blood: circulating tumor deoxyribonucleic acid  (ctDNA), ribonucleic acid 
(RNA), relevant prote ins/cytokines , and cellular biomarkers   
o In tumor tissue: DNA, RNA, protein, and cellular biomarkers (biopsies optional)   
Note:   Assay methodology a nd biomarker assessments to be determined ( TBD ).  Potential analyses may 
include but are not limited to : ctD NA sequencing ; RNA sequencing (RNA -seq)/whole -exome 
sequencing (WES) ; measurement of relevant proteins/cytokines in the blood ; cytometric  analysis 
of cells in blood, and immunohistochemistry (IHC) of tumor material when collected (tumor 
sampling is optiona l)   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 18 of 163 
 
 TRIAL DESIGN  
Design Summary  This is a Phase 1, multicenter, open -label, dose -escalation study designed to evaluate safety, 
tolerability, and DLTs to  establish the MTD or MAD, and  the RP2D of sequential escalating doses 
of Sym 022 (study drug) when administered Q2W (4 weeks equals 1 cycle) by IV infusion, to 
patients with advanced, refractory solid  tumor malignancies or lymphoma s. 
Approximately 15-30 male and fe male patients will be entered.  Dose-escalation will follow a 
standard 3+3 design, with a t arget toxicity level of 33.3% or less as determined by DLTs.  It is 
planned that 4  dose levels up to a maximum dose of 10 mg/kg will be evaluated. The number of 
patients treated, the number of cohorts evaluated, and the MTD/ MAD will depe nd upon the 
observe d tolerability of Sym 022 during Cycle 1 . 
In the absence of documented progressive disease (PD)  or unacceptable toxicity, patients may 
continue to receive additional 4 -week cycles of study drug at the same dose, infusion duration, and 
schedule established f or the patient.  
PATIENT SELECTION  
Recruitment Period  Enrollment Dates  
• Anticipated date of enrollment of first patient:  Q1 2018 
• Anticipated date of enrollment of last patient:  Q 2 2019  
End of Trial  (i.e. data cut -off for primary analysis)  
Will be reached  1 month (30 +7 days) after all  patient s have discontinued trial treatment or 
6 months after the last patient has started trial treatment, whichever occurs earlier.   
Investigational Sites  This is a multicenter trial. It is anticipated that approximately 2-4 centers in North America may 
participate b ased on accrual.  
Number of Patients  Considerations for estimating the number of patients are as follows:  
Sym 022 Dose -Escalation    
Approximately 15-30 patients in escalating dose cohorts:  
• Minimum of 3 patients  per dose cohort; assume approximately 4  cohorts to establish the MTD , 
and/or RP2D  
• Expansion of any cohort to 6 patients  in the event of a Cycle 1 DLT in any of the initial 3 
patients  
• Minimum of 6 patients  to be treated at the MTD and/or RP2D; expansion of this cohort (or any 
other) up to 12 patients may be considered to further evaluate tolerability  
In addition, there is potential for entry of additional patients to:   
• Ensure sufficient evaluable patients by adding an additional patient to a cohort  
• Expa nd a lower dose cohort(s) if an initially identified MTD and/or RP2D is subsequently 
determined to be not tolerated either with single or repeated cycles of therapy   
• Add and e valuate a previously unplanned intermediate dose level if indicated  (inclusion of  a 
dose higher than those listed would require a protocol amendment)  
Note:  This action would be taken in the event of an unacceptably high frequency of toxicities observed in 
patients treated at one dose level considered to be in marked contrast to the to lerability noted at the 
preceding dose level , or if after review of study data , a more gradual dose -escalation appears 
warranted.  
Eligibility  
 
 Patients to be Incl uded  (patients must meet all the following criteria)  
1. Male or female patients, ≥ 18 years   
2. Patients with a documented (histologically - or cytologically -proven) solid tumor malignancy 
that is locally advanced or metastatic; patients with documented lymphoma s   
3. Patients with a malignancy (solid tumor or lymphoma ) that is currently not amenable to 
surgical intervention due to either medical contraindications or non -resectability of the tumor  
4. Patients refractory to or intolerant of existing t herapy(ies) known to provide clinical benefit .   
Note:  Patients may have received and failed prior therap y with a PD -1/PD -L1 inhibitor and be considered 
eligible for this trial . 
5. Patients with measurable or non -measurable disease according to RECIST v1.1  or standard 
criteria for lymphoma (RECIL  2017 ).  
6. Patients with an Eastern Cooperative Oncology Group (ECOG) perf ormance status (PS) of 0 
or 1, and anticipated life expectancy of  ≥ 3 months  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 19 of 163 
 
 7. Patients, both male and female, who are either not of childbe aring potential or who agree to 
use a highly effective method of contraception during the study beginning within 2 weeks  
prior to the first dose and continuing until 6 months  after th e last dose of study drug.   
8. Patients with the ability to understand and give written informed consent for participation in 
this trial, including all evaluations and procedures as specified by this protocol .  
Patients to be Excluded  (patients must not meet  any of the following criteria)  
1. Women who are pregnant or lactating , or intending to become pregnant before, during,  or 
within 6 months after  the last dose of study drug. Women of childbearing potential (WOCBP) 
and fertile men with WOCBP partner(s), not us ing and not willing to use a highly effective 
method of contraception.  
2. Patients with central nervous system (CNS) malignancies; patients with known, untreated  
CNS or leptomeningeal metastases, or spinal cord compression , patients with any of the above  
not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS 
involvement for which treatment is required.  
Note:   Patients with treated CNS metastases will be eligible if they are asymptomatic, do not require 
corticosteroids , and have confirmation of at least stable brain disease status as assessed by 2 
imaging studies performed ≥ 4 weeks apart with the most recent performed within 4 weeks prior to 
first trial drug administration .  Prophylactic anticonvulsant medications are a llowe d. 
3. Patients with hematologic malignancies  other than lymphoma s   
4. Patients with any of the following hematologic abnormalities at baseline *: 
• Hemoglobin < 9 g/dL  
• Absolute neutrophil count (ANC) < 1, 000 per mm3 
• Platelet count < 75 ,000 per mm3 
*Throughout this  protocol “baseline” is defined as the last available observation prior to the first 
administration of study drug on Cycle 1/Day 1  (C1/D1). 
5. Patients with any of the following serum chemistry abnormalities at baseline:  
• Total bilirubin  > 1.5 × the upper limi t of normal (ULN) for the institution  
• Aspartate aminotransferase ( AST ) or alanine aminotransferase ( ALT ) > 3 × the ULN for 
the institution (> 5 × ULN if due to hepatic involvement by tumor)  
• Serum creatinine > 1.5 × ULN for the institution  
6. Patients with a ny of the following coagulation parameter abnormalities at baseline ( unless on 
a stable dose of anticoagulant therapy for a prior thrombotic event, as determined by the 
Investigator ): 
• Prothrombin time ( PT) (or international normalized ratio [INR ]) > 1.5 × ULN for the 
institution  (> 3× ULN for the institution if anticoagulated)  
• Partial thromboplastin time ( PTT) (or activated partial thromboplastin time [ aPTT ]) > 1.5 
× ULN for the institution  (> 3× ULN for the institution if anticoagulated)  
7. Patients with:  
• Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism 
(PE) within 4 weeks  prior to first administration of study drug unless adequately treated 
and considered by the Investigator to be stable  
• Active uncontrolled bleeding or a known bleeding diathesis  
8. Patients with a clinically significant (CS) cardiovascular disease or condition, including:  
• Need for antiarrhythmic medical therapy f or a ventricular arrhythmia or other 
uncontrolled arrhythmia (patients with controlled atrial fibrillation (heart rate [HR] < 90) 
for > 30 days prior to study entry are eligible)  
• Severe conduction disturbance (e.g. 3rd degree heart block)  
• HR-corrected QT interval ( QTc interval ) ≥ 480 milliseconds (msec)  
• Uncontrolled hypertension (per the Investigator’s discretion)  
• History of myocarditis  
• Left ventricular ejection fraction (LVEF)* known to be below the lower limit of normal (LLN) for the center, or < 50% by multi -gated acquisitio n (MUGA ) scan or 
echocardiogram ( ECHO) if no LLN is defined by the site  
• Congestive heart failure (CHF) currently requiring therapy  
• Class III or IV cardiovascular disease according to the New York Heart Association (NYHA) Functional Classification  
• History o f acute coronary syndromes (including myocardial infarction [MI] and unstable 
angina), coronary angioplasty, or s tenting within 6 months  prior to first study drug 
administration  
9. Patients with a significant pulmonary disease or condition, including:  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 20 of 163 
 
 • History  of interstitial lung disease (ILD), pulmonary fibrosis  
• History of pulmonary inflammatory disease, interstitial or other pneumonitis *, acute 
respiratory distress syndrome (ARDS)  
*Patients with prior evidence of Grade 1 pneumonitis will be eligible provide d they were 
asymptomatic and did not require treatment a nd provided pneumonitis has resolved prior to entry to 
this trial. 
10. Patients with a current or recent (within 6 months ) significant gastrointestinal (GI) disease or 
condition, including:  
• History of inf lammatory bowel disease  
• Diarrhea ≥ Grade 2 within 2 weeks  prior to first administration of study drug  
11. Patients with an active, known or suspected autoimmune disease, or a documented history of 
autoimmune disease or syndrome, requiring systemic steroids or  other immunosuppressive 
medication s  
Note:    Exceptions permitted include: type I diabetes mellitus, hypothyroidism only requiring hormone 
replacement, skin disorders such as vitiligo, psoriasis or alopecia not requiring systemic treatment, 
conditions not  expected to recur in the absence of an external trigger . 
12. Patients with a history of organ transplantation (e.g. stem cell or solid organ transplant)  
13. Patients with a known or suspected hypersensitivity to any of the excipients of formulated 
study drug  
14. Patients with a history of significant toxicities associated  with previous administration  of 
immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy   
15. Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy 
except for  persistent Grade 2 alopecia, peripheral neuropathy, decreased hemoglobin, 
hypomagnesemia, and/or end-organ failure being adequately managed by hormone 
replacement therapy    
16. Patients with inadequate recovery from any prior surgic al procedure, or patients having 
undergone any major surgical procedure within 4 weeks  prior to first administration of study 
drug 
17. Patients who are known or suspected drug or alco hol abuse rs where compliance with protocol 
requirements may be a concern  
18. Patients with a known history of human immunodeficiency virus (HIV) or known active 
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)  
19. Patients with any other serious/active/uncontrolled infection, any infection requiring 
parenteral antibiotics,  or unexplained fever > 38ºC within 2 weeks  prior to first administration 
of study drug  
20. Patients with any other serious, life -threatening, or uns table pre-existing medical condition 
(aside from the underlying malignancy) including significant organ system  dysfunction or 
failure, or CS  laboratory abnormality(ies), which, in the opinion of the Investigator, wo uld 
either compromise the patient’s  safety or interfere with obtaining  informed  consent, compliance 
with study procedures,  or evaluation of the safety of study drug 
21. Patients with a psychiatric disorder or altered mental status that would preclude understanding 
of the informed consent process and/ or completion of the necessary study-related evaluations  
22. Patients with known or foreseeable inability, in the opinion of the investigator, to comply with 
the protocol requirements  
Drugs and Other Treatments to be Excluded  (patients must not have received any  of the 
following)  
1. Other inhibitors of LAG -3 (e.g. mAbs)  
2. Any antineoplastic agent for the primary malignancy  (standard or investigational) without 
delayed toxicity within 4 weeks  or 5 plasma half -lives, whichever is shor test, prior to first 
administration of study drug and during study, except for : 
• Nitrosoureas and mitomycin C within 6 weeks  prior to first admin istration of study drug 
and during study  
Note:  Patients may have received and failed prior therapy with a PD -1/PD -L1 inhibitor and be 
considered eligible for this trial.  
3. Any other investigational treatments within 4 weeks  prior to and during study. This includes 
participation in any medical devi ce or other therapeutic intervention clinical trials.    
4. Radiotherapy :  
• For target lesions within 4 weeks  prior to first administration of study drug unless PD has 
been documented in the lesion following treatment,  and during study.  
• For non-target lesions  within 1 week prior to first administration of study drug,  
Note:   Palliative (limited -field) radiotherapy for management of pain associated with bone 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 21 of 163 
 
 metastases  present at baseline is permitted during study . Patients with suspected new bone 
lesions requiring pain management should be treated and evaluated for potential PD  
5. Use of live vaccines against infectious diseases (e.g. varicella) 4 weeks  prior to first 
administration of study drug and during study  
6. Immunos uppressive or systemic hormonal therapy (> 10 mg daily prednisone equivalent) 
within 2 weeks  prior to first administration of study drug and during study.  The following 
therapies are al lowed:  
• Hormonal therapy for appetite stimulation  
• Nasal, ophthalmic, i nhaled, and topical glucocorticoid preparations  
• Hormone replacement therapy at standard doses for end -organ failure   
• Stable hormonal therapy for prostate carcinoma  
• Stable hormonal therapy for ovarian suppression, hormonal contraceptive therapy, or 
post-menopausal hormone replacement therapy (HRT)  
• Neuroendocrine tumor patients: stable hormonal therapy with a somatostatin analog 
(SSA)  
• Steroid therapy for contrast reaction prophylaxis  
• Intra -articular steroid injections  
• Low-dose maintenance steroid therapy for  other conditions (e.g. asthma exacerbation, 
stable steroid therapy [excluding tapering dose of steroids] for brain 
edema/metastases/radiation)  
• Higher dose steroid thera py for treatment of an acute intercurrent illness (e. g. immune-
related AEs or other adv erse conditions) in patients with SD or an ongoing response.  In 
such situations , study drug treatment should be interrupted for the duration of 
immunosuppressive therapy.  
7. Prophylactic use of hematopoietic growth factors within 1 week  prior to first admini stration of 
study drug and during Cycle 1 of study; thereafter -prophylactic use of growth factors is 
allowed as clinical ly indicated. Use of growth factors as treatment is permitted at any time 
after initiation of study drug  as clinically indicated.  Trans fusions are permitted as needed.  
Questions regarding patient eligibility must  be addressed and resolved by the Investigator in 
consultation with the Sponsor prior to enrollment.  
EXPERIMENTAL PLAN  
Design Elements  • Open -label, u ncontrolled, non -randomized  
• Escalating doses of study drug in sequential patient cohorts  
• Enrollment staggered between first and second patient in each new higher dose cohort to 
allow for initial safety observations  
Study Schedule  Screening P eriod  
• Written informed consent  
• Safety screening, disease assessment, and eligibility confirmation  
Treatment P eriod  
• C1/D1 initial dose of study drug  
• Continued dosing Q2W   
• 28-day cycles until confirmed PD, unacceptable toxicity, or another  discontinuation criterion is 
met 
• End of Treatment (EOT) vis it within  approximately  10 days following treatment 
discontinuation, or before initiation of a new treatment, whichever occurs  first. 
• 1-Month Follow -up (1M FUP) visit 30 days (+7 days) following last dose  
Follow -Up P eriod  
• Response follow -up ( FUP) every 2 months (Q2M) following discontinuation for reasons other 
than confirmed  PD until the end of trial 
Observation 
Requirements  Patients wil l be treated and followed on an outpatient basis.  
• Patients will be observed for a minimum of 2 hours  following completio n of the first 
administration of study drug on C1/D1 and a minimum of 1 hour  following completion of 
subsequent infusions of study drug  (C1/D15, onward).   
• At the end of each infusion the IV line must remain in place during the observation period  to 
allow for administration of IV drug s, if necessary.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 22 of 163 
 
 Infusions will take place unde r the close supervision of a physician or other study personnel 
experienced in administration of IV agents, and  in an environment where full resuscitation facilities 
are immediatel y available.  
INVESTIGATIONAL MEDICINAL PRODUCT ADMINISTRATION  
Doses to be 
Administered  Doses to be Evaluated  
Dose cohorts will be numbered and entered sequentially.  The number of cohorts evaluated will be 
based upon toxicities experienced by patients during Cycle 1 .   
Sym022 will be administered at up to 4  planned dose level s; anticipated dose levels include:  
• Dose Cohort 1:  0. 3 mg/kg 
• Dose Cohort 2:  1.0 mg/kg 
• Dose Cohort 3:  3.0 mg/kg  
• Dose Cohort 4:  10.0 mg/kg  
Changes in Dose to be Administered  
Once assigned to a dose cohort , patient s will continue to be treated with study drug at that same 
dose level throughout the duration of their time on study. There will be no intra -patient dose -
escalation.  
Dose adjustments should be made in the event of noted we ight change ( ± 10%; less at the site’s discretion or if 
required by institution procedures) at visits that require weight measurement. Adjustments may be made in the 
event of lesser incremental changes in weight and more frequently at the site's discretion .   
Route of 
Administration  IV infusions via indwelling venous access catheter, utilizing a controlled infusion device  
Infusion Materials  Standard i nfusion set to be used . An additional point -of-use (0.22 micron or other ) in-line filter is 
not to be used .  
Diluent and Delivery  Commercially available sterile 5% dextrose  in water (D5W)  solution for IV infusion . Once diluted : 
• Store refrig erated between 2° C to 8° C (36 º F to 46º F) and protected from direct sunlight  
• Allow to warm to room temperature before administration  
• Administer within 8 hours  
Infusion Volume  100 mL ; further instructions for infusion preparation and delivery are provided in the IMP Manual . 
Infusion Duration  Cycle 1 : 60 minutes (+10 minute s) 
Cycle 2 and thereafter :  If no Grade 2 IRR is  observed in ≥ two thirds of the patients in a cohort, a 
decision may be made to decrease the infusion time to 30 minutes (+10 minutes) as patients within 
a cohort are treated in Cycle 2 and thereafter.  
Start an d stop times of each infusion, and any interr uptions in infusion will be recorded.   
Schedule  Q2W ( ± 2 days) on Day 1 and Day 15 of each cycle (4 weeks [28 days] equals 1 dosing cycle)  
End of Cycle 1 (EOC1) assessments are to be performed on C1 /D28 ( ±2 days).  Subsequent cycles 
may be administered Q2W ( ± 2 days), unless further delay is required to allow for amelioration of 
toxicities (or in the event of scheduling difficulties associated with weekends, holidays, etc.).  
Premedication  Premedication for Infusion -Related Reactions  
Since the mechanism  of action of the  study drug is to stimulate the immune system premedication 
with agents such as glucocorticoids which are immunosuppressive  is to be avoided. As a result, n o 
premedication is required  to be administered prior to patients receiving the firs t dose of study drug.  
In patients with a history of  infusion-related reactions ( IRRs ) to mAbs or similar products , it is 
recommended that premedication be administered . In such cases, patients should be premedicated 
with a regimen that includes acetaminop hen as well as an H1 (e.g. diphenhydramine/hydroxyzine) 
and possibly an H2-antagonist (e.g. ranitidine/famotidine).   
In the event of an IRR during study:  
• For Grade 1 or G rade 2 reactions , premedication prior to subsequent infusions should be 
considered.  Thereafter, if a patient is without recurrence of an IRR, the Investigator may 
choose to withdraw premedication to determine whether such continued therapy is necessary for that patient.  
• For Grade 3  reactions, premedication prior to subsequent infusions is r equired.  Patients 
experiencing a Grade 3 reaction after having received premedication will be discontinued 
from treatment.  
Premedication for Other Toxicities  
In the event of other study-drug related toxicities (e.g. nausea, vomiting, diarrhea, etc.), pati ents 
may be premedicated with standard therapies to reduce the potential for such reactions in the 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 23 of 163 
 
 future.  Based on ongoing review of patient safety data, the Sponsor may implement mandatory 
premedication for all patients should a pattern begin to emerge of mild -to-moderate study drug -
related reactions that are amenable to prophylaxis with standard agents.  
DOSE -ESCALATION DECISION POINTS  
Dose -Escalation  
 
 Cycle 1  
A minimum of 1 cycle of study drug will be administered, if tolerated. Determinations regar ding 
dose-escalation and MTD will be based on tolerability during these initial 4 weeks (Cycle 1) of 
treatment, and the occurrence of DLTs thought to be related  (i.e. possibly -related, probably-related, 
or related) to study drug.   
• Patients completing Cycl e 1, and receiving their full planned doses of study drug in the 
absence of a DLT, will be considered to have tolerated the dose level they were assigned to 
receive.   
• Patients will be replaced if they have received < 2 full doses of study drug plus follow -up 
through EOC1 (C1 /D28 ± 2 days) for any reason other than a DLT to ensure MTD 
determination rules can be followed with an adequate number of evaluable patients in any 
dose cohort.      
Dose -Escalation and Cohort Expansion Decision Rules  
A standard 3+3 d ose-escalation design will be used , with a target toxicity level of 33.3% or less as 
determined by DLTs.  The decision rules for dose -escalation are as follows:  
1. Minimum of 3 patients  will be entered to each cohort.     
• If during Cycle 1 no DLTs are encount ered in any of the first 3 patients, dose -escalation 
may continue to the next level when all patients have completed Cycle 1  
• If during Cycle 1, any 1 patient experiences a DLT considered possibly-, probably-, or 
related to  study drug, the cohort will be ex panded to 6 patients .  If no DLTs are 
encountered in the additional 3 patients, dose -escalation may continue to the next level 
when all patients have completed and tolerated Cycle 1.  
• If during Cycle 1, > 1 patient experiences a DLT, dose-escalation will STOP.  This will indicate that the MTD has been exceeded . 
2. If it is determined that a dose level is not tolerated:  
• The previous  lower dose cohort will be expanded to 6 patients (if this has not already been 
accomplished) as a total of 6 patients must be treated before establishing a dose as the MTD.  
• There is also the potential to evaluate and expand a previously unplanned intermed iate dose 
level between 2 established dose levels to 6 patients to more fully characterize tolerability.  
3. The MTD will be the highes t dose level of study drug at which no more than 1 of 6 evaluable 
patients has had a DLT.  
4. Once the MTD (or maximum dose to be studied) is achieved and/or the RP2D is identified, that 
cohort may be expanded up to 12 patients  to more fully evaluate safety an d tolerability at that 
dose level, at the Sponsor’s discretion. Should the DLT rate equal or exceed 33.3% in an 
expanded cohort, it will be determined that the dose is not tolerated.  If this occurs, the previous lower dose  cohort or an intermediate dose l evel may be expanded as above.  
Therefore:  
• There is potential for expansion of lower dose cohort(s) if an initially identified MTD and/or RP2D is subsequently determined to be not tolerated (either with single or repeat 
cycles of therapy), and  
• There is pot ential to evaluate and expand a previously unplanned intermediate dose level(s) 
between 2 established dose levels to  more fully characterize tolerability  
The RP2D may be equal to or lower than the MTD  or the MAD . The RP2D w ill be selected based 
on safety data, as well as available PK , pharmacodynamic/biomarker results , and other data , as 
applicable.  
Duration of Exposure Prior to Start of Next Patient and Start of Next Cohort  
Enrollment will be staggered by 2 week s between th e first and second patient in each new higher 
3+3 dose level cohort tested.  The first patient within a cohort must complete and tolerate the first 
dose of Cycle 1, including follow -up until C1/ D15 to allow for review of clinical and laboratory 
assessments. Thereafter patients within a co hort may be added concurrently.  
Dose -escalation and accrual to the next cohort will occur only after the minimum  number of 
patients required for tolerability assessmen t in the current cohort have completed Cycle 1  (i.e. 3 
patients, or 6 patients in an expa nded cohort) , and only after acceptable tolerance has been 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 24 of 163 
 
 demonstrated in at least 3 of 3 or 5 of 6 patients treated in the current cohort (depending on cohort 
size),  and after consultation with the Study Safety Team  
For all patients, EOC1 assessments ar e to be performed on C1/ D28 ( ± 2 days).  
Establishment of the MTD and/or RP2D  
The MTD will be the highest dose level of study drug at which no more than 1 of 6 evaluable 
patients has had a DLT.  
The MAD, MTD , or a dose lower than the MAD or MTD , will be iden tified as the RP2D, provided 
a minimum of 6 evaluable patients have been treated at that dose, and provided acceptable 
tolerance has been demonstrated  in at least 5 of 6 patients treated.  
The RP2D will be based on the MTD evaluation as well as  other toxici ties observed in the study, 
including observations in later cycles of administration of study drug, as well as on PK, pharmacodynamic/ biomarkers, and/or other data.  
Rules for Stopping the Study  
The study will be stopped if the MTD is exceeded at the lowest  dose level.  
CONTINUED TREATMENT  
Continued Treatment 
after Cycle 1  
 
 Upon completion of Cycle 1, in the absence of unacceptable toxicity or documented disease 
progression, patients may continue to receive additional cycles of study drug unless further delay is required to allow for amelioration of ongoing AEs .   
Administration will be at the same dose level and infusion duration established for the patient, and on the same Q2W schedule provided retreatment guidelines are met.  If a delay is required, 
additional cycles should be initiated within approximately 2 weeks  of the completion of the 
previous cycle, if feasible.  
Retreatment Guidelines :  To  start any new cycle,  a patient must meet the following criteria: 
• ANC ≥ 1,000 per mm3 
• Platelets ≥ 75,000 per mm3 
• Ongoing study drug-related  AEs should NOT meet the criteria for DLT  
• Ongoing study drug-related  AEs should have either ameliorated to ≤ Grade 1  severity, returned 
to baseline status, or resolved, with the exceptions of : 
o Grade 2 alopecia,  
o Grade 2 clinical  events that are being adequately controlled with best supportive care (e.g. 
fatigue, nausea, vomiting, diarrhea), and  
o Asymptomatic laboratory abnormalities that are considered clinically insignificant and 
clinically uncomplicated , and/or that are resolvin g spontaneously or with conventional 
medical interventions  
• Dosing must be delayed in patients with evidence of Grade 2 immune -mediated toxicities, 
including:  
o Pneumonitis, myocarditis, adrenal insufficiency, encephalitis, nephritis /renal dysfunction 
(serum  creatinine elevation), episcleritis /uveitis /iritis 
o Colitis, hypophysitis, hyperglycemia, inflammatory arthritis, myositis, rash 
o Hepatitis (transaminitis, total bilirubin elevation)  
Retreatment cycles may continue up to 12 months  at which time plans for co ntinued therapy will 
be discussed by the Medical Monitor(s) and Investigator. Patients who stop therapy with an 
ongoing OR or prolonged SD may be retreated in the event of relapse , if the trial is still open .   
Continued Treatment 
after Radiologic 
Disea se Progression  Immunotherapeutic agents may produce antitumor effects that can manifest as response after initial 
evidence of PD, a phenomenon referred to as “pseudoprogression”  (PSPD) . 
Patients will be permitted to continue treatment beyond initial RECIST v 1.1 (or RECIL  2017) 
defined PD while waiting for confirmation of PD, provided they are clinically stable as defined by the following criteria (per iRECIST ): 
• Investigator -assessed clinical benefit and absence of rapid disease progression  
• Tolerating study dr ug 
• Stable PS 
• Absence of progressive tumor at critical anatomical sites (e.g. cord compression) requiring 
urgent alternative medical intervention.  
Retreatmen t 
Following an 
Objective Response  Treatment with study drug may be restarted in a patient who previ ously achieved a documented OR 
or prolonged SD (> 16 weeks) in this study, stopped treatmen t, and subsequently progresses.  Such 
action may be taken at the Investigator’s discretion, following  discussion with the Medical 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 25 of 163 
 
 Monitor(s), provided retreatment cri teria are met, no anti -cancer treatment was administered since 
the last dose of study drug, and the trial is still open.  
This option for retreatment does not  apply to patients who previously experienced an immune-
mediated toxicity that required permanent discontinuation from study drug (see Treatment 
Discontinuation Criteria ).  
ADVERSE EVENTS and DOSE -LIMITING TOXICITIES  
Adverse Event 
Grading  For reported adverse events (AEs), the Common Terminology Criteria for Adverse Events (Version 
5.0) (CTCAE  v5.0), will be used to grade the severity of the AE.  
Management of D ose-
Limiting Toxicitie s 
and Other Toxicities  Management of Dose -Limiting Toxicit ies 
AEs that meet the protocol definition of DLT will be managed by either discontinuing the patient 
from further participation in the study, or the patient may continue if there is evidence of response 
or other clinical benefit, but dosing must be delayed and  the patient may not  be retreated until 
retreatment criteria are met.   
Patients experiencing certain immune-mediated toxicities may not  be retreated and will be 
discontinued from further participation (see Treatment Discontinuation Criteria) . 
Management of Other Toxicities  
AEs that do not meet the protocol definition of DLT, but nevertheless warrant dose modific ation 
may be managed by delay  of study drug to allow for amelioration of the toxicity.  
Dose-Limiting 
Toxicities  Definition  
 Any of the following toxicities  occurring during Cycle 1 , if judged to be related to study drug  (i.e. 
possibly-related, probably -related, or related), will be considered a DLT for the purposes of this 
trial.  
1. ≥ Grade 3  evidence of any of the following immune -mediated  toxicities (patient must be 
permanently discontinued):  
• Pneumonitis  
• Myocarditis  
• Adrenal insufficiency  
• Encephalitis  
• Neph ritis, renal dysfunction (serum creatinine elevation)  
• Episcleritis, uveitis, or iritis  
 
2. ≥ Grade 3  evidence of any of the following immune -mediated toxicities (if > Grade 3, patient 
must be permanently discontinued):  
• Colitis  
• Hypophysitis, hyperglycemia  
• Inflammatory arthritis  
• Myositis  
• Rash  
3. ≥ Grade 2:  
• Uveitis, eye pain or blurred vision that does not resolve with topical therapy within 2 weeks  
• AEs that are prolonged excessively based upon the medical judgment of the investigator, and/or lead to permanent disco ntinuation of the investigational agent due to poor 
tolerance 
• Immune-mediated toxicity that re quires use of glucocorticoids at a dose of ≥ 1 mg/kg/day 
of prednisone equivalents for treatment of the toxicity  
4. Hepatic-related findings consistent with Hy’s Law criteria : 
• AST and/or ALT elevation > 3 × ULN (or > 3 × baseline if elevated at study entry due to hepatic involvement by tumor ), with  
• total bilirubin ≥  2 × ULN without initial findings of cholestasis (i.e. serum alkaline 
phosphatase [ALP]  < 2 × ULN ), and   
• No explanation for the above findings such as viral hepatic injury, preexisting or acute liver disease, or another drug or condition capable of causing the observed liver injury  
5. Any other  ≥ Grade 3 or 4  non-hematologic toxicity regardless of duration wit h the exceptions 
of:  
• Grade 3 fatigue  
• Grade 3 nausea, vomiting, or diarrhea  lasting ≤ 2 days  with best supportive care  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 26 of 163 
 
 • Grade 3  asymptomatic electrolyte abnormalities lasting ≤ 3 days  that are not clinically 
complicated, and resolve spontaneously or respond to conventional medical interventions  
• Other Grade 3 asymptomatic laboratory abnormalities that are clinically non -significant 
in the investigator’s opinion, and that resolve spontaneously or with conventional medical 
interventions  
6. Neutropenia that is:  
• Grade 3 meeting the CTCAE v5.0 criteria for febrile neutropenia (ANC < 1000 per mm3 
and a single temperature > 38.3º C [10 1º F] or sustained temperature ≥  38º C [100.4º  F] 
for > 1h)  
• Grade 4  
7. Thrombocytopenia that is:  
• Grade 3 with CS  hemorrhage or requirement for transfusion  
• Grade 4 (platelets < 25,000 per mm3) 
8. Anemia that is Grade 4 and not explained by underlying disease  
9. Any death where a relationship to study drug cannot be ruled out  
10. Inability to complete Cycle 1  at the assigned dose (i.e. receipt of < 2 full planned doses of 
study drug plus 2 weeks  of follow -up) due to ≥ Grade 3 toxicity  
11. Treatment delays > 2 weeks  from the scheduled next dose during Cycl e 1 or the initiation of 
Cycle 2 due to Grade 2 toxicity  that has occurred in Cycle 1  
Other toxicities may be considered a DLT as determined by the Investigator in conjunction with 
the Study Safety Team . 
The above criteria will be used to make individual p atient determinations regarding dose delays  
or discontinuation throughout the course of the trial, however,  only those DLTs occurring 
during Cycle 1  will be used to make decisions regarding cohort dose -escalation and 
tolerability.  
Events occurring after Cy cle 1 will also be evaluated by the Study Safety Team and taken into 
consideration when deciding upon further dose levels to be assessed as well as establishment of the 
RP2D.  
TOXICITY SAFETY MANAGEMENT AND SAFETY MONITORING  
Infusion -Related 
Reaction  Mana gement  In addition to premedication as management f or IRRs , the following infusion prolongation 
instructions are provided:  
• For Grade 1 reactions , the infusion may be slowed to 50%  of the prior rate such that the 
remaining dose to be delivered is  administer ed in 2× the amount of time as was initially 
scheduled.  
• For Grade 2 reactions , the infusion should be interrupted for a minimum of 30 minutes , and at 
least until there is either amelioration to ≤ Grade 1 severity or return to baseline status.  
Supportive care should be provided. The infusion should then be restarted and slowed to 50% 
of the prior rate, as described. Subsequent infusions should be administered at the prolonged 
rate. 
• For Grade 3 reactions , the infusion will be STOPPED  and s upportive care wil l be provided.  
The occurrence will be considered a DLT and the patient will be either discontinued from treatment, or must receive subsequent doses at a prolonged infusion rate  (slowed to 50% of the 
prior rate, or longer).  
• For Grade 4 reactions , the infus ion will be STOPPED and supportive care will be provided.  
The occurrence will be considered a DLT and the patient will be discontinued from treatment.  
In all cases the Investigator should use best clinical judgment in managing such reactions. For 
Grade 1 and 2 IRRs, rechallenge with a shorter duration of infusion (no less than 60 minutes) may 
be attempted at the Investigator ’s discretion, after a minimum of 2 doses  with no evidence of 
infusion-related toxicity  at the prolonged rate . For Grade 3 IRRs, conti nue administration at the 
prolonged rate.  
Dose Delays  Toxicities may be managed by delay  in dosing, provided they do not meet the criteria for study 
discontinuation.  
For toxicities that are to be managed by dose delay , dosing may be restarted at the same dose, once 
study retreatment criteria have been met .   
Safety Monitoring  Clinical and laboratory safety data will be reviewed on an ongoing basis throughout the study by 
the Investigators and Sponsor’s Medical Representative(s) so that decisions regardin g the 
advisability of continuing accrual to a dose cohort, and/or escalatin g the dose and allowing accrual 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 27 of 163 
 
 to a higher dose cohort may be made. In addition, patients will be carefully evaluated for evidence 
of potential cumulative and/or delayed toxicities  throughout the duration of their time on study.   
To do so, Serious Advers e Events (SAEs), immune-related AEs of significance, AEs resulting in 
permanent discontinuation from study (regardless of seriousness or relationship to study drug), 
DLTs, IRRs, and  dose delays  will be promptly reported to the Sponsor (or designee).  
A Stud y Safety Team will be established and will be comprised of the Investigat ors(s) and the 
Sponsor’s Medical Representative(s).  Biweekly Study Safety Team teleconferences will be held  to 
discuss ongoing patient status and any emerging safety concerns; the frequency of teleconferences 
may fluctuate based on accrual and study activity, as indicated.  
STUDY ASSESSMENTS  
Screening  
(within 14 days prior to 1st 
dose unless otherwise 
stipula ted) • Informed consent  
• Eligibility assessment 
• Demography  
• Past medical history  
• History of the primary malignancy (including data on the extent, duration, and best response 
to prior therapy, if available)  
Safety Assessments  Patients to be monitored throughou t the treatment and follow -up period for occurrence of AEs 
(acute, delayed, and/or cumulative), as well as for changes in clinical status, vital signs (VS), and laboratory data.   
Safety Assessments (1)  (within 14 days prior to 1st dose unless otherwise st ipulated)  
• Concomitant Medication/Procedure surveys  
• AE reporting (collection of data from signing of informed consent to 30 days after final dose, with long -term follow -up to surveil for [up to 6 months]and follow [up to 2 years] immune -
mediated toxicities)  
• DLT assessment (Cycle 1)  
• PS evaluation (ECOG)  
• VS assessment (including temperature, pulse, respiratory rate, blood pressure [BP], and oxygen saturation by pulse oximetry at rest and exertion)  
• Physical examination (with  weight, and pulmonary/cardiac assess ment at each visit)  
• Hematology panel  
• Biochemistry panel (to include creatine kinase [CK] for cardiac assessment)  
• Coagulation panel  
• Thyroid function studies (to include measurement of thyroid stimulating hormone [TSH], free 
triiodothyronine [fT3] and free thyroxine [fT4])  
• Urinalysis (by multi -panel chemical test strip analysis; include microscopic examination of 
sediment if clinically indicated ) 
• Pregnancy testing (if applicable)  (serum test within 14 days, urine test rep eated within 2 
working days prior to 1
st dose)  
• Electrocardiogram (ECG), 12 -lead  
Safety Assessments (2)  (results from assessments previously performed as standard of care  within 
28 days [+2 days] prior to 1st dose may be utilized , provided no antineoplastic therapy has been 
delivered between a ssessment and 1st dose; otherwise within 14 days prior to 1st dose) 
• Ophthalmology examination  
• MUGA scan or ECHO (To be performed ONLY in patients with a history of CHF)  
• Pulmonary function tests (PFTs) (to include spirometry and assessment of diffusing capacity 
of carbon monoxide [DL CO]) 
Disease Assessments  
 Disease Status  (within 28 days [+2 days] prior to 1st dose)  
• Tumor marker measurement (as indicated by tumor type)  
• Diagnostic imaging for assessment of disease (computed tomography [CT]/magnetic resonan ce imaging [MRI]) (The same method and technique should be used throughout the 
study.) For safety, imaging of the chest required at each evaluation to assess pulmonary s tatus  
• Response assessment (per RECIST v1.1, RECIL 2017 , and iRECIST). Data on evidence of 
and duration of any OR (CR or PR) or SD, as well as disease progression  to be collected.  
Other Assessments  
(Specialty Lab)  
  Immunogenicity  
Serum sampling to assess  the potential for anti -drug antibody (ADA) formation  
Pharmacokinetics  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 28 of 163 
 
 Serum sampling t o assess the PK profile of the study drug   
Pharmacodynamic and other Biomarker Studies  
Peripheral blood sampling (pre - and post -dosing)  
• Pharmacodynamic evaluation (e.g. receptor occupancy ) 
• Evaluation of DNA, RNA, proteins/cytokines , and cellular biomarkers  
Tumor tissue sampling  (pre- and post -dosing) (biopsies o ptional ) 
• Evaluation of DNA, RNA, protein, and cellular biomarkers  
DISCONTINUATION AND FOLLOW -UP 
Key Treatment 
Discontinuation 
Criteria  Patients are to be discontinued from treatment in the event of  any of the following:  
1. Adverse Events, including : 
• ≥ Grade 3  evidence of any of the following immune -mediated toxicities:  
o Pneumonitis  
o Myocarditis  
o Adrenal insufficiency  
o Encephalitis  
o Nephritis, renal dysfunction (serum creatinine elevation)  
o Episcleritis, uveitis, or iritis  
• > Grade 3  evidence of any of the following immune-mediated toxicities:  
o Colitis  
o Hypophysitis, hyperglycemia  
o Inflammatory arthritis  
o Myositis  
o Rash  
• Hepatotoxicity characterized by:  
o AST and/or ALT elevation > 3 × ULN (or > 3 × baseline if elevated at study 
entry due to hepatic involvement by tumor), with  
o total bilirubin ≥ 2 × ULN without initial findings of cholestasis (i.e. serum ALP 
< 2 × ULN), and  
o No explanation for the above findings, such as  viral hepatic injury, preexisting or 
acute liver disease, another drug or condition capable of causing the obs erved 
liver injury   
• > Grade 3  IRR; Grade 3  IRR in a patient who has received premedication  
• Any DLT considered by the Investigator to require treatment discontinuation  
• Another AE or SAE considered by the Investigator to require treatment discontinuation  
2. Progressive Diseas e: Confirmed radiologically  
3. Clinical Progression: Treatment failure not meeting the criteria for PD, but considered by the 
Investigator to require treatment discontinuation   
4. Physician Decision, including:  
• Use of or requirement for a non -permitted concomitant medication  
• Requirement for a significant surg ical procedure  
• Intercurrent illness that would prevent completion of study-related evaluations  
• Any other reason in the opinion of the Investigator that would justify treatment 
discontinuat ion   
5. Withdrawal by Patient: Withdrawal of consent and election to discontinue treatment  
Replacements  Should a patient discontinue treatment with study drug for reasons other than the occurrence of a 
DLT prior to completing Cycle 1, a replacement patient  will be obtained using the original 
eligibility criteria.   
Follow -up All follow -up visits and assessments, as described, should be conducted to the extent possible.  
• End of Treatment  (EOT) evaluations to be conducted within approximately 10 days  followin g 
treatment discontinu ation , or before initiation of a new treatment, whichever occurs first    
• 1-Month Follow -up (1M FUP) evaluations to be conducted approximately 30 days  (+7 days) 
following the last dose of study drug.   
• Long -Term FUP for Safety : If an observed toxicity (non-immune-mediated) thought to be 
related to study drug has not resolved by t he 1M FUP  evaluation, an additional FUP AE 
assessment will be conducted approximately 2 months  (may be repeated at 4 months if needed) 
following the last dose of study drug, if feasible, to confirm that the event has either resolved, 
returned to baseline s tatus, or been adequately explained  and assessed by the Investigator as 
chronic and/or stable, and that no long-term deleterious effects have become evident   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 29 of 163 
 
 Since late -occurring immune -mediated toxicities have been reported to occur several weeks to 
mont hs after treatment with other immune checkpoint inhibitors, long-term surveillance for 
such toxicities will be conducted in this study. Patients will be follow ed at approximately 2 -
month intervals following the last dose of study drug for up to 6 months to assess for the onset 
of any post -therapy immune-mediated event thought to be related to study drug.  
Any patient who develops an immune -mediated toxicit y duri ng study, or during the 6-month 
post-therapy FUP period, will be followed at approximately 2-month intervals following the 
last dose of study drug for up to 2 years to assess the course of the condition and evaluate potential reversi bility of the finding.  
• Long -Term FUP for Response: In the event of an ongoing OR or SD at the EOT, response 
assessments  based on imaging studies will continue to be performed every 2 months  following 
the last dose of study drug, until confirmed PD or another therapeutic interven tion is initiated , 
until the end of trial , so that data may be collected on the duration of SD or OR, as well as 
disease progression  
ANALYSIS PLAN 
Endpoints  Primary Endpoint  
DLTs to establish MTD and/or recommended RP2D  
 
Secondary Endpoints  
• Safety pro file 
• Incidence and characterization of immunogenicity (ADA)  
• PK profile  
• Preliminary antineoplastic activity, to include occurrence/duration of OR or SD, and TTP  
Pharmacokinetic 
Parameters  Evaluations to delineate dose -response and PK parameter -response rel ationships will be 
undertaken.  Based on the concentrations determined, the following PK parameters for the study 
drug will be calculated for each subject: area under the concentration-time curve (AUC) from start 
of first infusion (SOI) to 336 hours (AUC τ), from SOI to infinity (AUC inf), terminal elimination 
half-life (T 1/2), clearance (CL), volume of distribution (V d), maximum concentration (C max), 
concentration at end of infusion (C EOI), trough concentration (C trough), and time to reach C max (Tmax) 
Explo ratory 
Pharmacodynamic 
and Biomarker 
Parameters  A summary of the changes in potential pharmacodynamic and other biomarker(s) will be presented.   
Statistical Methods 
and Sample Size 
Calculation  The primary endpoint of Sym 022 dose-escalation is the occurre nce of DLTs during Cycle 1 for 
each dosing regim en. The number of enrolled patients will depend on the extent of observed DLTs 
independently in each cohort. Based on the dose -escalation design, it is planned to enroll 
approximately ( 15-30) patients during this part of the trial.  
All DLT events will be listed by dose cohort and patient. A summary table of DLTs across dose 
cohorts by System Organ Class (SOC) and preferred term will be presented, if applicable. The 
summaries will include number of DLTs and num ber and percentages of patients experiencing a 
DLT. 
Safety evaluation will be based on reported AEs and safety laboratory test results, immunogenicity, 
and other safety data. Unless otherwise specified, all summaries will be descriptive.  
Interim Analysis  Safety evaluation will be performed prior to ea ch dose -escalation. No other interim analyses are 
planned.  
TRIAL REPORTING  
Final Clinical Trial 
Report  Final integrated clinical/statistical trial report to be prepared at the end of trial  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 30 of 163 
 
 2 SCIENTIFIC BACKG ROUND AND RATIONALE  
2.1 Background  
2.1.1 Tumor Malignancies  
Cancers are malignant tumors formed by an abnormal growth of cells and tissue leading to organ 
failure. They fall into two categories: solid and hematological cancers. Solid tumors are formed 
by an abnormal  growth of body tissue cells other than blood, bone marrow  (BM),  or lymphatic 
cells. A solid tumor consists of an abnormal mass of cells, which may stem from different tissue 
types such as lung, breast, colon, prostate, stomach , and liver, and which initia lly grows in the 
organ of its cellula r origin.  In advanced stages of the disease, solid tumors may spread to other 
organs through metastatic tumor growth.   
Cancer is the second -leading cause of death and disability in the world, only surpassed by heart 
disease. In 2012, 14.1 million people w ere diagnosed with cancer worldwide. An estimated 8.2 
million people died from the disease. The World Health Organization (WHO) projected that by 
2035, these figures could increase to 24 million new cases and 14.6 milli on cancer deaths 
worldwide. Lung, bre ast, colorectal, prostate, and stomach cancer are the most common 
malignancies ( 1). 
2.1.2 Overview of the Target: LAG -3 
Lymphocyte -activation gene 3 (LAG -3 or CD223) is a cell surf ace receptor that belongs to the 
immunoglobulin (Ig) superfamily ( 2). LAG- 3 binds to major histocompatibility complex (MHC) 
class II molecules found on the surface of antigen presenting cells with a much higher affinity 
than CD 4. LAG- 3 associates with the T -cell receptor (TCR):CD3 complex following TCR 
engagement, and it is hypothesized that LAG -3 competitively inhibits the interaction between the 
MHC:antigen complex and CD4+T -cell TCR.  However, since LAG -3 also impacts the func tion 
of CD8+ T cells and natural killer ( NK) cells, neither of which interact with MHC class II, 
additional ligands expressed in the tumor microenvironment, the Liver Sinusoidal Endothelial 
Cell lectin (LSECtin) and Galectin -3, have been proposed as altern ative binding sites potentially 
explaining LAG -3 action on other cell populations ( 2). 
LAG- 3 is primarily expressed by activated CD4+ and CD8+ T -cells and regulatory T -cells, but it 
is also expressed on subsets of NK -cells, B - and dendritic cells ( 2-3).  LAG -3 acts as an immune 
checkpoint that negatively regulates (inhibits) proliferation, activat ion, and homeostasis of T -
cells. LAG- 3 upregulation is requi red to control over -activation and prevent the onset of 
autoimmunity.  LAG- 3 may also play a role in the maturation and activation of dendritic cells. 
Importantly, cancer cells can  upregulate expre ssion of MHCII, which binds LAG -3 on effector 
T-cells, thus inhibiting their activity and resulting in tumor immune escape ( 4).  
Antibody- mediated blockade of LAG -3 has been shown to induce increased proliferation and 
cytokine production by T -cells activated in vitro , as well as tumor g rowth inhibition in tumor 
xenograft models, especially in combination with Programmed Cell Death Protein 1 ( PD-1) 
blockade  (5, 6). Four anti -LAG3 antibodies, BMS -986016 (B ristol- Myers Squib), LAG525 
(Novartis), REGN3637 (Regeneron), and TSR -033 (Tesaro) are in early clinical development for 
use as cancer immunotherapy in solid and hematologic malignancies. Additional LAG -3 
antibodies are in pre -clinical development. BMS -986016 (relatlimab) , a fully human IgG4 
monoclonal antibody that blocks the inhibitory effect of LAG -3 on activated T -cells, is the only 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 31 of 163 
 
 antibody drug c andidate for which any clinical results have been published to date.  Objective 
tumor regression has been observed in phase 1/2a studi es with BMS -986016 administered as 
monotherapy or in combination with nivolumab (anti -PD-1) in patients with advanced soli d 
tumors or hematologic malignancies ( 7). In one case, a partial response to BMS -986016 
monotherapy was observed in a patient with nivolumab- refractory lung adenoc arcinoma and in a 
second case, a complete response to BMS -986016 monotherapy was observed in a patient with 
marginal zone B -cell lymphoma. Additional evidence of clinical efficacy has also been obse rved 
with BMS -986016 administered in combination with nivolumab in patients with various solid 
tumors, including melanoma ( 7, 8).  BMS -986016 is currently being evaluated in additional 
indications in  combination with nivolumab.  
IMP321 (Prima BioMed) is a recombinant soluble LAG -3Ig fusion protein that binds to MHC 
class II with high avidity. Although the molecule has been described as an activator of antigen -
presenting cells, resulting in CD8+ memory T -cell activation, the mechanism by which IMP321 
modulates anti -tumor responses remains somewhat unclear ( 3). Binding of IMP321 to MHC 
class II antigens may also block the negative regulation of T -cells through cell-bound LAG -3 
(Prima BioMed company webpage). In addition, since IMP321 has a human IgG1 Fc, it is also 
capable of mediating Fc- dependent effector functions. In phase 1 studies in advanced renal 
carcinoma and advanced pancreatic adenocarcinoma (in comb ination with gemcitabine), IMP321 
was well tolerated with no treatment- related adverse events ( 3). Additional studies with IMP321 
are ongoing.  
2.1.3 Overview of the Product: S ym022 
The investigational medicinal product (IMP) tested in this trial is Sym022. Sym022 is a 
recombinant, fully human, effector function- silenced IgG1 -LALA antibody that binds human 
and cynom olgus LAG -3 with nanomolar affinity, but does not cross -react with murine LAG -3. 
Sym022 blocks LAG -3 binding to MHC class  II proteins, resulting in increased T -cell 
proliferation and cytokine production in vitro and in vivo . Sym022 enhances cytokine produc tion 
in a superantigen peripheral blood mononuclear cell (PBMC) stimulation assay. 
2.2 Summary of Nonclinical Studies  
2.2.1 Noncli nical Pharmacology Studies  
The pharmacologic characterization of Sym022 includes in vitro  functional evaluation and in 
vivo testing in mouse models of human cancer. Sym022 stimulates cytokine production and T -
cell proliferation in relevant in vitro  assays.  To limit antibody -dependent cellular cytotoxicity 
(ADCC) and complement -dependent cytotoxicity (CDC) against LAG -3 expressing cells, two 
mutations, L234A, L235A (LALA), have been engineered into the IgG1 Fc portion of Sym022. 
IgG1 -LALA antibodies show gre atly reduced binding to both human and macaque FcRs and the 
complement protein complex C1q ( 9, 10) . Because of these mutations, Sym022 does not mediate 
secondary  effector functions, such as ADCC and CDC . 
In the Staphylococcal Enterotoxin B ( SEB) stimulated PBMC assay, Sym022 induces a dose -
dependent increase in IL -2 secretion in the SEB -stimulated cells similar to that of an in -house 
produced BMS -986016 analogue. Sym022 also blocks the LAG -3-MHC clas s II protein 
interaction to the same extent as the BMS -986016 analogue in a functional cell -based assay. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 32 of 163 
 
 Combination of Sym022 with an anti -PD-1 antibody (pembrolizumab or Sym021) increases IL -2 
secretion further in the  SEB -stimulated PBMC assay.  
The abili ty of Sym022 to stimulate immune cells in vitro  also translates into an effect on tumor 
growth in vivo . In a human A375 melanoma xenograft tumor model in mice reconstituted with 
PBMC from different human donors, Sym022 induced a tumor growth inhibitory res ponse with a 
number of the tested donors. These i n vivo  studies demonstrate that administration of Sym022 
induces a tumor -specific immune response . 
2.2.2 Nonclinical Toxicology Studie s 
Based on amino acid sequence homology of the receptors, receptor binding studies, and 
functional studies, cynomolgus monkey was sele cted as the only relevant species for toxicology 
studies. Sym022 binds human and cynomolgus LAG -3 with nanomolar affinity, but does not 
cross -react with murine LAG -3. Repeat dose toxicity studies in cynomolgus monkeys were 
conducted as standard toxicity st udies with an enhanced focus on immunotoxicity endpoints. 
In a pilot toxicology study, cynomolgus monkeys were administered a single dose of 1 or 10 
mg/kg Sym022 for PK assessment, or administered a once weekly dose of 100 mg/kg/week Sym022 for four weeks for toxicity and toxicokinetic (TK) assessment. Dose -proportionality was  
observed for the dose range of 1- 100 mg/kg. Sym022 was well tolerated at doses up to and 
including 100 mg/kg/week with no advers e findings . No treatment -related changes were 
recorded in clinical pathology, thyroid stimulating hormone (TSH), cytokines, immunophenotyping, ex vivo SEB  stimulation of interleukin 2 (SEB -IL2), or anatomic 
pathology.  
In a subsequent pivotal 4 -week Good L aboratory Practice (GLP) compliant toxicology study 
cynomolgus monkeys were administered 0 (control), 10, or 100 mg/kg Sym022 once weekly on 
Days 1, 8, 15, 22, and 29 of the dosing phase by IV infusion. An assessment of delayed onset 
toxicity and/or revers ibility of toxicity was made during a 12- week recovery period for animals 
administered vehicle or Sym022 at 10 mg/kg/week. The exposure increased in a dose -
proportional manner and no differences in the TK attributable to gender were observed. The 
incidence and serum titers of ADA inversely correlated with dose  level. However, the majority 
of the animals were adequately exposed to Sym022 throughout the entire study. 
The GLP study concluded that once weekly administration of 10 or 100 mg/kg/week Sym022 to 
the cynomolgus m onkey for 4 weeks was generally well tolerated and n o immunotoxicity was 
observed. Observations included a slight to moderate suppression of activity as determined by the interleukin -2 (IL -2) response to SEB at the 10 and 100 mg/kg Sym022 dose  level in males 
and the 100 mg/kg Sym022 dose level in females. A delayed antigen recall response to keyhole limpet hemocyanin ( KLH)  was observed in males and females, at all dose levels. No organ 
weight changes and no macroscopic or microscopic findings w ere considered related to 
administration of Sym022 at the terminal and recovery sacrifices.  
In summary, the nonclinical toxicology studies in cynomolgus monkeys showed that Sym022 
was well tolerated with no adverse findings . The No Observed Adverse Event L evel (NOAEL) 
for Sym022 in monkeys was 100 mg/kg/week, the highest dose level tested in the pivotal study.  
In vitro  safety pharmacology was addressed by assessing cytokine release, complement 
activation, as well as platelet -, and white blood cell counts in human whole blood from six 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 33 of 163 
 
 healthy donors. The response to Sym022 was overall comparable to vehicle. The likelihood of 
acute cytokine release syndrome associated with administration of Sym022 to humans is, therefore, considered to be low.  
The half -life in cynomolgus monkeys was 5 days and the half -life of Sym022 in humans is 
anticipated to be at least 7- 10 days . The planned dosing, every 2 weeks, is predicted to ensure 
sustained exposure to Sym022 during repeated dosing with little or no accumulation . No PK or 
pharmacodynamic properties have been identified which precludes administering Sym022 t o 
humans . 
2.3 Clinical Experience 
2.3.1 Clinical Experience with Agents Related to S ym022 
2.3.1.1 Clinical Evidence of Activity in Malignant Diseases  
As noted, several anti -PD-1 monoclonal antibodies ( mAbs ) have been approved (accelerated and 
full approvals) for the treatme nt of various human cancers . These  include : (a) solid tumors (non-
small cell lung carcinoma, renal cell carcinoma, malignant melanoma, squamous cell carcinoma 
of the head and neck, urothelial carcinoma, Merkel cell carcinoma; (b) hematological 
malignancies ( classical H odgkin L ymphoma ); as well as (c) a number of tumors in adults or 
children char acterized by high microsatellite instability without other available ther apies ( 11-15). 
Additional agents targeting PD -1 are in development.   
These agents continue to be studied alone and in combination with other modalities including other agents with im mune system targets . For example, the combination of ant i-PD-1 mAbs and 
an antibody targeting Cytotoxic T -Lymphocyte -Associated Protein 4 ( CTLA -4) (ipilimumab) 
has been approved in patients with melanoma. These agents are also being studied with standard therapeutics such as chemotherapy, radiotherapy,  and various targeted agents , all in efforts to 
both improve  the initial efficacy of immune checkpoint blockers and/ or to circumvent the 
refractoriness that emerges during or after treatment with these agents.   
Anti-PD-L1 mAbs have also been a pproved and are being developed alone and in combination 
with other agents.  
2.3.1.2 Safety and Tolerability of anti -LAG -3 mAbs  
Data are available from a single Phase 1 study of BMS -986016, a human monoclonal IgG4 
antibody to LAG -3, which evaluated this agent alone  and in combination with nivolumab ( 7). 
Sixty ( 60) patients with either advanced solid tumors  or B cell malignancies received BMS -
986016 every 14 days in a 56- day cycle for up to 12 cycles  at fixed doses of 20 mg (8 patients), 
80 mg (13 patients ), 240 mg (24 patients ), or 800 mg (15 patients) ( 7). No maximum tolerated 
dose (MTD) was reached in patients treated, and evaluation of anti -drug antibody (ADA) did not 
sugge st a major problem with immunogenicity.  Treatment -related adverse events (TRAE) were 
observed in 14/23 (61%) patients with sol id tumors with available data.  Fatigue (26%), 
decreased appetite (13%), arthralgia (9%), dry mouth (9%), headache (9%), elevated lipase (9%), 
myalgia (9%), nausea (9%), pruritus (9%), rash (9%), and rash maculopapular (9%) were 
observed in 2 or more patients. Other TRAEs observed in patients with solid tumors included 
elevated amylase, and an in fusion- related reaction (IRR). Thirtee n percent (13%) of these AE s 
were ≥ Grade 3, including both cases of  elevated lipase and a single case of  maculopapular rash. 
The TRAE profile in patients with hematological malignancies was similar with 18/38 patients 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 34 of 163 
 
 treated with BMS -986016 alone experiencing an event  of any grade . Fatigue (18%), headache 
(5%), influenza -like illness (5%), IRR (5%), rash (5%), and aseptic meningitis (3%) were 
observed. Only the event of ase ptic meningitis was ≥ Grade 3. The authors noted that the 
observed toxicities seen in patients receiving single  agent BMS -986016 included many events 
that are often associated with immune checkpoint inhibitors  (7). TRAE were predominantly 
Grade 1 to 2, with only 3% leading to treatment discontinuation in patients  receiving BMS -
986016 al one. Studies of combinations of BMS -98016 and nivolumab are being pursued, so 
more complete data on the safety of this agent is limited at this time.   
Although the mechanism of action is distinct, inhibitors of LAG -3 have many simi larities to 
blockers of other immune checkpoint pathways . Preclinical data have  documented that inhibition 
of the  PD-1/PD -L1 pathway results in immune stimulation that may lead to antitumor effects, 
autoimmunity, effects on immune responses to viral infect ions, and alloimmunity f ollowing 
hematopoie tic stem cell transplantation. Because of these similarities, data on the potential 
adverse events (AEs) seen after treatment with antibodies to PD -1 and PD -L1 are being included 
in this clinical trial protocol (CTP) since there are limi ted available data on toxicities associated 
with administration of antibodies to LAG -3 alone  (16).  
AEs associated with immune checkpoint blockers targeting PD -1 or PD -L1 have been well 
described in publications of clinical trials of these agents, in prescribing information from 
approved products  (11-15), as well as in literature reviews ( 17-20). Unlike AEs observed after 
standard cancer therapy, many of the toxicities of these agents are only observed after several weeks to months and may not be clearly dose -related. The wide varie ty of potential AEs  as well 
as their variable time s of onset ha ve complicated development , although the safety profiles of 
these agents have become clearer over time as additional agents targeting these pathways  have 
been evaluated.   
The warnings and prec autions variably associated with checkpoint inhibitors , specifically those 
directed to PD -1/PD -L1, have included  risk of developing: immune -mediated pneumonitis, 
immune -mediated colitis, immune -mediated hepatitis, immune -mediated endocrinopathies, 
immune -mediated nephritis and renal dysfunct ion, immune -mediated skin adverse reactions, and 
immune -mediated encephalitis/ meningoencephalitis, immune -mediated myasthenic syndrome, 
myasthenia gravis, or Guillain -Barre, immune -mediated ocular inflammatory toxicity , and 
immune -mediated pancreatitis . Increased infection  risk, embryo- fetal toxicity, as well as 
increased complications associated with allogeneic hematopoietic stem cell transplantation 
(HSCT) have also been noted . Other immune -mediated and non- immune -mediated AEs  have 
been reported in the a rchival literature and/or prescribing information for PD -1/PD -L1 pathway 
inhibitors and are listed in Appendix 8  (11-15). 
2.3.1.3 Patient Selection for Treatment with Sym 022 
Preliminary studies have been undertaken to evaluate biomarkers that allow for selection of 
patients who may have an increased likelihood of responding to anti -LAG- 3 mAbs, but there are 
no definitive data available  at this time .   
2.3.1.4 Potential Pharmacodynamic  Biomarkers  
Limited information is available on potential pharmacodynamic biomarkers measuring responses to therapy with anti -LAG -3 mAbs. Assessment of antitumor effect in this study will be 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 35 of 163 
 
 performed using standar d response criteria as well as a modificat ion of the Response Evaluation 
Criteria in Solid Tumors (Version 1.1) (RECIST v1.1) referred to as Immunotherapeutics 
Response Evaluation Criteria in Solid Tumors (iRECIST ) (21, 22 ). 
2.3.2 Clinical Experience with S ym022 
The study described in this clinical trial protocol is ongoing. Sym022 is also being studied in a Phase 1 study in combination with Sym021 (anti -PD-1 monoclonal antibody; ClinicalTrials.gov 
number [STUDY_ID_REMOVED]) . 
2.4 Trial Rationale  
Data from the literature as well as nonclinical pharmacology, toxicology, PK and the in vitro  
safety study in human whole blood indicate that Sym 022 can be safely evaluated  in human 
cancer patients  at an appropriate starting dose. Data on both Sym 022 as well as other anti -LAG -3 
mAb s have been considered in developing this clinical trial. Sym 022 is  being evaluated as a 
single agent in preparation for subsequent studies in combination with other mAbs designed to 
improve antitumo r responses by further interactions with other immune system targets. 
Combinations of immune checkpoint inhibitors and other  agents that either increase immune 
function directly or interrupt immune suppressive pathways are under active development with an aim of improving the efficacy of currently available therapies . 
2.5 Dose  Rationale  
The proposed starting dose of 0.3 mg/kg Sym 022 is based on a combined evaluation of the 
toxicity studies in cynomolgus monkeys, in vitro safety pharmacology and the Minimal Anticipated Biological Effect Level (MABEL) for Sym 022. In the pivotal toxicity study in 
cynomolgus monkeys, Sym 022 was dosed at  10 and 100 mg/kg/week for 4 weeks. The 100 
mg/kg dose  given weekly for 4 weeks (5 dose occasions)  in this study was determined to be the 
NOAEL. Applying a standard safety factor of 10, the Maximum Recommended Starting Dose (MRSD) is 10 mg/kg.  
The MABEL o f 0.01 mg/kg of Sym022 was used as a very cautious benchmark for initial 
pharmacological activity. The MABEL represents an average S ym022 serum concentration that 
could elicit 50% of the maximal response in an in vitro  pharmacology assay using human SEB -
stimulated PBMCs. Sym022 and the anti -LAG -3 antibody in early clinical development 
(BMS986016, see Section 2.3.1.2) gave similar results in this and other in vitro  assays, so their 
clinical pharmacodynamic and safety properties are expected to be similar.   
Based on a combined evaluation of the data, a st arting dose higher than the MABEL is justifiable 
because:  
• The in vitro  assay for the MABEL is artificially sensitive as compared to in vivo  and a 
higher dose is predicted to be needed for clinically meaningful activity  
• There is prior clinical experience wi th LAG- 3 blockade  
• The in vitro  safety p harmacology study indicated a low risk of immediate cytokine 
release  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 36 of 163 
 
 • The NOAEL in cynomolgus monkeys was 100 mg/kg.  A starting dose of 0.3 mg/kg 
gives a large margin to the NOAEL in terms of exposure ( 260-fold lower)  and the MRSD 
(33-fold lower) .  
In conc lusion, the proposed starting dose is  0.3 mg/kg. The maximum dose to be administered in 
this trial is not to exceed 10 mg/kg.  
The subsequent dose levels are planned to be 1, 3 and 10 mg/kg, i.e. with 3- fold steps at a ll dose -
escalations. The dose -escalatio n steps were based on a combined evaluation of the steepness of 
the concentration -response, non- clinical safety studies and the nature of the anticipated adverse 
events based on the initial experience with BMS986016. The concentration -response curve in the  
in vitro  SEB -PBMC assay did not indicate a steep concentration -response which would have 
called for smaller escalation steps. Furthermore, no safety issues have been identified in the non-
clinical safety studies and the maximum proposed dose of 10 mg/kg i s 10- fold below the 
NOAEL in cynomolgus monkeys and the maximum dose is expected to be the MAD rather than 
the MTD. The adverse events so far reported from LAG -3 blockade appear manageable and 
resemble those reported with PD -1 inhibiting antibodies. 
2.6 Overal l Benefits/Risk  
No clinical information is available for patients treated with Sym022, therefore the benefits and 
the safety profile of Sym 022 ha ve not been fully established. However, responses have  been 
reported in a single Phase 1 trial  of the anti -LAG- 3 mAb BMS -986016 in a patient with NSCLC 
(partial response; PR) and a patient with B -cell lymphoma ( complete response; CR) . Results 
from preclinical studies indicate that Sym022 has antitumor activity in different cancer  model s. 
Sym022 has also been shown to be efficacious in preclinical models at dose levels that are well 
tolerated in cynomolgus monkeys. 
During this trial, there will be an ongoing assessment of the risks with periodic evaluation of 
safety data.  The trial will be discontinued in the event o f any new finding indicating a risk that 
would render continuation of the trial unjustifiable. A Study Safety Team will review clinical 
and laboratory safety data on an ongoing basis and make decisions regarding the advisability of continuing accrual and/or dose -escalation.  
To mitigate potential risks, the trial is designed to detect dose -limiting toxicities ( DLTs ), if any, 
and to define a n MTD in accordance with the dose -escalation scheme planned for  the trial.   
Enrollment will be staggered by 2 week s betw een the first and second patient in each new dose 
level tested to evaluate safety before allowing concurrent enrollment of further patients at the given dose level. If the dose administered in a coho rt is well tolerated, dose -escalation may 
proceed and enr ollment of subsequent cohorts may occur to  establish a recommended P hase 2 
dose (RP2D). The options to slow infusions, interrupt dosing, and discontinue administration of study drug in the event of specific AEs are outlined in this CTP  (Section 8.5 ).   
Information on AEs  observed with an agent targeting the LAG- 3 pathway is in cluded  (Section 
2.3.1.2, Section 11.2). Inform ation on AEs observed with agents targeting the PD -1/PD -L1 
pathways is also included ( Section 11.2, Appendix 8 ), along with recommendations for the 
management of IRR s (Appendix 9 ) and immune -mediated toxicities  (Appendix 10 ). 
Patients participating in Sym022 studies will be closely monitored for anticipated adverse reactions as well any unant icipated safety findings. Because the risks associated with immune 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 37 of 163 
 
 checkpoint  inhibitors can occur several weeks to months after treatment, patients will be 
monitored for up to 6 months  following the last dose to assess for the onset of any post -therapy 
immune -mediated event thought to be related to study drug. Any patient who develops an 
immune -mediated toxicity during study, or during the 6- month post -therapy follow -up period, 
will be followed for up to 2 years  after the end of treatment to assess the cou rse of the condition 
and evaluate potential reversibility of the finding. 
FOR ADDITIONAL INFORMATION, PLEASE REFER TO THE INVESTIGATOR’S 
BROCHURE  (IB)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 38 of 163 
 
 3 TRIAL OBJECTIVES AND DESIGN  SUMMARY 
3.1 Objectives :  Sym 022 (anti -LAG -3) Dose -Escalation  
3.1.1 Primary  Objective  
Evaluation of the safety , tolerability, and dose -limiting toxicities (DLTs)  to establish the 
maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential 
escalating doses of Sym 022 (anti -LAG- 3) when administered once every 2 weeks (Q2W)  by 
intravenous (IV) infusion to patient cohorts with loc ally advanced/unresectable or metastatic 
solid tumor malignancies  or lymphoma s that are refractory to available therapy  or for which no 
standard therapy is available   
Note:  Q2W dosing; 4 weeks equal s 1 dosing cycle.  Goal is the identification of the MTD or determination of a 
RP2D dose based on clinical data , including safety, PK, and pharmacodynamic  (e.g. receptor occupancy in 
peripheral blood)  outcomes . The MTD , if identified , and the RP2D dose may  not be the same  as the RP2D 
may be lower . If an MTD is not identified a maximum administered dose (MAD) will be determined and will 
not exceed 10 mg/kg .    
3.1.2 Secondary Objectives   
• Evaluation of the immunogenicity of Sym 022  
• Characterization of the PK profil e of Sym 022 
• Evaluation of the preliminary antineoplastic effect s of S ym022, including:  
o Evidence of objective response (OR) or stabl e disease (SD) *   
o Duration of OR  or SD *  
o Time to progression (TTP) of disease *  
* As assessed by RECIST v1.1  (Appendix 5 ), iRECIST  (Appendix 6 ), and Respo nse Evaluation Criteria 
in Lymphoma  (RECIL  2017; Appendix 7 ) 
3.1.3 Exploratory Objective s  
• Evaluation of potential pharmacodynamic markers , e.g. receptor occupancy i n peripheral 
blood mononuclear cells (PBMCs) (peripheral blood to be collected)  
• Evaluation of potential biomarkers, including but not limited to  assessment of :  
o In peripheral blood: c irculating tumor DNA ( ctDNA) , RNA, relevant 
proteins/cytokines , and cellular biomarkers  
o In tumor tissue: DNA, RNA, protein, and cellular biomarkers (biopsies optional)  
Note:  Assay methodology and biomarker assessments to be determined (TBD).  Potential analyses may 
include but are not limited to: ctDNA sequencing; RNA  sequencing (RNA -seq)/whole-exome 
sequencing (WES);  measurement of relevant proteins/cytokines in the blood; cy tometr ic analysis of 
cells in blood ; and immunohistochemistry (IHC) of tumor material when col lected (tumor sampling 
optional) .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 39 of 163 
 
 3.2 Trial Design  Summary   
Patient Population and Objectives  
Approximately 15- 30 m ale and female p atients with documented either solid tumor malignancies 
that are locally advanced /unresectable or  metastatic , or lymphoma s, and with disease that is 
either refractory to standard therapy or for whom  no standard therapy is available, will be entered 
into th is Phase 1, multic enter, open- label, dose -escalation , cohort study. The trial is designed to 
evaluate the safety, tolerability, and DLTs to  establish the MAD or MTD and  the RP2D  of 
sequential escalating doses  of S ym022 (study drug) , an anti -LAG -3 mAb.    
Secondary objectives include evaluation of immunogenicity, characterization of the PK profile, 
and preliminary assessment of the antineoplastic effects  of Sym 022 in this patient population. 
Exploratory evaluation of the utility of potential pharma codynamic and other biomarkers of 
Sym022 will also be undertaken in pre - and post -dosing peripheral blood samples  and tumor 
tissue (tumor biopsies optional) . Patients will be treated and followed on an outpatient basis 
throughout the trial, unless hospital ization is required for other reasons, or to ensure patient 
safety.   
Dosing Schedule and Treatment Duration  
• No premedication is required prior to receiving the first dose of study drug, except in patient s with a history of IRR s to mAbs  or similar products ; in these patients , it is 
recommended that premedication be administered . Thereafter, p remedication of 
individuals is at the Investigator ’s discretion. Mandatory premedication will be 
implemented for all patients should a pattern begin to emerge of mild -to-moderate study 
drug- related reactions that are amenable to prophylaxis with standard agents .   
• On Day 1 of study, patients will receive study drug administered by 60- minute  (+10 min) 
IV infusion in a fixed 100 mL volume. S ym022 will be administered  once every 2 weeks 
(Q2W) with administration on Day 1 and Day 15, with each dose followed by a 2- week 
recovery period. This 4- week (2 8 day) per iod will be considered Cycle 1.  
Determinations regarding infusion duration, cohort escalation, DLTs, and MTD wi ll be 
based on the toxicities observed during this initial cycle. Patients must receive their full planned dose s of study drug, plus complete the designated 2- week follow -up period, to  be 
considered evaluable for tolerability, unless dose delay  or discontinuation was the result 
of a DLT.  End of Cycle 1 (EOC 1) assessments are to be performed no sooner than Cycle 
1/Day 28 ( C1/D28) (± 2 days ).   
   
• In all patients entered, a minimum of at least Cycle 1 of study drug will be completed, if 
tolerated, after which in the absence of confirmed progressive disease (PD)  or 
unacceptable toxicity a patient may continue to receive additional 4- week cycles  of st udy 
drug at the same dose and infusion duration established for the patient , and on the same 
Q2W schedule , at the Investigator’s discretion and provided specified retreatment criteria 
have been met . Retreatment cycles may continue for up to 12 months  at wh ich time plans 
for continued therapy will be discussed by the Medica l Monitor(s) and Investigator. 
Patients who stop therapy with an ongoing OR or prolonged SD may be retreated in the 
event of relapse, if the trial is still open . Confirmed  PD as defined by response criteria 
(RECIST  v1.1, iRECIST, RECIL  2017) at any point in the study will necessitate 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 40 of 163 
 
 withdrawal of the patient from further participation so that alternative management of 
their malignancy may be considered.   
Doses to be Evaluated  
At study ent ry, patients will be sequenti ally assigned to fill escalating dose  cohorts of S ym022 
beginning at the dose of 0.3 mg/ kg, with potential doses 1.0 mg/kg, 3.0 mg/kg, and 10.0 mg/kg 
to follow. These doses will be evaluated until the MTD is identified, a MAD i s reached, or until 
a RP2D is determined based on clinical data , including safety, PK, and pharmacodynamic ( e.g. 
receptor occupancy  in peripheral blood)  outcomes . The MAD, MTD if identified,  and the RP2D 
may not be the same as the RP2D may be lower.     
A standard 3+3 dose -escalation design will be used with a target toxicity level of 33 .3% or less 
as determined by DLTs. The number of cohorts evaluated and the MAD will depend upon the observed tolerability of S ym022 during Cycle 1  of patient treatment; howev er, the maximum 
dose to be administered in this trial is not to exceed 10 mg /kg. Doses escalation will be  as shown 
in Figure 1 .   
The Investigator(s) and Sponsor ’s Medical Representative(s) as members of a Study Safety 
Team will review clinical and laboratory safety data on an ongoing basis throughout the study 
and make decisions regarding the advisability of continuing accrual to a dose cohort, and/or 
escalating the dose and allowing accrual to a higher dose cohort . Patients will also be monitored 
for evidence of cumulative or delayed toxicities , including the occurrence of delayed immune -
mediated toxicities .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 41 of 163 
 
 Figure 1:  Dose -Escalation Schema  
 
Abbreviations (in alphabetical  order): AE, ad verse event; DLT, dose -limiting toxicity; kg, kilogram; MAD, maximum administered dose; MTD, 
maximum tolerated dose; mg, milligram; N, number; Q2W, dosing every 2 weeks; RP2D, recommended phase 2 dose; SAE, serious adverse 
event .  
Note: 15-30 patients anticipated for dose -escalation . Minimum of 6 patients  to be  treated at the MAD, MTD and/or RP2D dose; expansion of this 
cohort (or any other) up to 12 patients may  be considered to further evaluate tolerability ; therefore approximately 1 5-30 patients to be en tered.  
Filling  of Cohorts  
The first patient within a co hort must complete and tolerate the first dose of Cycle 1 , including 
follow -up until C1/ D15 before entry of the next patient to a cohort  (i.e. 2- week  stagger) ; 
thereafter patients within a coh ort may be added concurrently. Dose -escalation and accrual to the 
next cohort will occur after the minimum number of  patients required for tolerability assessment 
in the current cohort  have completed Cycle 1  (3 patients, or 6 patients in an expanded cohort) , 
and only after acceptable toleran ce has been demonstrated in  at least 3 of 3 or 5 of 6 patients 
treated in the current cohort (depending on cohort size), and review of the data with the Study 
Safety Team .   
Should the DLT rate equal or exceed 33.3% in any cohor t, the previous lower dose cohort will be 
expanded to 6 patients (if not already accomplished) .  Thus, there is potential for expansion of a 
lower dose if an initially identified MTD and/or RP2D is found to exceed tolerability , as well as 
potential to  eval uate and expand a  previously unplanned intermediate dose between 2 established 
dose levels, if indicated, to  more fully characterize safety and tolerability. Once the MTD (or 
maximum dose to be studied) is achieved and/or the RP2D is identified, that cohor t may  be 
expanded up to 12 patients  to more fully evaluate safety and tolerability at that dose level, at the 
Sponsor’s discretion. Should the DLT rate equal or exceed 33.3% in an expanded cohort, it will 

Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 42 of 163 
 
 be determined that the dose is not tolerated  and ex ceeds the MTD . If this occurs, the previous 
lower dose cohort or an intermediate dose level may  be expanded as above. There will be no 
intrapatient dose -escalation in this trial.   
Study Assessments  
For safety, patients will be monitored throughout the  treatment and 1 -month follow -up (1M 
FUP) period for evidence of AEs , including changes in clinical status, laboratory data, 
electrocardiogram ( ECG ) findings , and either multi- gated acquisition ( MUGA)  scans or 
echocardiograms  (ECHO) in patients with a history o f congestive heart failure ( CHF ). Patients 
will be evaluated for evidence of immune -mediated toxicities , evidence of certain specified 
conditions will result in immediate discontinuation from treatment with study drug . Patients will 
also be evaluated for evidence of antibody formation to study drug. Patients experiencing a DLT 
regarded as possibly- , probably- , or related to  study drug at any point during treatment will either 
be discontinued from treatment with study drug, or may continue if there is evidence of an OR , 
SD, or other clinical benefit , but may do so ONLY following discussion with the Sponsor’s 
Medical Monitor(s) . Patients may not  be retreated following the occurrence of a DLT until there 
is amelioration to ≤  Grade 1 severity, return to baseline  status , or resolution of the toxicity. Only 
DLTs occurring during Cycle 1 will be used to make determinations regarding dose -escalation 
and tolerability.  Exceptions to continuing on- study include evidence of certain immune -mediated 
toxicities,  as detailed  in Section 9.1; in such instances patients must be permanently discontinued 
from treatment with study drug.    The overall trial plan is introduced in Table 1 . 
    
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 43 of 163 
 
 Table 1:  Overall Trial Plan  
Screening Period  
Screening  • Written informed consent  
• Disease assessment and eligibility confirmation (within 28 days  [+2 days] prior to 1st dose) 
• Safety screening and eligibility confirmation  (within 14 days prior to 1st dose unless otherwise 
stipulated ) 
• Allocated dose of study drug dependent upon cohort assignment; to be confirmed on Screening and 
Allocation Form  
Treatment Period  
Treatment  • C1/D1 initial dose of study drug  
• Continued dosing once Q2W  
• 28-day cycles until confirmed PD, unacceptable toxicity, or other discontinuation criterion is met  
for up to 12 months at which time plans for continued therapy to be discussed by the Medical 
Monitor(s) and Investigator.  Patients who stop thera py with an ongoing OR or prolonged SD may 
be retreated in the event of relapse, if the trial is still open . 
• EOT visit within approximately 7-10 days following treatment discontinuation , or before initiat ion 
of a new treatment, whichever occur s first  
• 1M FUP  visit 30 days (+7 days) following last dose *   
*Completion of the 1M FUP visit will be considered the end of the treatment period    
Follow -up Period  
Post-Treatment 
Follow -up  • Safety FUP if an observed non-immune -mediated toxicity thought to be related t o study drug has 
not resolved by the 1M FUP evaluation (2 and 4 months following last study drug dose)  
• Safety FUP surveillance to assess for delayed onset immune-mediated  toxicity  (Q2M for up to 6 
months following last study drug dose)  
• Safety FUP for ongoi ng at the 1M FUP, and for delayed onset , immune-mediated toxicit y (Q2M 
for up to 2 years following last study drug dose)   
• Response FUP following discontinuation for reasons other  than confirmed PD until the end of trial 
(Q2M until PD or initiation of anoth er therapy)  
*Completion of all  indicated fo llow-up will be considered the EOS  
Abbreviations (in alphabetical order): 1M FUP, 1-month follow -up; C1/D1, Cycle1/Day1; EOS, end of study; EOT, end of treatment ; FUP, 
follow -up; PD, progressive disease; Q2M, eve ry 2 months ; Q2W, every 2 weeks  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 44 of 163 
 
 4 PATIENT SELECTION  
4.1 Number of Patients  
4.1.1 Investigational Sites  
This is a multicenter  trial. It is anticipated that approximately 2 -4 investigational sites in North 
America may participate based on accrual.  
4.1.2 Number of Patients  
Considerations for estimating the number of patients to be entered are as follows:  
• Approximately 15- 30 patients in escalating do se cohorts  
o Minimum of 3 patients  per dose cohort;  assume  approximately 4 dose cohorts to 
be evaluated  to establish the MTD  and/or RP2D  dose  
o Expansion of any cohort to 6 patients  in the event of a Cycle 1 DLT in any of the 
initial 3 patients   
o Minimum of 6 patients  to be treated at the MTD  and/or RP2D dose ; expansion of 
this cohort (or any other) up to 12 patients may  be considered to further evaluate 
tolerability   
In addition, t here is potential for entry of additional patients to : 
• Ensure sufficient evaluable patients by adding an additional patient to a cohort  (e.g. 
increase a 3- patient cohort to 4 patients , or a 6- patient cohort  to 7 patients )   
Note:   Should this action be taken, cohort tolerability  assessment  and subsequent dose-escalation  will 
occur when the minimum number of patients required to evaluate tolerability have completed 
Cycle 1 . However , if any additional patient experiences an event that would, per protocol, result in 
either cohort expansion or the halting of dose -escalation, protocol rules as outlined herein will be 
followed ( Section  6.6.1 ). 
• Expand a lower dose cohort(s) if an initially identified MTD and/or RP2D is 
subsequently determined to be not tolerated either with single or repeated cycles of 
therapy   
• Add and e valuate a previously unplanned intermediate dose level(s) to further 
characterize safety and tolerabi lity, if indicated  (inclusion of a dose higher than those 
listed would require a protocol amendment)  
Note: This action would be taken in the event of an unacceptably high frequency of toxicities observed 
in patients treated at one dose considered to be in marked  contrast to the tolerability noted at the 
preceding dose level , or if after review of study data , a more gradual dose -escalation appears 
warranted.  
Expanded accrual in any cohort will take place at the Sponsor ’s discretion, after discussion with 
the Inves tigator(s).  
4.2 Criteria for Inclusion  
Patients must meet all  the following criteria to be eligible  for participation in the trial:  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 45 of 163 
 
 1. Male or female patien ts, ≥ 18 years of age  at the time of obtaining informed consent  
2. Patients with a documented (histologically - or cytologically- proven) solid tumor 
malignancy  that is locally advanced  or metastatic ; patients with documented lymphoma s   
3. Patients with a malignancy (solid tumor or lymphoma) that is currently not amenable to 
surgical intervention due to either medical contraindications or non- resectability of the 
tumor  
4. Patients refractory to or intolerant of existing therapy(ies) known to provide clinical 
benefit .   
Note:  Patients may have received and failed prior therapy with a PD -1/PD -L1 inhibitor  and be considered 
eligible for this trial.  
5. Patients with measurable or non- measurable disease  according to RECIST  v1.1 or RECIL  
2017 ( Appendix 5  and Appendix 7 , respectively )   
6. Patients with a n Eastern Cooperative Oncology Group (ECOG) performance status (PS) 
of 0 or 1 ( or equivalent Karnofsky PS; Appendix 1 ), and anticipate d life expectancy of ≥ 
3 months  
7. Patients, both male and female, who are either not of childbearing potential or who agree 
to use a highly effective method of contraception during the study beginning within 2 
weeks  prior to the first dose and continuing unti l 6 months  after  the last dose of study 
drug.   
Note: Women are considered of childbearing potential unless they have undergone hysterectomy and/or 
bilateral tubal ligation or oophorectomy, or have been postmenopausal for at least one year.  
Postmenopausal status in  non-surgerized females under 55 years of age should be confirmed with 
a serum follicle -stimulating hormone (FSH) level within laboratory reference range for 
postmenopausal women.   
A highly effective method of contraception is  defined as non- hormonal contraception equivalent to 
a double -barrier method (includes a  single -barrier method in combination with a spermicide ) or 
intrauterine device ( Section 11.1).  
Women of childbearing potential (WOCBP) must ha ve a negative pregnancy test , serum at 
screening, serum or urine thereafter; negative test must be confirmed within  ≤ 2 working days  
prior to a dministration of the first dose of study drug.    
8. Patients with the ability to understand and give written informed consent for participation 
in this trial, including all evaluations and procedures as specified by this protocol  
Note: Informed consent must be obtained prior to patient screening, and before any evaluations or 
procedures specifically related to this study are performed.  
4.3 Criteria for Exclusion  
Patients meeting any  of the following criteria are ineligible  for participat ion in the trial.  
4.3.1 Patients  to be Excluded  
1. Women who are pregnant or lactating or intending to become pregnant before, during, or 
within 6 months  after the last dose of study drug. WOCBP, and fertile men with 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 46 of 163 
 
 WOCBP -partner (s) not using and not willing to use a highly effective method of 
contraception.  
Note:  WOCBP includes any female who has experienced menarche and who has not undergone surgical 
sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or is no t 
postmenopausal.  Post -menopause is defined as: 1) amenorrhea for > 12 months with no other 
cause, or 2) irregular menstrual periods, on hormone replacement therapy (HRT), with a documented FSH level > 35 mIU/mL.  
WOCBP and fertile men will be informed as  to the potential r isk of procreation while participating 
in this trial. A pregnancy test will be performed, and the results reviewed, on each premenopausal 
WOCBP  prior to fi rst study drug administration. A negative pregnancy test performed within <  2 
work ing days  prior to f irst study drug administration must be documented i n the patient’s case 
report form (CRF) (Section 11.1).  
2. Patients with central nervous system (CNS) malignancies; patients with known, untreated  
CNS or leptomeningeal  metastases , or spinal cord compression, patients with any of the 
above  not controlled by prior surgery or radiotherapy, or patients with symptoms 
suggesting CNS involvement for which treatment is required  
Note: Patients with treated CNS metastases wi ll be eligible if they are asymptomatic, do not require 
corticosteroids, and have confirmation of at least stable brain disease status as assessed by 2  
imaging studies performed ≥  4 weeks apart with the most recent performed within 4 weeks prior to 
first trial drug administration.  Prophylactic anticonvulsant medications are allowed.   
Patients with newly identified CNS disease during study treatment will be considered to have 
disease progression and will be discontinued from study to allow for appropriate management.  
3. Patients with hematologic malignancies  other than lymphoma s   
4. Patien ts with any of the following hematologic abnormalities at baseline*:   
• Hemoglobin < 9.0 g/dL  
• Absolute neutrophil count (ANC) < 1,000 per mm3 
• Platelet count < 75,000 per mm3 
Note: Patients may have received  a blood/blood product  transfusion prior to study, if clinically 
warranted .   
*Throughout this protocol “base line” is defined as the last available ob servation prior to the first 
administration of study drug on C1/D1 . 
5. Patients with any of the following serum chemistry abnormalities  at baseline:  
• Total bilirubin > 1.5 × the upper limit of normal ( ULN)  for the institution *  
• Aspartate aminotransferase ( AST ) or alanine aminotransferase ( ALT ) > 3 × the 
ULN for the institution (> 5 × ULN if due to hepatic involvement by tumor)  
• Serum creatinine > 1.5 × ULN for the institution  
*Patients with evidence of Gilbert’s Syndrome as the etiology of elevated total bilir ubin will be eligible, 
provided all other eligibility criteria are met.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 47 of 163 
 
 6. Patients with  any of  the following coagulation parameter  abnormalities at baseline  
(unless on a stable dose of anticoagulant thera py for a prior thrombotic event , as 
determined by the Investigator ): 
• Prothrombin time ( PT) (or international normalized ratio [ INR]) > 1.5 × ULN for 
the institution  (> 3× ULN for the  institution if anticoagulated)  
• Partial thromboplastin time ( PTT)  (or activated partial thromboplastin time 
[aPTT ]) > 1.5 × ULN  for the institution  (> 3× ULN for the institution if 
anticoagulated)  
7. Patients with:  
• Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary 
embolism (PE), within 4 weeks  prior to first study drug administration, unless 
adequately treat ed and considered by the Investigator to be stable  
• Active uncontrolled bleeding or a known bleeding diathesis   
8. Patients with a clinically  significant  (CS) cardiovascular disease or condition, including:  
• Need for antiarrhythmic medical therapy for a ventricular arrhythmia  or other 
uncontrolled arrhythmia (patients with controlled atrial fibr illation (heart rate 
[HR] < 90) for > 30 days prior to study entry are eligible)  
• Severe conduction disturbance  (e.g. 3rd degree heart block)  
• HR-corrected QT interval ( QTc interval ) ≥ 480 milliseconds (msec)  
• Uncontrolled hypertension (per the Investigator’s discretion)  
• History of myocarditis  
• Left ventricular ejection fraction (LVEF) * known to be below the lower limit of 
normal ( LLN ) for the center, or < 50% by MUGA scan or ECHO if n o LLN is 
defined by the site  
• CHF currently requiring therapy  
• Class III or IV cardiovascular disease according to the New York Heart 
Association (NYHA) Functional Classification ( Appendix 2 ) 
• History of acute coronar y syndromes (including myocardial infarction [MI] and 
unstable angina), coronary angioplasty, or stenting within 6 months  prior to first 
study drug administration 
*Assessment  of LVEF will not be performed routinely in all patients.  Patients with a history  of CHF 
will have either a MUGA scan or ECHO at Screening. If LLN is not defined for a given institution, 
then LVEF  must be ≥ 50% . 
9. Patients with a significant pulmonary disea se or condition, including:  
• History of interstitial lung disease (ILD), pulmonary fibrosis  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 48 of 163 
 
 • History of pulmonary inflammatory disease , interstitial or other pneumonitis *, 
acute respiratory distress syndrome (ARDS)  
*Patients with prior evidence of Grade 1 pn eumonitis will be eligible provided they were 
asymptomatic and did not require tre atment  and provided pneumonitis has resolved prior to entry 
to this trial.  
10. Patients with a current or recent (within 6 months ) significant gastrointestinal (GI) 
disease or condition, including:  
• History of inflammatory bowel disease  
• Diarrhea ≥ Grade 2 withi n 2 weeks  prior to first study drug administration 
Note:  Patients with recent Grade 2 diarrhea secondary to administration of oral contrast are allowed , 
provided symptoms have resolved prior to first study drug administration 
11. Patie nts with an active, known or suspected autoimmune disease, or a documented 
history of autoimmune disease or syndrome, requiring systemic steroids or other 
immunosuppressive medications  
Note:     Exceptions permitted include: type I diabetes mellitus, hypo thyroidism only requiring hormone 
replacement, skin disorders such as vitiligo, psoriasis or alopecia not requiring systemic treatment, 
conditions not expected to recur in the absence of an external trigger.  
12. Patients with a history of organ transplantation (e.g. stem cell or solid organ transplant)  
13. Patients with a known or suspected hypersensitivity to any of the excipients of 
formulated s tudy drug  
14. Patient s with a history of significant  toxicities associated with previous administration of 
immune checkpoint  inhibitors that necessitated per manent discontinuation of that therapy     
15. Patients with unresolved > Grade 1 toxicity* associated with any prior antineoplastic 
therapy except for  persistent Grade 2 alopecia, peripheral neuropathy, decreased 
hemoglobin, hypomagnesemia , and/or end- organ failure being adequately managed by 
hormone replacement therapy  
*Toxicity assessments based on Common Terminology Criteria for Adverse Events  (Version 5.0) (CTCAE 
v5.0) 
16. Patients with inadequate recovery from any prior surgica l procedure, or patients having 
undergone any major surgical procedure within 4 weeks  prior to first study drug 
administration   
Note:  Patients having undergone recent placement of a central venous access device will be considered 
eligible for enrollment.  
17. Patients who are known or suspected drug or alcohol abuse rs where compliance with 
protocol requirements may be a concern   
18. Patients with a known history of human immunodeficiency virus (HIV) or known active 
infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 49 of 163 
 
 19. Patients with any other serious/active/uncontrolled infection, any infection requiring 
parenteral antibiot ics, or unexplained fever > 38ºC within 2 weeks  prior to first study 
drug administration  
20. Patients with any other serious, life -threatening , or unstable pre -existing medical 
condition (aside from the underlying malignancy), including significant organ syst em 
dysfunction, or CS  laboratory abnormality(ies) , which, in the opinion of the Investigator, 
would either compromise the patient’ s safety or interfere with  obtaining informed 
consent, compliance with study procedures, or  evaluation of the safety of the study drug  
21. Patients with a psychiatric disorder or altered mental status that would preclude 
understanding of the informed consent process and/or completion of the necessary study-related evaluations    
22. Patients with the inability  or with foreseeable incapacity , in the opinion of the 
Investigator, to comply with the protocol requirements  
4.3.2 Drugs and Other Treatments to be Excluded  
1. Other  inhibitors of LAG -3 (e.g. mAbs)  
2. Any antineoplastic agent  for the primary malignancy (standard or investigational) without 
delayed toxicity within 4 weeks  or 5 plasma half -lives, whichever is shortest, prior to first 
administration of study drug and during study, except for :  
• Nitrosoureas and mitomycin C  within 6 weeks  prior to first study drug 
administration and during study 
Note:  Patients may have received and failed prior therapy with a PD -1/PD -L1 inhibitor and may still be 
considered eligible for this trial.  
3. Any other investigational treatments  within 4 weeks  prior to and during study. This 
includes participation in any medical device or other therapeutic intervention clinical trials.    
4. Radiotherapy:  
• For target lesions  within 4 weeks  prior to first ad ministration of s tudy drug unless 
disease progression has been documented in the lesion following treatment, and during study 
• For non- target lesions within 1 week  prior to first administration  of study drug  
Note:  Palliative (limited -field) radiotherapy f or management of pain associated with bone 
metastases present at baseline is permitted  during study .  Patients  with suspected  new bone 
lesions requiring pain management should be treated and evaluated for potential disease 
progression.  
5. Use of live vaccines  against infectious diseases (e.g. varicella) 4 weeks  prior to first study 
drug administration and during study  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 50 of 163 
 
 6. Immunosuppressive or s ystemic hormonal therapy (> 10 mg daily prednisone equivalent) 
within 2 weeks  prior to first study drug administration an d during study. The following 
therapies are allowed:  
• Hormonal therapy for appetite stimulation  (e.g. Megace)  
• Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations  
• Hormone replacement therapy at standard doses for end- organ fail ure 
• Stable horm onal therapy for prostate carcinoma * 
• Stable hormonal therapy for ovarian suppression, hormonal contraceptive therapy, 
or post -menopausal HRT * 
• Neuroendocrine tumor patients: stable hormonal therapy with a somatostatin 
analog  (SSA) ** 
• Steroid t herapy for cont rast reaction prophylaxis  
• Intra -articular steroid injections  
• Low-dose maintenance steroid therapy for other conditions  (e.g. asthma 
exacerbation, stable steroid therapy [excluding tapering dose of steroids] for brain 
edema/metastases/radiation ) 
• Higher dose  steroid therapy for treatment of an acute intercurrent illness (e .g. 
immune -related AEs or other adverse conditions) in patients with stable disease or 
an ongoing response.  In such situations , study drug treatment s hould be 
interrupted for the duration of immunosuppressive therapy.  
*Prior or concomitant therapies are permitted;  however, patient s must have been on a stable dose for 
at least 6 months  prior to study start , and if continuing must remain on the stable dose while receiving 
study treatment (i.e.  such treatment will not be considered as systemic hormonal therapy  for the 
purpose of study eligibility).  
** Patients with metastatic low -grade neuroendocrine tumors (c arcinoid tumors) are permitted to 
remain on concomitant SSA therapy ; however, patients must have been on a stable dose for at least 2 
months ( 8 weeks)  prior to study start and progressed on that dose, and if continuing,  must remain on 
the stable dose while  receiving study treatment (i.e. such treatment will not be considered as systemic 
horm onal therapy for the purpose of study eligibility).  
7. Prophylactic use of hematopoietic growth factors within 1 week  prior to first study drug 
administration and during Cycle 1 of study; thereafter prophylactic use of growth factor s 
is allowed as clinically indicated    
Note: Interventional/therapeutic use of growth factors is allowed at any time during study, including 
during Cycle 1, if deemed necessary by the Investigator.  Growth factor use must be consistent 
with product package insert instructions.  Trans fusions are permitted as needed.  
 
Questions regarding patient eligibility must  be addressed and resolved by the Investigator in 
consultation with the Sponsor's Medical Monitor (s) prior to enrollment. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 51 of 163 
 
 5 INVESTIGATIONAL MEDICINAL PRODUCT  
In advance of study st art, the Sponsor (or designee)  will provide labeled supplies of 
investigational medicinal product (IMP) (also referred to as study drug)  to the site  pharmacy.  
Instructions for handling, administration, and disposal will be provided in the IMP Manual  and 
are summarized below.  
5.1 Sym022  
The study drug Sym 022 will be provi ded by Symphogen. 
Sym022 is a clear to opalescent, colorless to slightly yellow liquid formulation for IV infusion 
after dilution . Each single -use, glass vial contains a nominal fill volume of  8.0 mL. Each vial 
contains S ym022 at a concentration of 20 mg/mL for a total vial content of 160 mg. 
5.1.1 Formulation Excipients  
Formulation excipients include:  
• Sodium Acetate/Acetic Acid  (20 mM)  
• Trehalose dihydrate  (5% w/v) 
• Tween  (polysorbate) 20 (0.02% w/v)  
5.2 Storage  and Handling of IMP  
Unused vials of IMP must be stored refrigerated between 2 ° C to 8° C (36 º F to 46º F) and 
protected from direct sunlight . IMP may not be frozen.   
There is no evidence that ultraviolet ( UV) light exposure affects study drug , but as a precaution , 
vials should be stored protected from direct sun light in the carton  until use . 
All handling, storage and preparation of IMP should take place at the site  pharmacy.  
The site  will be required to maintain a temperature log documenting study drug storage 
conditions. The temperature must be logged and evaluated at minimum on all working days.  
Any deviations from the recommended storage conditions should be immediately reported to the 
Sponsor (or designee)  and the use of study drug interrupted until authorization for its continued 
use has been given .   
Study drug may be accessed only by the Investigator, a member of the Investigator’s staff 
specifically authorized by the Investigat or, or a pharmacist, as appropriate.  The site  must ensure 
that stu dy drug is  accessible to authorized personnel only.  
5.3 Stability  of IMP   
Long- term stability of study drug is being assessed on an ongoing basis  and expiry will be 
updated as data accrue. The stability of the IMP  will be monitored for at least the duration o f the 
proposed clinical trial.   
When diluted for use , the study drug must be stored refrigerated at 2° C to 8° C (36º F  to 46º F), 
protected from direct sunlight, and should be administered within an 8- hour time window  
(Section 5.8).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 52 of 163 
 
 5.4 Labeling of IMP  
Vials of study drug will be open- label; label text will be in accordance with applicable local 
regulatory requirements . Each vial will be uniquely numbered for allocation, dispensing, and 
traceability purpose s.    
5.5 Packaging of IMP  
Study drug will be packed in cartons containing multiple  vials. The vial number range in each 
carton will be detailed on the carton label.   
5.6 Administration of IMP  
Study drug will be administered by IV infusion via an indwelling catheter . An appropriate dose, 
based on the patient’s cohort assignment, diluted to a total volume of  100 mL  with 5% dextrose 
in water (D5W) solution for IV infusion will be administered once  every 2 week s (Q2W; 4 
weeks [2 8 days] equals 1 dosing cycle).   
• Cycle 1 : Study drug will be administered over 60 minutes  (+10 minutes)  
• Cycle 2 and thereafter :  If no Grade 2 IRR is observed in ≥ two thirds of the patients in a 
cohort, a decision may be made to decrease the infusion time to 30 minutes  (+10 minutes) 
as patients  within a cohort are treated in Cycle 2 and thereafter  
5.7 Dose Calculation  
The Investigat or (or designee) will be responsible for calculating the amount of study drug and 
the appropriate dose to dispense to the patient as determined by the patient’s dose cohort 
assignment.   
The dose level  will be multiplied by the patient's weight in kilogram s to arrive at t he total dose to 
be delivered. In sit uations w here this calculation results in a value with an unwieldy number of 
decimal places, it is permissible to round the value to the nearest " tenth ". As a convention, values 
> 5 should be " rounded"  to the next higher number.  
5.8 Dose Preparation   
The desi gnated dose of study drug must be prepared by the study pharmacist (or designee) and 
should be administered by the study staff as soon as possible following preparation, within 8 
hours , and considering:   
• The total volume of study drug to be delivered will be withdrawn from the study drug 
vial(s) and added to a prefilled IV bag containing 5% D5W for IV infusion  (prior to 
adding the study drug and an appropriate volume of dextrose solution is removed, such that the final volume to be infused equals  100 mL).      
• The IV bag containing the diluted study drug solution to be administered should be gently 
inverted  to ensure that the material is well mixed.   
• Once diluted , store refrigerated between 2° C to 8° C (3 6º F to 46º F) and protected from 
direct sunlight.  Allow to warm to room temperature before administration.  
• Standard i nfusion sets to be used. An additional point -of-use (0.22 micron or other) in-
line filter is not to be used .   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 53 of 163 
 
 Further instructions for i nfusion preparation and delivery are provided in the IMP  Manual.  
5.9 Accountability  
The Investigator acknowledges that study drug supplies are investigational and, as such, must be 
used strictly in accordance with the protocol and only under the supervision of the Principal Investigator. No study drug will be sent to the site until all required regulatory documents, 
including Institutional Review Board (IRB) or Ethics Committee (EC) approval, are received by 
the Sponsor  or its designe e. 
The Investigator and si te staff are responsible for maintaining an accurate inventory and 
accounting of study drug.  Receipt , use, and destruction of study drug will be recorded on the 
dispensing log in use .   
5.10 Disposition of Used IMP  
Once study drug is prepared for delivery and administered, the health care professional will  
maintain an inventory of all open/ used vials of study drug. S uch residual supplies may be 
destroyed in an appropriate manner according to institutional policy.   
Note: No other us e of study drug intended for use in this trial is authorized by the Sponsor.  The Investigator 
(or designee) will be responsible for the appropriate handling and disposition of residual study drug in 
partially used vials.   
 
5.11 Unused IMP  
Unused study materia ls MUST be returned to the Sponsor (or designee)  upon expiry or at the 
conclusion of the site’s participation in the trial, unless otherwise authorized in writing. 
5.12 Destruction of IMP  
No unused IMP  may be destroyed or discarded at the site without the writt en authorizatio n of the 
Spons or (or designee). The destruction of study drug materials must be carefully documented per 
instructions outlined in the IMP Manual . Disposition records must be available for review by a 
representative of the Sponsor . 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 54 of 163 
 
 6 EXPERIMENTAL PLAN  
6.1 Design Element s 
• Open-label, uncontrolled, non- randomized  
• Escalating doses of study drug in sequential patient cohorts  
• Enrollment staggered between first and second  patient in each new higher dose cohort to 
allow for initial safety observations  
6.2 Projected Recruitment Period and Duration of  this Trial  
It is anticipated that enrollment to this study will be completed in approximately 12 months .  
• Anticipated date of enrollment of first patient: Q1 2018 
• Anticipated date of enrollment of last pat ient: Q2 2019 
• End of Trial  (i.e. data cut -off for primary analysis):  W ill be reached 1 month (30 +  7 
days) after all patient s have discontinued trial treatment, or 6  months after the last patient 
has started trial treatment, whichever occurs earlier , at which point the trial objectives 
will be  considered to have been met .     
• Patients still in treatment will be given the opportunity to continue receiving study drug.  
In such an event, w hile the Sponsor still needs to collect certain safety -related data to 
meet its regulatory obligations (AEs, s erious adverse events [SAEs], study drug dosing, 
reason for discontinuation, etc.), the Sponsor may elect to reduce non- safety -related 
protocol -stipulated assessments , and/or transition  patients to an ext ension/rollover 
protocol  
6.3 Cohort Management  
For the purposes of this study, "enrollment" is defined as patient registration to participate in 
this trial; at that time , the patient's study identification code and dose cohort will be assigned.  
6.3.1 Patient Screeni ng and Dose Cohort Assignment  
Once a patient has giv en written informed consent , screening assessments will be conducted, and  
if the patient is identified as meeting the study eligibility criteria , the Investigator (or designee) 
will contact the Sponsor’s re presentative to  authoriz e enroll ment of the patien t into the trial.  
Patients will be enrolled into the study in the order of confirmation of their eligibility and assigned to a cohort on a “first -come -first-served” basis.   
6.3.1.1 Screening of Potential Patients  
All screening activities must be performed within 14 days prior to the first day of dosing (C1/D1), unless otherwise specified.   
The Sponsor (or designee) will be made aware of potential patients for enrollment to  track such 
study- related activities.    
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 55 of 163 
 
 Patients who  sign informed consent and are ultimatel y deemed to be screen failures will be 
followed for the occurrence of SAEs/AEs during the screening process unti l such time that it is 
determined that they will not be participating in this trial.  
6.3.1.2 Submission of Patient Enrollment Documentation 
Once eligibi lity has been confirmed in accordance with the protocol -stipulated inclusion and 
exclusion criteria, p atient enrollment information must be submitted to the Sponsor (or designee)  
via a Patient Screening and Allocation Form  signed by the Principal Investiga tor (or designee). 
This information will serve to confirm patient eligibility and in itiate the enrollment process. The 
following information must be provided by the site :   
• Patient gender   
• Date of birth  (or age), as allowed by local regulatory requirements  
• Date written informed consent was obtained  
• Underlying diagnosis  
• Confirmation of compliance with all inclusion/exclusion criteria.  
The following information may be requested  of the site : 
• Patient weight (for dose calculation)  
• Date of screening  
• Stage of dise ase and current PS  
• Sites of metastases (if applicable)  
• Brief description of the prior therapy for  the primary diagnosis, including dates of 
initiation and discontinuation as well as best response  
• Planned date of first dosing 
The Sponsor (or designee) will review the information provided and by signing the form will 
authorize eligible patients for star t of treatment. A copy of the fully executed Patient Screening 
and Allocation Form  will be returned to the trial site for archiving. This form will document th e 
allocated dose of study drug and will serve to assign patients to a dose cohort at the time of enrollment.   
6.3.1.3 Patient Identification Code Assignment  
Each patient who completes the study screening assessments and is enrolled for study participation will be  assigned a unique  identification code by the Sponsor  (or designee) . 
Identification codes will be assigned in chronological order , and will be concatenated to indicate 
relevant study information, including at minimum: the participating trial site  and the patient’ s 
order of enrollment to the trial . 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 56 of 163 
 
 6.3.1.4 Screen Failures  
A patient found not eligible for the  trial after giving informed consent will be considered a screen 
failure.  A list of patients failing screening and the reason for ineligibility will be maintain ed by 
the site on a Patient Screening Log or other similar document.   
Re-screening of a patien t is allowed  using the specified criteria and timing , if felt to be justified 
by the Investigator . 
6.3.2 Cohort Closure  
The Sponsor (or designee) will be in communicat ion with the site s when the target total 
enrollment for a cohort has been attained . Once recruitment to a cohort is completed, accrual to 
the cohort will be closed, and sites w ill be so notified in writing. Cohorts will remain closed to 
further accrual , unless a decision is  later made by the Sponsor (or designee) to further expand 
that cohort, based on protocol -defined criteria.  
6.4 Requirements for Patient Observation  
Patients will be treated on an outpatient basis and will be evaluated and discharged from the  
clinic on days of  scheduled study visits*, unless hospitalization is required for other reasons or to 
ensure patient safety.   
Study drug must be administered under close supervision of a physician, or other study personnel 
experienced in administration of IV agents, and in an environment where full resuscitation facilities are immediately available.  IV infusions will be carefully monitored to assess safety and 
tolerability by qualified site medical personnel. Such personnel must be available to  evaluate and 
treat any AE s, as well as to evaluate whether continued participation of the patient in the study is 
warranted or advisable.  
• Patients will be carefully observed for a minimum of 2 hours  following completion of the 
first administration of study drug ( C1/D1) for evidence of any treatment -related AE (s), 
and a minimum of 1 hour  following completion of subsequent infusions  (C1/D15 and 
onward) .   
• At the end of each infusion, the IV line must remain in place during the observation period to allow for administra tion of IV drugs, if necessary.   
Patients will be followed on an outpatient basis during the interval between each scheduled study visit.   
*Clinical and laboratory ass essments will occur at the frequencies indicated ( Sectio n 7).  In the event of an AE, 
assessment frequencies may  be increased, as clinically indicated.  
6.5 Drug Treatment Regimen  
6.5.1 Study Start Day   
All patients will receive the initial dose of study drug on Day 1  of Cycle 1  (C1/D1).   
On the day of the first scheduled study drug infusion, and prior to the start of infusion (SOI), the 
Investigator must assess whether any changes have occurred in the clinical state of the patient 
since Screening which would exclude the patient from the trial. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 57 of 163 
 
 6.5.2 Patient Ava ilability   
The site should calculate study assessment days as well as sample collecti on dates and times in 
advance of scheduling a patient’s first day of study drug administration in order  to plan 
accordingly to avoid assessment or collection requirements during non- routine clinic times such 
as weekends, holidays, etc.   
Given the schedule  of study drug administration outlined herein, and the PK sampling schedule  
(Section  7.6),  patients must be available : 
• Cycle 1 : Days 1, 2, 3 ( ± 1 day) ; Days 8, 15, and 22 (each ± 2 days) ; therefore, 
consideration should be given to scheduling Day 1  on a Monday, Tuesday , or 
Wednesday *   
• Cycles thereafter: Day 1 and Day 15 ( ± 2 days)  
• Patients must also be available at the end of cy cles to determine  whether continuation to 
the next cycle is feasible based on tolerability, and at the end of even -numbered cycles to 
evaluate disease status.  
*unless the study site has weekend hours of operation  
6.5.3 Therapy with Study Drug  
Based on their cohort assignment , patients will receive the assigned dose  of study drug by the 
route and schedule  as described below : 
6.5.3.1 Dose s to be Administered  
6.5.3.1.1 Doses to be Evaluated  
Dose cohorts will be numbered sequentially (i .e. Cohort 1, Cohort 2, etc.). The number of 
cohorts evaluated will depend upon toxicities experienced during Cycle 1 .   
Anticipated dose levels include : 
• Dose Level 1:  0.3 mg/kg  
• Dose Level 2:  1.0 mg/kg  
• Dose Level 3:  3.0 mg/kg  
• Dose Level 4:  10 mg/kg 
6.5.3.1.2 Changes in Dose to be Administered  
Once assigned to  a dose cohort , patient s will continue to be treated with study drug at that same 
dose level throughout the duration of their time on study.  There will be no intrapatient dose -
escalation.  
Dose adjustments should be made in the event of noted weight chang e (± 10% ; less at the site’s 
discretion or if required by institution procedures) at visits that require weight measurement. 
Adjustments may be made in the event of lesser incremental changes in weight and more frequently at the site's dis cretion.    
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 58 of 163 
 
 6.5.3.2 Route  of Administration  
Study drug will be administered by the IV route, via indwelling venous access catheter , utilizing 
a controlled infusion device .  
Standard i nfusion sets to be used. An additional point -of-use (0.22 micron or other) in -line filter 
is not t o be used.   
The catheter may be placed into a peripheral vein (if accessible); administration via central 
venous catheter or port (if in place) is allow ed. 
In those instances when study drug administration is associated with PK sampling, and 
administratio n is via peripheral IV catheter, infusions will be delivered into the arm contralateral 
to that from which blood samples for PK analysis are being obtained.  
6.5.3.3 Diluent and Delivery  
Commercially available sterile 5% D5W for IV infusion is to be used as the di luent.  Once 
diluted for IV administration, study drug should be administered within 8 hours.   
The IV bag containing diluted study drug is to be stored refrigerated between 2° C to 8° C (36º F 
to 46º F) and protected from direct sunlight.  Allow to warm to room temperature before 
administration to the patient.  
6.5.3.4 Volume of Infusion  
Infusions will be delivered in a final volume of  100 mL .  
6.5.3.5 Duration of Infusion  
• Cycle 1 :  Study drug will be administered over 60 minutes  (+10 minutes)   
• Cycle 2 and thereafter :  If no Grade 2 IRR is observed in ≥ two thirds of the patients in a 
cohort, a decision may be made to decrease the infusion time to 30 minutes  (+10 
minutes), as patients  within a cohort are treated in Cycle 2 and thereafter.  
Administration should be at a const ant rate using a programmable volumetric infusion pump to  
ensure accuracy of delivery (as well as integrity of PK sampling). Start and stop times of each infusion, a nd any interruptions in infusion will be recorded on the appropriate page of the 
patient’s CRF.  
Note: Any patient experiencing an infusion reaction will receive future doses at a prolonged rate, as instructed 
(Section 8.5.1 , Appendix 9 ). 
Study drug will be ad ministered over a longer period for all patients entered to the trial in the 
following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients entered to a cohort, the 
duration of infusion for subsequent patients entered to the trial will  be extended by 30 
minutes  (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient within a cohort, the duration of infusion for subsequent patients entered to the trial will be extended by 30 minutes  (or 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 59 of 163 
 
 longer, if indicated). S uch a case will also be considered to have met the protocol criteria 
for a DLT, thus requiring expansion of the cohort . 
These same criteria will be applied in the event IRRs occur on the extended infusion schedule.  
In such a case, the duration of infusion for subsequent patients entered to the trial will be further extended  by 30 minutes (or longer, if indicated).  
6.5.3.6 Schedule  
Study drug is to be administered once  Q2W on Day 1 and Day 15 of each cycle ( 4 weeks [ 28 
days] equals 1 dosing cycle) .    
EOC1 assessm ents are to be performed on C1 /D28 (± 2 days ). Subsequent cycles may be 
administered Q 2W (± 2 days) , unless further delay is required to allow for amelioration of 
toxicities  (or in the event of scheduling difficulties associated with weekends, holidays, et c.).   
6.5.4 Premedication  
Since the mechanism of action of the study drug is to stimulate the immune system, 
premedication with agents such as glucocorticoids which are immunosuppressive is to be avoided. As a result, n o premedication is required to be adminis tered prior to patient s receiving 
the first dose of study drug.  
In patients with a history of IRR s to mAbs or similar products , it is recommended that 
premedication be administered . In such cases, patients should be premedicated with a regimen 
that includ es acetaminophen  as well as an H1 (e.g. diphenhydramine/hydroxyzine) and possibly 
an H2 -antagonist  (e.g. ranitidine/famotidine).   
Should a patient experience an IRR while on study, guidelines for instituting premedication prior 
to subsequent infusions are provided ( Section  8.4.3). Guideline s for the grading and 
management of IRRs  of all severities are also provided ( Appendix 9 ). 
6.6 Cycle 1  
A minimum of 1 cycle of study drug will be adminis tered, if tolerated.  Any delays  in dosing and 
the reasons for such delays  must be documented. If an AE is the cause for dosing delay , it must 
be detailed on the Adverse Events  page of the CRF.   
Determinations regarding cohort escalation  and MTD will be based on the toxicities observed 
during this 4- week period (Cycle 1) of treatment , and the occur rence of DLTs* thought to be 
related  (i.e. possibly- related, probably- related, or related) to study drug.  
• Patients completing Cycle 1 and receiving their full pl anned doses of study drug in the 
absence of a DLT, will be considered to have tolerated the dose level they were assigned 
to receive.   
• Patients will be replaced  if they have  received < 2 full dose s of study drug plus follow -up 
through EOC1 ( C1/D28 ± 2 days ) for any reason other than a DLT, to  ensure MTD 
determination rules can be f ollowed with an adequate number of evaluable patients in any 
dose cohort .   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 60 of 163 
 
 • All treated  patients will be considered in the assessment of safety and tolerability.  
*See Section 6.8.3 and Section 6.9 
6.6.1 Rules for Dose -Escalation and Cohort Expansion   
A standard 3+3 dose -escalation design will be used , with a target toxicity level of 33.3% or less 
as determined by DLTs.   
Dose cohort s will be filled sequentially. Up to 6 patients may be treated at each dose level until 
the MTD and/or RP2D is determined. The  decision rules  for dose -escalation and cohort 
expansion are as follows:  
1. Minimum of 3 patients  will be entered to each cohort .  
• If during Cycle 1 no DLTs are encountered in any of the first 3 patients, dose -
escalation may continue to the next level when all patients have completed Cycle 
1 
• If during Cycle 1, any 1 patient experiences a DLT considered possibly- , 
probably- , or related to  study drug, the cohort will be expanded to 6 patients . If no 
DLTs are encountered in the additional 3 patients, dose -escalation may contin ue 
to the next level when all patients have completed and tolerated Cycle 1.  
• If during Cycle 1, >1 patient experiences a DLT, dose -escalation will STOP .  This 
will indicate that the MTD has been exceeded.  
2. If it is determined that a dose level is not tolera ted: 
• The previous lower dose cohort will be expanded to 6 patients (if this has not 
already been accomplished)  as a total of 6 patients must be treated before 
establishing a dose as the M TD. 
• There is also the potential to evaluate and expand a previously unplanned 
intermediate dose level between 2 established dose levels to 6 patients  to more 
fully characterize tolerability.  
3. The MTD will be the highest dose level of study drug at which no more than 1 of 6 
evaluable patients has had a DLT.  
4. Once the MTD (or maximum dose to be studied) is achieved and/or  the RP2D is 
identified , that cohor t may  be expanded up to 12 patients  to more fully evaluate safety 
and tolerability at that dose level at the Sponsor’s discretion. Should the DLT rate  equal 
or exceed 33.3% in an expanded cohort, it will be determined t hat the dose is not 
tolerated. If thi s occurs, the previous lower dose cohort  or an intermediate dose level  may  
be expanded as above.  Therefore:  
• There is potential for expansion of a lower dose cohort(s) if an initially identified MTD and/or RP2D is subsequently determined not to be tolerate d (either with 
single or repeat cycles of therapy), and  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 61 of 163 
 
 • There is potential to evaluate and expand a previously unplanned intermediate 
dose level(s) between 2 established d ose levels to more fully characterize 
tolerability.  
Note: Such action would be taken by the Sponsor (or designee)  in the event of an unacceptably 
high frequency of toxicities observed in patients treated at one dose  level  considered to be 
in marked contrast to the tolerability noted in the immediately preceding dose cohort , or if 
after rev iew of study data , a more gradual dose -escalation appears warranted.  
The RP2D may be equal to or lower than the MTD  or the MAD . The RP2D  will be selected based 
on safety data, as well as available PK , pharmacodynamic/biomarker , and other data , as applicabl e. 
6.6.2 Rules for Duration of Exposure Prior to Start of Next Patient  and Next Cohort   
Enrollment will be staggered by 2 week s between the fi rst and second patient  in each new higher 
3+3 dose level cohort . The first patient within a cohort must complete and tol erate the first dose 
of Cycle 1  including follow -up until C1/ D15 to  allow for review of clinical and laboratory 
assessments. T hereafter , patients within a cohort may be added concurrently. 
Dose -escalation and accrual to the next cohort will occur only afte r the minimum number of 
patients required for tolerability assessme nt in the current cohort have completed Cycle 1  (i.e. 3 
patients, or 6 patients in an expanded cohort) , and only after acceptable tolerance has been 
demonstrated in at least 3 of 3 or  5 of 6 patients treated in the current cohort (depending on 
cohort size) , and after consultation with the Study Safety Team . 
For all patients, EOC1 assessments are to  be performed no sooner than C1/ D28 (± 2 days) . 
6.6.3 Rules for Establishing the MTD and/or RP2D 
The MTD will be the highest dose level of study drug at which no more t han 1 of 6 evaluable 
patients has had a DLT.   
The MAD, MTD , or a dose lower than the MAD or MTD , will be identified as  the RP2D, 
provided a minimum of 6 patients have been treated at that dose, and provided acceptable tolerance has been demonstrated in at least 5 of 6 patients treated. The RP2D choice will be 
based on the MTD evaluation as well as other toxicities observe d in the study, including 
observations in later cycles of administration of study drug, as well as on PK , 
pharmacodynamic s/biomarkers, and/or other data.  
6.6.4  Rules for Stopping the Study  
The study will be stopped if the MTD is exceeded at the lowest dose leve l. 
6.7 Continued Treatment  After Cycle 1  
Upon completion of Cycle 1, in the absence of unacceptable toxicity  or documented PD , patients 
may continue to receive additional cycles of study drug, unless further delay is required to allow 
for amelioration of ongoing AEs .   
Administration of subsequent dosing cycles is allowable at t he discretion of the Investigator, 
provided the patient meets the retreatment criteria listed below.  Additional cycles should be 
initiated as soon as possible, but not longer than 2 weeks  after  the completion of the previous 
cycle, if feasible.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 62 of 163 
 
 6.7.1 Retreatment  Guidelines  
Clinical judgment will be used when determining whether it is advisable to continue a pat ient on 
to the next cycle(s) of dosing. To  start any new cycle, a patient must meet the following criteria:  
• ANC ≥  1,000 per mm3 
• Platelets ≥  75,000 per mm3 
• Any ongoing study drug- related  AE should NOT meet the criteria for DLT  
• Any ongoing study drug- related  AE should have either ameliorated to ≤ Grade 1 severity, 
returned to baseline status, or resolved, with the exc eptions  of: 
o Grade 2 alopecia,  
o Grade 2 clinical events  that are being adequately controlled with best supportive 
care (e.g. fatigue, nausea, vomiting, diarrhea) , and  
o Asymptomatic laboratory abnormalities that are considered clinically 
insignificant , clini cally uncomplicated , and/ or that are resolving spontaneously or 
with c onventional medical interventions . 
• Dosing must be delayed in patients with evidence of Grade 2 immune -mediated 
toxicities, including  (Appendix 10 ):  
o Pneumonitis, myocarditis, adrenal insufficiency, encephalitis, nephritis /renal 
dysfunction (serum creatinine elevation), episcleritis /uveitis /iritis 
o Colitis, hypophysitis, hyperglycemia, inflammatory arthritis, myositis, rash  
o Hepatitis (transaminitis,  total bilirubin elevation)  
Note:  Patients may receive standard doses of replacement hormonal therapy for adrenal insufficiency, 
hypothyroidism, or other endocrine end -organ failure, and may resume study drug once considered 
by the Investigator to be stab le on such therapy.   
Should above criteri a not be met, dosing must  be delayed  until further evaluation is completed , 
and it is determine d that the patient is eligible for continued treatment.  
6.7.2 Doses and Regimens  
For a given patient, subsequent cycles of t herapy with study drug will be administered at the 
same dose level* and infusion duration established for the patient, and on the same Q2W 
schedule.  
* unless a dose adjustment is necessary due to ± 10% fluctuation in patient weight ( less at the site’s disc retion or if 
required by institution procedures )  
6.7.3 Evaluation Schedules  
The same evaluations required during Cycle 1 of the study will be conducted during subsequent cycles, at the frequencies indicated ( Section  7). 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 63 of 163 
 
 6.7.4 Duration of Treatment  
Additional cycles of study drug may continue to be administered if tolerated and in the absence 
of documented PD , at the Investigator’s discretion, provided retreatment  criteria have been met 
(Section 6.7.1) .   
Such extended therapy will continue for a period of up to 12 months  after achieving the “best 
response,” at which time the Medical Monitor (s) and Investigator will discuss the advisability of 
continued therapy based upon the patie nt’s ongoing response stat us and the degree of 
demonstrated tolerability.  Patients who stop therapy with an ongoing OR or prolonged SD may 
be retreated in the event of relapse, if the trial is still open  (Section 6.7.6).  
6.7.5 Continued Treatment after Radiologic Disease Progression  
Immunotherapeutic agents may produce antitumor effects that can manifest as response after 
initial evidence of PD, a phenomenon referred to as “pseudopr ogression”  (PSPD) . 
Patients will be p ermitted to continue treatment beyond initial RECIST v1.1 (or RECIL  2017) 
defined PD while waiting for confirmation of PD, provided they are clinically stable as defined by the following criteria (per i RECIST ): 
• Investig ator-assessed clinical benefit and ab sence of rapid disease progression 
• Tolerating study drug  
• Stable PS  
• Absence of progressive tumor at critical anatomical sites (e.g. cord compression) requiring urgent alternative medical intervention. 
6.7.6 Retreatment Following an Objective Response  
Treatment wi th study drug may be restarted in a patient who previously achieved a documented 
OR or prolonged SD (>  16 weeks) on this study, stopped  treatment,  and subsequently progresses . 
Such action may be taken  at the Investigator’s discretion, following discussion with the Medical 
Monitor (s), provided retreatment criteria are met , no anti -cancer treatment was administered 
since the last dose of study drug, and the trial is still open .   
This option for retreatm ent does not  apply to patients who previously experience d an 
unacceptable toxicity that required permanent discontinuation of study drug ( Section 9.1). 
Retreatment with study drug may be initiated at the same dose and infusion duration established 
for that patient during their previous course of treatment, and on the same schedule.  
The same evaluations required during previous treatment will be conducted during subsequent 
cycles, at the frequencies indicated.  
Retreatment cycles of study drug may continue to be admini stered if tolerated and in the absence 
of further PD , at the Investigator’s discretion, as long as retreatment criteria continue to be met.  
6.8 Adverse Events and Dose -Limiting Toxicit ies 
6.8.1 Adverse Event  Grading  
For reported AE s, the CTCAE v5.0* will be used to grade the severity or the AE . 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 64 of 163 
 
 *See < https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm > 
6.8.2 Management of D ose-Limiting Toxicitie s and Other Toxici ties 
If a significant toxicity thought to be related to study drug is experienced at any point during the 
patient’s participation in the study, the Investigator will determine:   
• Whether that toxicity is dose -limiting ( Section 6.8.3 ), thus requiring either 
discontinuation from study, or the patient  may continue if there is evidence of response or 
other clinical benefit, but  dosing must be delayed and the patient  may not  be retreated 
until retreatment criteria are met.   
Patients experiencing certain immune -mediated toxicities may not  be retreated an d will 
be discontinued from further participation ( Section 9.1) 
• Whether the toxicity does not meet the protocol definition of DLT, but nevertheless 
warrants dose modification, in which case the Investigator may elect to temporarily delay  
dosing with study drug to  allow fo r amelioration of the toxicity .   
For additional information on toxicity management and dose modification, see Section 8.  
6.8.3 Definition of D ose-Limiting T oxicity 
Any of the following toxicities  occurring during Cycle 1, if judged to be related to  study drug 
(i.e. possibly- related, probably -related, or related), wi ll be considered a DLT for the purposes of 
this trial.   
1. ≥ Grade 3  evidence of any of the following immune -mediated toxicities (patient must be 
permanently discontinued):  
• Pneumonitis  
• Myocarditis  
• Adrenal insufficiency  
• Encephalitis  
• Nephritis, renal dysfuncti on (serum creatinine elevation)  
• Episcleritis, uveitis, or  iritis  
2. ≥ Grade 3  evidence of any of the following immune -mediated toxicities (if > Grade 3, 
patient must be permanently discontinued):  
• Colitis  
• Hypophysitis, hyperglycemia  
• Inflammatory arthritis  
• Myositis  
• Rash  
3. ≥ Grade 2:  
• Uveitis, eye pain or blurred vision that does not resolve with topical therapy within 2 weeks  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 65 of 163 
 
 • AEs that are prolonged excessively based upon the medical judgment of the 
investigator, and/or lead to permanent discontinuation of the study drug due to poor tolerance  
• Immune -mediated toxicity tha t requires use of glucocorticoids at a dose of ≥ 1 
mg/kg/day of prednisone equivalents for treatment of the toxicity  
4. Hepat ic-related findings consistent with Hy’s Law criteria : 
• AST and/or ALT el evation > 3 × ULN (or > 3 × baseline if elevated at study ent ry 
due to hepatic involvement by tumor ), with  
• Total bilirubin ≥  2 × ULN without initial findings of cholestasis (i.e. serum 
alkaline phosphatase [ALP]  < 2 × ULN ), and  
• No explanation for the above findings such as viral hepatic injury, preexisting or 
acute liver disease, or another drug or condition capable of causing the observed 
liver injury  
5. Any other ≥  Grade 3  non-hematologic toxicity regardless of duration, with the exceptions  
of:  
• Grade 3 fat igue 
• Grade 3 nausea, vomiting, or diarrhea lasting ≤  2 days  with best supportive care   
• Grade 3  asymptomatic electrolyte abnormalities lasting ≤  3 days  that are not 
clinically complicated, and resolve spontaneously or respond to conventional medical interventions  
• Other Grade 3 asymptomatic laboratory abnormalities t hat are clinically non -
significant in the investigator’s opinion, and that resolve sponta neously or with 
conventional medical interventions  
6. Neutropenia that is:  
• Grade 3  meeting the CTCA E v5.0 criteria for febrile neutropenia ( ANC < 1000 
per mm3 and a singl e temperature > 38.3ºC  [101ºF] or sustained temperature >  
38ºC [100.4ºF] for > 1 hour ) 
• Grade 4  
7. Thrombocytopenia  that is :  
• Grade 3 with CS hemorrhage  or requirement for transfusion  
• Grade 4  (platelets < 25,000 per mm3)  
8. Anemia that is Grade 4 and not explai ned by underlying disease  
9. Any death where a relationship to study drug cannot be ruled out  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 66 of 163 
 
 10. Inability to complete Cycle 1  at the assigned dose  (i.e. receipt of < 2 full planned dose s of 
study drug plus 2 weeks  of follow -up) due to ≥  Grade 3  toxicity  
11. Treatment delays > 2 weeks  from the scheduled next dose during Cycle 1  or the initiation 
of Cycle 2 due to Grade 2 toxicity  that has occurred in Cycle 1  
Other toxicities may be considered a DLT as determined by the Investigator in conjunction 
with the Study Safet y Team . 
The above criteria will be used to make individual patient determinations regarding dose delays  
or discontinuation throughout the course of the trial ; however, only those DLTs occurring 
during Cycle 1  will be used to make decisions  regarding  cohort  dose -escalation and 
tolerability.   
Events occurring after Cycle 1 will also be evaluated by the Study Safety Team and taken into consideration when deciding upon further doses to be assessed as well as to establish the RP2D.  
6.9 Definition of Maximum Tolerate d Dose  
MTD will be defined as the dose below that which produces, during Cycle 1 of treatment, any of 
the indicated DLTs either in > 1 patient in a 3 to 6 patient cohort, or in ≥  33.3% of patients in the 
event of an expanded 7 to 12 patient  cohort .  
The MTD will not be established until all patients in the cohort under evaluation have either 
completed Cycle 1  or discontinued further participation in the trial  due to the occurrenc e of a 
DLT.   
Previously established tolerability of a dose lev el will be reevaluated if DLTs thought to be 
possibly- , probably- , or related to study drug are observed in later cycles  or in the event of 
expansion of a cohort to > 6 patients . 
6.10 Review of Safe ty Data During Study  
Clinical and laboratory safety data will be reviewed on an ongoing basis throughout the study by 
the Investigator s and Sponsor’s Representative(s) so that  decisions regarding the advisability of 
continuing accrual to a dose cohort, and/or escalating the dose and allowing accrual to a higher 
dose cohort  may be made . In addition, patients will be carefully evaluated for evidence of 
potential cumulative and/or delayed toxicities throughout the duration of their time on study.   
To do so, S AEs, immune -related AEs of significance,  AEs resulting in  permanent 
discontinuation from study ( regardless of seriousness or relationship to study drug), DLTs , IRRs , 
and dosing delays  will be promptly reported to the Sponsor (or designee) . 
A Study Safety T eam will be established and will be comprised of the Investigator(s) and the 
Sponsor’s Medical Representative(s). Biwe ekly Study S afety Team T eleconferences will be held 
to discuss ongoing patient status and any emerging safety concerns ; frequency of teleconferences 
may fluctuate  based on accrual and study activity, as indicated ( Section 12.1) .  
6.11 Duration of Study Follow -Up 
Upon discontinuation of a patient from further treat ment with study drug, every effort will  be 
made to conduct follow -up assessments as detailed below.    
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 67 of 163 
 
 For patients continuing to another therapy, the expectation is that Investigators will show due 
diligence in obtaining adequate follow -up for this study, as indicated. In the event of ongoing 
toxicities, Investigators will do their best to continue patient follow -up, based on both patient 
availability and Investigator ability to determine the etiology of noted toxicities within the context of initiation of  any new therapy  (i.e. whether the findi ng is due to study drug or due to 
the other therapy) .   
• End of Treatment  (EOT) evaluations will be conducted within approximately 10 days  
following treatment discontinuation , or before initiation of a new treatment, whichever 
occur s first .   
• 1-Month Follow -up (1M FUP ) evaluations will be conducted approximately 30 days  (+7 
days) following the last dose of study drug.  
Note: The 1M FUP evaluation should be conducted ≥  30 days  following the last dose of study drug a s all 
patients are to be followed for a minimum of 30 days after study drug discontinuation to  monitor 
for the occurrence of suspected AEs that are both serious and unexpected .      
• Long- Term Follow -up (FUP) for Safety :  If an observed toxicity (non- immune -mediated) 
thought to be related to study drug has not resolved by the 1M FUP  evaluation, an 
additional FUP  AE assessment will be conducted  approximately 2 months  (may be 
repeated at 4 months  if needed) following the last dose of study drug, if feasible,  to 
confirm that the event has either resolved, returned to baseline status, or been adequately 
explained  and assessed by the Investigator as chronic and/or stable , and that no long- term 
deleterious effects have become evident *      
Since late- occurring immune -mediated toxicities have been reported to occur several 
weeks to months after treatment with other immune checkpoint inhibitors, long- term 
surveillance for such toxicities will be conducted in this study. Patients will be followed at approxim ately 2 -month intervals following the last dose of study drug for up to 6 
months  to assess for the onset of any post -therapy immune -mediated event thought to be 
related to study drug.*  
Any patient who develops an immune -mediated toxicity during study, or during the 6-
month post -therapy FUP period, will be followed at approximately 2- month intervals 
following the last dose of study drug for up to 2 years  to assess the course of the 
condition and evaluate potential revers ibility of the finding.* 
*Investigator discretion may be used with respect to the method of contact for this AE assessment; clinical 
events may be followed in writing or by telephone ; an in-person visit will not be required.  
• Long- Term FUP for Response : In the event  of an  ongoing OR  or SD  at the EOT , 
response assessments  based imaging studies (as indicated by disease type) will continue 
to be performed every 2 months  following the last dose of study drug, until confirmed PD  
or another therapeutic intervention is initiated,  so that data may be collected on the 
duration of SD  or OR , as well as disease progression *   
*To continue at the intervals specified until disease progression or another therapeutic intervention is 
initiated , or until the end of trial ; documentation may be submitted in writing  or by e -mail, an in- person 
visit will not be required.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 68 of 163 
 
 6.12 Concurrent Treatments and Supportive Care  
Therapy for other ongoing medical conditions, as well as palliative and supportive care for the 
underlying malignancy wil l be provided prior to and during this trial, as clinically indicated, and 
in accordance with the standard practices of the institution, except as stipulated by study 
eligibility  criteria ( Section 4.3.2).  
Other therapies allowed during the conduct of this trial include:  
1. Prophylaxis for IRRs and Study Drug- Related Toxicities : Patients with a history of IRRs 
to mAbs  or similar products , and patients who experience IRRs while on study, should 
receive premedication w ith standard therapies as defined herein prior to each dose of 
study drug to  reduce the risk of such events. Patients experiencing other study drug-
related reactions  may be premedicated with standard therapies to  reduce the potential for 
such reactions in the future  (Section 8.4). 
 
2. Treatment of Study Drug -Related AEs  or Concurrent Diseases : Clinical judgment should 
be used in the treatment of any treatment- related AEs or concurrent disease s that occurs 
during the  study and follow -up period.   
 
3. Blood Products and Growth Factors : Prophylactic hematopoietic growth factors should 
not be administered during Cycle 1 of study; thereafter prophylactic use of growth factors 
is allowed as clinically indicated. Interventiona l/therapeutic use of growth factors is 
allowed during study, including Cycle 1, if deemed necessary by the Investigator.  Growth factor use must be consistent with product package insert instructions. 
 
4. Radiotherapy: Radiotherapy for pain control against non- target lesions, provided it does 
not influence BM  function.  Such treatment should be discussed with the Sponsor’s 
Medical Monitor(s).  
5. Bisphosphonates and denosumab : Bisphosphonates and denosumab for bone metastase s 
and other skeletal conditions  are allo wed, provided the patient is on a stable dose for at 
least 2 months prior to study start and remains  on the stable dose while receiving study 
treatment.  
 
6. Immunosuppressive or systemic hormonal therapy not exceeding  10 mg daily prednisone 
equivalent, as wel l as: 
• Hormonal therapy for appetite stimulation (e.g. Megace)  
• Nasal, ophthalmic, inhaled, and topical glucocorticoid preparations  
• Hormone replacement therapy at standard doses for end- organ failure  
• Stable hormonal therapy for prostate carcinoma*  
• Stable hor monal therapy for ovarian suppression, hormonal contraceptive therapy, 
or post -menopausal HRT* 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 69 of 163 
 
 • Steroid therapy for contrast reaction prophylaxis  
• Intra -articular steroid injections  
• Low-dose maintenance steroid therapy  for other conditions (e.g. asthma 
exacerbation, stable steroid therapy [excluding tapering dose of steroids] for brain 
edema/metastases/radiation)  
• Higher dose steroid therapy for treatment of an acute intercurrent illness (e .g. 
immune -related AEs or other adverse conditions) in patients with SD  or an 
ongoing response. In such situations study drug treatment should be interrupted for the duration of immunosuppressive therapy.  
*Concomitant therapies are permitted;  however, patients must have been on a stable dose for at least 6 
months  prior to stu dy start, and if continuing must remain on the stable dose while receiving study 
treatment (i.e. such treatment will not be considered as systemic hormonal therapy for the  purpose of study 
eligibility).  
Information on all concomitant therapies administered , as well as other interventions or 
procedures occurring during the trial period, must be recorded on the appropriate page of the 
patient’s CRF.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 70 of 163 
 
 7 STUDY ASSESSMENTS    
All pa tients will be assessed by scheduled clinical, laboratory, and other diagnostic asses sments 
throughout the study. All efforts should be made to perform assessments as close as possible to 
the scheduled timepoints. The projection of visit days within each c ycle should be made from 
Day 1 of the respective cycle. Visit windows are provided be low. Study assessments are to be 
performed as follows:  
• Screening  evaluations  are to be performed within 14 days  prior to first study drug dose , 
unless otherwise specified ( for exceptions see Section  7.2.7.6, Section  7.3, Section  7.4).   
• The day of first administration  of study drug will be considered Day 1  of study.   
• C1/D3  evaluations may be conducted +1 day.  
• On-study evalu ations  (including laboratory assessments) are to be performed  on or about 
the indicated study day ( i.e. ±  2 working days)  (a slightly longer allowance for routine 
assessments is permissible in the event of scheduling difficulties associated with weekends, holidays, etc .).   
• End of Cycle  assessments may be conducted at any time during the week prior to Day 1 
of the next cycle, including on Day 1 of the next cycle , prior to dosing. 
• EOT * evaluation s are to be performed within approximately 10 days  following tr eatment  
discontinuation, or before initiation of a new treatment, whichever occurs  first.   
• 1M FUP * evaluations  are to be performed  approximately  30 days  (+7 days) following the 
last dose of study drug ( i.e. as all patients are to be followed for a minimum  of 30 days 
after study drug discontinuation to  monitor for the occurrence of AEs ). 
Note:  When a patient discontinues treatment with study drug , for any reason, every effort will be made 
to collect routine E OT evaluations as well as subsequent 1M FUP evaluations, per protocol, until 
all protocol -specified assessments have been conducted .   
If during the study, significant changes from baseline are noted, additional monitoring or on-
study assessments may be undertaken by the Investigator, or requested by the Sponsor (or 
designee), to  determine both the relevance of the finding(s) and the duration of t he event(s).  
Refer to Appendix 11  and Appendix 12  for the maximum total blo od collection volumes and 
the schedule of assessments, respectively.  
7.1 Consent and Medical History  
7.1.1 Signing of Informed Consent /Assessment of Eligibility  
• Screening  
Note:  All patients must sign an IRB /EC-approved informed conse nt form  (ICF) prior to enrollmen t and prior 
to submitting to any protocol -related procedure, unless such testing was performed previously as part 
of the routine clinical management of the patient.  Disease evaluations ( e.g. computed tomography [ CT] 
scan, magnetic resonance imaging [ MRI] ) performed as part of standard of care and obtained prior to 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 71 of 163 
 
 patient consent for this trial may be allowed as screening evaluations if conducted within 28 days  (+2) 
prior to the first study drug dose.  A copy of the f ully executed ICF will be given to the pa tient.    
7.1.2 Demography  
(To include date of birth, sex, race, and ethnicity)  
• Screening  
7.1.3 Past Medical History  
(To include prior and ongoing medical illnesses and conditions, prior surgical procedures 
[not related to the primary diagnosis])  
• Screening  
• C1/D1 (pri or to dosing)  
7.1.4 History of the Primary Malignancy  
(To include details of the primary malignancy, including:  diagnosis and histological/  
cytological classification;  date of initial diagnosis; date metastatic disease is identified;  
stage of disease at entry ; current sites of metastases; prior surgical procedures for the 
malignancy  and dates ; prior antineoplastic t herapy ; prior radiation therapy ; dates of 
treatments, numbers of cycles, and best response to each  therapy ; and date of most recent 
disease progres sion)  
• Screening  
7.2 Safety Assessments (1)  
(To be performed within 14 days  prior to first dose of study drug unless otherwise specified)  
7.2.1 Medication and Procedure Surve ys  
(To include all medications taken other than study drug and all procedures performed duri ng 
trial. For medications: Include name, indication for use, route of administration, start and stop dates or if ongoing at 1M FUP Visit. For procedures: Include date and reason for 
procedure. C orresponding illness or condition must appear  on the Medical H istory  or 
Adverse Event  pages of the CRF , as appropriate ) 
• Prior Medication /Procedure Surveys  
o Screening (to assess eligibility)  
o For 14 days  prior to first study drug dose   
• Concomitant Medication /Procedure  Survey s  
o Throughout the study 
o For 30 days  following last study drug dose  
7.2.2 Adverse Event  Reporting  
• Starting from signing of i nformed c onsent *  
• Throughout the study 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 72 of 163 
 
 • For 30 days  following last study drug dose   
• Long- Term FUP  for Safety  
o For AEs (non -immune -mediated) ongoing at the 1M FUP  
 For 2 to 4 months follow ing last study drug dose, if events related to study drug 
persist**#   
o For immune -mediated toxicity surveillance following 1M FUP  
 For up to 6 months (at 2- month intervals) following the last study drug dose, to 
assess for delayed on set of immune -related to xicity***# 
o For immune -mediated toxicity ongoing at the 1M FUP, and for delayed onset 
immune -mediated toxicity noted in the initial 6 -month FUP period  
 For up to 2 years (at 2 -month intervals) following the last study drug dose***#   
• As clinically indicated  
*To detail any symptoms that may be present prior to first study drug dose .  Patients who sign informed 
consent and are subsequently deemed to be screen failures will be followed for the occurrence of SAEs/AEs 
until it is determined that they will not be p articipating in the trial.  
**To confirm that events have resolved, returned to baseline status, or been adequately explained.   
*** Patients will be followed to assess for the onset of any post -therapy immune -mediated even t thought to be 
related to study drug. Any patient who develops an immune -mediated toxicity during study, or during the 6-
month post -therapy FUP period,  will be followed to assess the course of the disease and evaluate potential 
reversibility of the findin g.     
#Investigator discretion may be used with respect to the method of contact  for this AE assessment ; clinical 
events may be followed in writing or by telep hone; an in -person visit will not be required.  
7.2.3 Dose-Limiting T oxicity Assessment  
(To include det ails about AEs meeting DLT criteri a; Section 6.8.3)  
• Starting from first dose of study drug (C1/ D1) 
• Through EOC1 (C1/ D28 ± 2 days)  
7.2.4 Performance Status Evaluation  
(To be assessed by ECOG  score ; Appendix 1)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to dosing)*  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated  
*Need not be assessed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 73 of 163 
 
 7.2.5 Vital Signs   
(Vital signs  [VS]  to include temperature, pulse, respiratory rate, blood pressure  [BP] , and 
oxygen saturation by pulse oximetry ) 
• Screening  
• Cycle 1  
o Day 1  
 Prior to SOI 
 End of infusion ( EOI) (± 5 min)  
 2, 4, 8 hours * after EOI ( ± 15 min)  
o Day 2  
o Day 3 (+ 1 day)  
o Day 15  
 Prior to SOI 
 EOI ( ± 5 min)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT  
• 1M FUP  
• As clinically indicated  
*Comprehensive assessment of VS  is critical to the conduct of this study. In situations where an assessment at 8  
hours after EOI is logistically difficult due to clinic staff availability, the observation period may be shortened, 
and an "end of day" assessment may be obtaine d at the latest practical time .  Such an option (if to be routinely 
employed) is available only after discussion with and approval by the Sponsor . 
7.2.6 Physical Examination  
(Complete at screening  including height, weight, general appearance, skin, head, eyes, ears, 
nose, throat, neck/thyroid, chest  [includes pulmonary assessment, breasts] , cardiovascular 
[includes heart,  peripheral pulses]  abdomen, mus culoskeletal system, lymph nodes, 
neurologic and mental status ; directed thereafter , must include weight** and pulmonary and 
cardiac assessment s*** at each physical exam ) 
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
• Each cycle thereaf ter 
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated  
* Need not be assessed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 74 of 163 
 
 ** Dose adjustments may be made in the event of noted weight change ( ± 10% [less at the site’s discretion or if 
required by institution procedures] ).   
*** Pulmonary and cardiac findings will be evaluated in detail at each visit by the Principal Investigator (or 
physician designee); evaluation to include review of pulmonary symptoms including but not limited t o: cough, 
sputum production, hemoptysis, wheezing,  dyspnea, dyspnea  on exertion, chest pain, and/or chest pain 
associated with respirations , as well as review of cardiac symptoms including but not limited to chest pain, 
orthopnea, nocturia, edema, and palpitations  
7.2.7 Laboratory Assessments and Pregnancy Tes t 
All routine laboratory analyses will be performed at a laboratory facility local to the trial site.  
Sponsor (or designee)  must be provided with trial site laboratory normal ranges for all 
required parameters prior to screening of the first patient at th e site. Likewise, any change in 
laboratory normal ranges during the trial should be forwarded to the Sponsor (or designee)  
promptly during the trial. 
Blood samples will be taken at the scheduled visits and analyzed for the following 
parameters as clinically indicated  (Table 2 , Appendix 12 ). Results must be available and 
assessed prior to dosing of study drug, when sampling is  scheduled on days of dosing. 
Table 2:  Schedule of Safety Blood and Urine Sampling  
Sample Analysis  Screening  Cycle 1  Cycles 
Thereafter  EOT  1M 
FUP  
D1 D3 
D8 D15 D22 D1 D15   
Hematology Panel  X X1 X X X X X X X 
Biochemistry Panel  X X1 X X X X X X X 
Coagulation Panel  X X1  X  X  X X 
Thyroid Function Tests  X X1    X  X X 
Urinalysis  X X1  X  X  X X 
Pregnancy Test  X X      X  
Abbreviations (in alphabetical order): D, day; EOT, end of treatment; 1M FUP, 1-month follow-up 
1) Does not need to be performed prior to C1/D1, if performed during screening ≤7 days from C1/D1  
7.2.7.1 Hematology Panel   
(To include complete blood count [CBC] with hemoglobin, hematocrit, differential, ANC,  
and platelet count)  
• Screening  
• Cycle 1  
o Day 1 ( within ≤ 7 working days prior to  dosing)*  
o Day 3 (+1 day)  
o Day 8  
o Day 15 (prior to dosing)  
o Day 22  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 75 of 163 
 
 o Day 15 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated**   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
**In the event of hematologic toxicity, the evaluation frequency should be increased to include additional 
evaluations between the scheduled assessments, as clinically indicated.  
7.2.7.2 Bioc hemistry Panel   
(Fasting not required; t o include sodium [ Na], potassium [ K], chloride [ Cl], bicarbonate  
or carbon dioxide , blood urea nitrogen [ BUN ], creatinine, glucose, bilirubin [total and 
direct], AST, ALT, ALP, calcium [ Ca], magnesium [ Mg], phosphorus , albumin, total 
protein, uric acid, amylase, l ipase, and creatine kinase [CK] ***)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
o Day 3 (+ 1 day)  
o Day 8  
o Day 15 (prior to dosing)  
o Day 22  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
o Day 15 (prior to dosing)  
• EOT   
• 1M FUP  
• As clinically indicated **   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
**In the event of significant serum chemistry abnormalities, the evaluation frequency should be increased 
to include additional evaluations between the scheduled assessments, as clinically indicated.   CS 
electrol yte abnormalities should be corrected prior to dosing.  
***In the event of CK abnormalities while on study , please perform isoenzyme analysis  (to include at 
minimum CK -MB); in the event of ECG abnormalities while on study, please perform isoenzyme analysis 
(to include at minimum CK -MB), serial troponins, and measurement of brain natriuretic peptide (BNP)  
7.2.7.3 Coagulation Pa nel 
(To include PTT  [or aPTT] , PT and/or  INR)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
o Day 15 (prior to dosing)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 76 of 163 
 
 • Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP   
• As clinically indicated   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
7.2.7.4 Thyroid Fun ction Tests  
(To include measurement of thyroid stimulating hormone [TSH], free triiodothyronine 
[fT3], and free thyroxine  [fT4]) 
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT  
• 1M FUP  
• As clinically indicated   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
7.2.7.5 Urinalys is   
(Multi- panel chemical test strips are acceptable and should include assessment of 
specific gravity, pH, protein, glucose, ketones, l eukocytes,  nitrite, bilirubin, urobilinogen, 
and blood. M icroscopic examination of sediment , if clinically indicated,  to include 
assessment of cells [white blood cells {WBC } per high power field {HPF } and red blood 
cells { RBC } per HPF ] and casts ) 
• Screening  
• Cycle 1  
o Day 1 (within ≤ 7 working days prior to  dosing)*  
o Day 15 (prior to dosing)  
• Each cycle thereafter  
o Day 1 (prior to dosing)  
• EOT   
• 1M FUP   
• As clinically indicated   
*Need not be performed prior to the first dose of Cycle 1 if ≤ 7 days since screening  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 77 of 163 
 
 7.2.7.6 Pregnancy T esting  
(Beta-human chorionic gonadotropin [β -hCG] in WOCBP; serum at screening, serum or 
urine thereafter; negative test must be confirmed within 2 working days  prior to first dose 
of study drug)  
• Screening  
• Cycle 1  
o Day 1 (within ≤ 2 working days prior to  dosing)  
• EOT  
• As clinically indicated  
7.2.8 Electrocardiogram   
(To include standard 12- lead ECG with measurement of PR interval, QRS duration, QT 
interval, and QTc interval [msec], as well as HR [ beats per minute {BPM }]) 
(To be e valuated locally; t o be performed af ter patient has been supine for ≥ 10 minutes ) 
(Repeat subsequent timepoints in triplicate separated by 5 minutes for 4 cycles in patients 
with a  Cycle 1  QTc  interval that is either: a)  >500 msec ; b) increased  by 60 msec over 
baseline *; or c) decrease d by 2 0 msec below baseline *) (If abnormal ities suggest new 
evidence of myocardial ischemia,  perform isoenzyme analysis [to include at minimum CK -
MB], serial troponins, and measurement of BNP ) 
• Screening  
• Cycle 1   
o Day 1  
 Prior to SOI  
 EOI (+ 15 min)  
• Cycle 2  
o Day 1  
 Prior to SOI 
 EOI (+ 1 5 min)  
• Subsequent 4 cycles , if QTc interval abnormalities are observed during Cycle 1 or 2   
o Day 1  
 Prior to SOI  (in triplicate)  
 EOI (+ 15 min)  (in triplicate)  
• EOT  
• As clinically indicated ** 
*When evaluati ng QTc interval, baseline should be considered the ECG immediate preceding the start of  study 
drug infusion on the day of assessment.   
**In the event of significant electrolyte abnormalities, the evaluation frequency should be increased to include 
additional evaluations between the scheduled assessments, as c linically indicated.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 78 of 163 
 
 7.3 Safety Assessments (2)  
(Results from assessments previously performed  as standard of  care within 28 days  [+2 days] 
prior to first dose of study drug may be utilized , provided no antineoplastic therapy has been 
delivered between assessment and first dose of study drug; otherwise within 14 days of first  
dose) 
7.3.1 Multi-Gated Acquisition  Scan or Echocardiogram  
(For measurement of LVEF; to be performed ONLY in patients with a history of CHF; 
individual patients should be followed  with the same testing procedure throughout the study)    
• Screening  
• EOT  
• As clinically indicated  
7.3.2 Ophthalmology Examination  
(To include funduscopic and slit lamp evaluation s for assessment of retinal and corneal 
integrity , visual acuity , and any othe r noted ocular abnormality ) 
• Screening  
• EOC2  and every even -numbered cycle thereafter *, ** 
• EOT**  
• As clinically indicated  
*End of Cycle assessments may be conducted at any time during the week prior to Day 1 of the next cycle , 
including on Day 1 of the next c ycle, prior to dosing.  
**May be combined if patient discontinues treatment at the end of an even -numbered cycle 
7.3.3 Pulmonary Function Test s 
(To include spirometry and diffusing capacity  of carbon monoxide  [DL CO] to assess for 
evidence of pulmonary fibrosis . Spirometry assessments to include at minimum: forced vital 
capacity [FVC], forced expiratory volume in 1 second [FEV1], functional residual capacity [FRC], residual volume [RV ], and total lung capacity [TLC] ) 
• Screening  
• EOT  
• As clinically indicated * 
*To be re peated if evidence of interstitial pneumonitis, pulmonary fibrosis or other potential evidence of drug-
related pulmonary toxicity is documented on imaging studies or if pulmonary symptomatology indicates  
7.4 Disease Assessment s  
(Screening disease assessments to be performed within 28 days  [+2 days ] prior to first dose of 
study drug)   
Standard response criteria will be applied for disease assessments and response evaluations (RECIST v1.1, Appendix 5 ; iRECIST,  Appendix 6 ; and RECIL  2017, Appendix 7 ).  
Assessments should be performed at the intervals specified and in the event of suspected PD.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 79 of 163 
 
 If PD  and/or initiation of another therapeutic  intervention is documented at any time , no further 
disease assessments will be required. Patients with confirmed PD will be discontinued from 
further treatment with study drug so that alternative management of their malignancy may be considered.  
Duration of OR to be measured from date initial response is observed to date PD is confirmed .  
To be assigned a status of partial response (PR) or complete response (CR), changes in disease status must be confirmed by repeat studies performed 4 weeks  (+7 days) afte r the criteria for 
response are first met. In the case of SD, follow -up measurements must have met the SD criteria  
at least twice after study entry for a minimum duration in general not less than 16 weeks .   
In the event of an ongoing OR or SD at the EOT, data will continue to be collected on the 
duration of OR or SD, as well as on disease progression . 
7.4.1 Tumor Marker Measurement   
(As indicated by  tumor type)  
• Screening  
• EOC 2 and every even -number ed cycle thereafter * 
• At least 4 weeks  following documentation of a n OR  
• EOT  (if > 6 weeks since previous assessment)  
• 1M FUP (if PD was not confirmed before or at EOT)  
• Long- Term FUP for Response ** (in the event of an ongoing OR  or SD  at EOT)  
o Every 2 months  
7.4.2 Diagnostic Imaging for Assessment of Disease (and Pulmonary Status )  
The same method(s) of disease evaluation and the same technique should be used throughout the study.  
All patients : To include diagnostic imaging by CT or MRI of the chest with each evaluation 
(for disease evaluation where indicated, and to assess for e vidence of pulmonary fibrosis) 
plus abdomen and pelvis, and other sites as indicated based on tumor type and clinical judgment to  assess the status of the underlying malignancy. Use of contrast is preferred but 
is at the discretion of the Investigator, as med ically indicated.  
Lymphoma patients : In addition to above, patients will be followed as indicated and per 
Investigator discretion  by: fluorodeoxyglucos e-positron emission tomography ( FDG -PET), 
X-ray, ultrasound (U/S), and/or BM aspiration/biopsy  (Bx) . 
For all imaging timepoints, the following will be recorded as per RECIST v1.1 (or other response criteria, as indicated) : target lesions including size, location, and type (nodal/non-
nodal); sum of diameters of target lesions; any new lesions noted during trial, including size, location, and type (nodal/non- nodal ). 
• Screening  
• EOC 2 and every even -number ed cycle thereafter * 
• At least 4 weeks  following documentation of an OR  
• EOT  (if > 6 weeks since previous assessment)  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 80 of 163 
 
 • 1M FUP (if PD was not confirmed before or a t EOT)  
• Long- Term FUP for Response ** (in the event of an ongoing OR  or SD  at EOT)  
o Every 2 months  
Imaging data (imaging studies and derived assessments) will be stored according to usual 
practice by the sites and will be available upon request for potential  review by the Sponsor 
or an independent radiology reviewer.  
7.4.3 Response Assessment  
(To be assessed by the Investigator  or qualified designee  as per RECIST v1.1 [or other 
response criteria, as indi cated]; to be noted at each evaluation point as CR, PR, SD, P D, or 
Not Evaluable [NE])  
• EOC 2 and every even -numbered cycle thereafter*  
• At least 4 weeks  following documentation of an OR  
• EOT  (if > 6 weeks since previous assessment)  
• 1M FUP (if PD was not confirmed before or at EOT)  
• Long- Term FUP for Response ** (in the e vent of an ongoing OR or SD at EOT ) 
o Every 2 months  
*End of Cycle assessments may be conducted at any time during the week pri or to Day 1 of the next cycle, including 
on Day 1 of the next cycle,  prior to dosing.  
** To continue at the intervals specified until disease progression or another therapeutic intervention is initiated, or 
until the end of trial; documentation may be submitted in writing, an in- person visit will not be required . 
7.5 Immunogenicity  Assessment  
To assess formation of anti-drug antibody ( ADA ).  All samples must be taken prior to the study 
drug infusion of that visit. Analysis of ADA and re sidual serum levels of study drug will be 
performed at a central laboratory. A detailed laboratory manual specifying sample collection, 
handling, storage, and shipment will be provided to the trial sites ; retention time for specimens 
will be specified ther ein. If a collected serum sample is inadequate or insufficient for ADA 
analysis, the analysis of ADA can be done using a PK serum sample from the same time point, if 
available.  
7.5.1 Peripheral Blood for Immunogenicity Assessment (Specialty Lab)  
(To assess the potential immunogenicity of study drug; serum  to be isolated)  
ADA samples will be taken according to the schedule shown ( Table 3 ; Appendix 12 ). 
Note: Whole blood (~ 5 mL) to be collected in serum acquisition tubes at each of the indicated timepoints.   
7.6 Pharmacokinetic Assessment s  
Every effort will be made to collect PK sample s at the timepoints specified.  Sampling times may 
be adjusted according to early trial results to  optimize evaluation. No additional samples will be 
collected without form al amendment to this protocol. Analys is will be perf ormed at a central 
laboratory. A  detailed laboratory manual specifying sample collection, handling, storage, and 
shipment will be provided to the trial sites ; retention time for specimens will be specified therein .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 81 of 163 
 
 If a collected serum samp le is inadequate or insufficient for PK analysi s, the analysis of PK can 
be done using an ADA serum sample from the same timepoint, if available. 
7.6.1 Peripheral Blood for Pharmacokinetic Assessment  (Specialty  Lab)  
(To allow for assessment of parameters such as maximum concentration [ Cmax], trough 
concentr ation [ Tmax], area under the concentration- time curve [ AUC ], etc.; serum  to be 
isolated)  
PK samples will be taken according to the schedule shown ( Table 3 ; Appendix 12 ). 
Note: Whole blood (~ 5 mL) to be collected in serum  acquisition tubes at each of the i ndicated timepoints .  
Table 3:  ADA and PK Sampling Timepoints  
Sample  Sampling 
Time  Window  Cycle 1  Cycle 2  Cycle 3 
onward  EOT  1M 
FUP  Long -
Term  
FUP  
if OR/ SD at 
EOT  
(or ongoing 
critical AE); 
following PD  As 
Clinically 
Indicated  D1
-
D3 D8 D15 D22 D 1 D15 D 1 D15 
ADA Prior to 
SOI - 4h X  X  X  Odd # 
cycles   X X X2 X 
PK Prior to 
SOI - 4h X  X1  X1 X1 X1 X1     
EOI + 10 min  X  X1  X1 X1 X1 X1     
EOI + 2h  ±30 min  X            
EOI + 4h  ±30 min  X            
EOI + 8h4 ±90 min  X            
EOI + 
24h ±6h X            
EOI + 
48h -12h to          
+ 24h  X            
During 
Visit  NA  X  X     X X X2  
Abbreviations (in alphabet ical order): 1M FUP, 1-month follow -up; ADA, anti-drug antibody; AE, adverse event; D, day ; EOI, end of i nfusion ; 
EOT, end of treatment; FUP, follow -up; h, hour; min, minutes; NA, not applicable ; OR, objective response; PD, progressive disease; PK, 
pharmac okinetic; SOI, start of i nfusion  
1) If study drug  administration is delayed to another day , only one PK sample should be taken during the visit  
2) Collection of samples during Long -Term FUP to continu e at 2 -month intervals for 6 months  (for patients who are avai lable for blood 
collection)   
3) Actual collection times to be recorded i n the patient’s CRF and/or sampling log 
4) Comprehensive collection of clinical samples is critical to the conduct of this study. In situations where collection of the EOI + 8h 
sample is log istically difficult due to clinic staff availability, the observation period may be shortened, and an "end of day" sample 
may be obtained at the latest practical time. Such an option (if to  be routinely employed) is available only after discussion with and  
approval by the Sponsor  
7.7 Pharmacodynamic and Other Biomarker Assessments (Specialty Lab)  
To assess potential pharmacodynamic and other biomarkers; e very effort will be made to collect 
sampl es as  specified. Analys es will be perf ormed at a central laboratory . A detailed laboratory 
manual specifying sample collection, handling, storage, and shipment will be provided to the 
trial sites ; retention time for specimens will be specified therein .   
All analyses will be related to and used only in connection with the  data collected in the present 
trial or other Sym 022-related trials, and the identity of the pat ient will remain confidential. The 
analyses will not have any medical consequences for the patient or their relatives .  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 82 of 163 
 
 7.7.1 Pharmacodynamic Assessments 
(To include peripheral blood collection for evaluation of receptor occupancy)  
• Cycle 1  
o Day 1 (prior to dosing)  
o Day 1 (24 hours after dosing ±  6 hours , i.e. Day 2)  
o Day 15 (prior to dosing)  
• Cycle 2  
o Day 1  (prior to dosing)  
o Day 15 (after dosing , + 7 days)  (at the time of b iopsy if performed)  
• EOC 2* (combined with EOT if patient discontinues treatment prior to or at EOC2)  
• End of every 4th cycle thereafter * (i.e. EOC6, EOC10, etc .; may be combined with EOT 
if patient discontinues treatment)  
• EOT  
• 1M FUP  
Note: Whole blood (~ 10 mL) to be collected at each of the indicated timepoints; handling instructions will 
be provided.  
*End of Cycle assessments may be conducted at any time during the week prior to Day 1 of the next cycle, 
including on Day 1 of the next cycle, prior to dosing . 
7.7.2 Biomarker Assessments  
The purpose of biomarker assessments is to develop an approach for the identification and 
validation of genes or proteins that may predict which patients are likely to respond to study drug, and that may change with the possible de velopment of acquired resistance.  
Analyses may include genes and/or proteins that are unknown or have not been included in the scientific hypotheses of this trial, but that, during the collection of data from this trial, may emerge as new candidate genes a nd markers related to study drug safety, efficacy, or mechanism 
of action.  
All analyses will be related to and used in connection with the data collected in the present trial and the ongoing and future development of Sym022 as a single drug and in combina tion.  The 
identity of the patient will remain confidential. The analyses will not have any medical consequences for the patient or their relatives.  
Residuals from samples collected will be stored for up to 15 years after completion of the trial, whereaft er all samples will be destroyed.  
7.7.2.1 Blood Samples for Biomarker Assessments  
(To include peripheral blood collection for evaluation of  potential biomarkers , including but 
not limited to ctDNA, RNA, relevant proteins/cytokines , and cell ular biomarkers)  
• Screeni ng (after confirmation of eligibility and study enrollment ; may be collected C1D1  
prior to dosing)  
• Cycle 2  
o Day 15 (after dosing + 7 days) ( at the time of biopsy if performed)  
• EOT   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 83 of 163 
 
 Note: Whole blood (~ 30 mL) to be collected at each of t he indicated timepoints; handling instructions will 
be provided. For those timepoints where both a blood sample and a tumor biopsy are to be obtained,  
the blood sample is to be collected first.  
7.7.2.2 Tumor Sample s for Biomarker Assessment ( Biopsies Optional)  
(To include tumor tissu e collection for evaluation of potential biomarkers, including but not 
limited to DNA, RNA, protein, and cellular biomarkers ) 
• Screening (after confirmation of eligibility and study enroll ment ; may be collected C1D1 
prior to dosing)  
• Cycle 2  
o Day 15 (after d osing, + 7 days) ( with paired pharmacodynamic  and biomarker 
peripheral blood)  
• EOT  at the time of PD for patients with a previous OR or prolonged SD (> 16 weeks)   
Note: Tumor tissue for formalin -fixed paraffin -embedding (FFPE) to be collected at each of the indicated 
timepoints; handling instructions will be provided. For those timepoints where both a blood sample 
and a tumor biopsy are to be obtained, the blood sample is  to be collected first.  
Tumor biopsies to include core samples of a locally recurrent or  metastatic lesion; to be 
performed with minimal morbidity to the patient by a percutaneous core needle biopsy either 
with or without the aid of an imaging modality chosen at the discretion of the physician performing the biopsy.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 84 of 163 
 
 8 MANAGEMENT OF TOXICITY 
Comprehensive assessments of any toxicity experienced by the patient will be performed 
throughout the course of this study.  Anticipated toxicities that may be experienced with study 
drug are detailed in this protocol ( Section 2.4, Section 11), as well as in the IB.     
Grades of toxicity (CTCAE  v5.0*), as well as clinical judgment, will be used to determine 
appropriate management of the patient experiencing any AE  while participa ting in this study.  
*See < https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm > 
8.1 Grading and Recording of Toxicity 
Any clinical AE , whether observed by the Investigator, or observed or experienced by the 
patient, will be r eported.  Any CS  change from baseline in a laboratory assessment will be 
recorded as an AE.  All clinical and laboratory AEs must be carefully evaluated for:  
• Severi ty (Grades 1 -5; or mild , moderate, severe, life- threatening, fatal) ( Appendix 3 )* 
• Duration 
• Relationship to study drug ( not-related , unlikely, possible, probable, related) ( Appendix 
4)   
*In those cases where further definition of an event is provided by the CTCAE  v5.0, please refer to  those 
criteria  for grading and severity information.  
This information will be documented on the appropriate page of the CRF.  
8.2 Evaluation and Treatment of Toxicity  
The Principal Investigator, Sub- Investigator, or designated health prof essional must be available 
throughout the course of the study to  evaluate and treat any AE (s), as well as to evaluate whether 
continued participation in the trial is warranted or advisable.  
If, at any point during the study, significant changes occur in e ither the patient’s clinical status or 
laboratory assessments , such changes will be follow ed until the abnormality  either resolves, 
returns to baseline status, or is adequately explained. 
8.3 Determination of DLT versus Non -DLT  
Patients will be evaluated throu ghout the course of the trial for evidence of acute as well as 
delayed and/or cumulative t oxicities.   
If a significant toxicity thought to be related to study drug is experienced at any point during the 
patient’s participation in the study, the Investigat or will determine whether that toxicity meets 
the protocol criteria for DLT ( Section 6.8.3).  
If the protocol definition of DLT is met , the patient will be either discontinued from further 
treatment, or may conti nue if there is evidence of  an OR, SD, or other clinical benefit, but may 
do so ONLY following discussion with the  Sponsor’s Medical Monitor(s). Patients may not  be 
retreated following the occurrence of a DLT until there is amelioration to ≤ Grade 1 severi ty, 
return to baseline stat us, or resolution of the toxicity.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 85 of 163 
 
 Exceptions to continuing on study include evidence of certain immune -mediated toxicities as 
detai led in Section 9.1. In such instances patients must be permanently discontinued from 
treatment with study drug.   
Alternatively, the Investigator may determine that the toxicity does not meet the protocol 
defini tion for DLT , but nevertheless warrants dose modification, because it is:  
• Not controlled by optimal supportive care, or  
• Not tolerated due to symptomatology or interference with normal daily activities  
For toxicity that does not meet the protocol definition of DLT, the Investigator may, as described 
below, elect to  prolong the infusion duration (for IRRs), or temporarily delay dosing with study 
drug, to allow for amelioration of the toxicity. 
8.4 Premedication  
8.4.1 Infusion -Related Reactions  
There is an inherent ris k for IRRs with the administration of mAbs. An IRR is defined as an AE 
occurring during the study drug infusion and up to 24 hours after the EOI, which is assessed by 
the Investigator to be related to the infusion. Signs  and symptom s of IRRs may include but are 
not limited to :   
• facial flushing and swelling 
• rash including urticaria  
• headache  
• fever  
• chills, rigors  
• diaphoresis  
• tachycardia  
• hypotension 
• nausea  
• dry mouth  
• chest/back/abdominal pain/discomfort  
• chest and throat tightness  
• shortness of breath 
• cough, wheeze, stridor  
• hypoxia  
• bronchospasm  
• laryngeal edema  
• angioedema  
• shock  
The risk of an IRR is highest for the first administration of a mAb and diminishes with 
subsequent infusions. If an IRR occurs, it should be classified according to the CTCAE v5.0. 
Guidelines for the grading and management of IRRs  of all severities are pro vided ( Appendix 9 ).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 86 of 163 
 
 8.4.2 Premedication  for IRRs (Prior to the First Dose)  
Since the mechanism of action of the study drug is to stimulate the immune system 
premedication with agents such as glucocorticoids which are immunosuppressive is to be 
avoided. As a result, no premedication is required to be administered prior to patients receiving the first dose of study drug. In pa tients with a history of IRR s to mAbs  or similar products , it is  
recom mended that premedication be administered . In such cases, patients should be 
premedicated with a regimen that includes acetaminophen  as well as an H1 (e.g. 
diphenhydramine/hydroxyzine) and an H2- antagonist  (e.g. ranitidine/famotidine) .   
8.4.3 Premedication for IRRs (Following an IRR)  
For IRRs while on study, the following premedication instructions are provided:  
• For Grade 1 or Grade 2 reactions , premedication prior to subsequent infusions should be 
considered. Ther eafter, if a patient is without recurrence of an IRR, the Investigator may 
choose to withdraw premedication to  determine whether such continued therapy is 
necessary for that patient. Where practical, it is recommended that withdrawal of premedication b e done in a gradual fashion  (e.g. by reduction in dose, frequency, or 
number of agents administered, at the Investigator’s discretion). For those patients who 
experience recurrent signs/ symptoms suggestive of an IRR, premedication should be re -
instituted f or at minimum 2 additional doses  before any future attempt to withdraw.  
• For Grade 3 reactions , premedication prior to subsequent infusions will be required (if the 
patient is to be retreated). Patients experiencing a Grade 3 reaction after having received  
premedication will be discontinued from treatment.  
• For Grade 4 reactions , not applicable as no further treatment with study drug is allowed. 
If premedication is to be administered, institutional standards may be followed ; however, a 
recommended regimen includes administration of the following approximately 30 minutes prior 
to the start of infusion ( Table 4 ).   
Table 4:  Recommended Premedication Regimen  
 Medication  
 Dose and Rou te 
 Alternative 
Medication  Dose and Route  
 
1 acetaminophen  1000 mg IV (or PO)    
2 diphenhydramine  50 mg, IV hydroxyzine  25 mg, PO 
3 ranitidine  50 mg, IV famotidine  20 mg, IV 
Abbreviations (in alphabetical order): IV, intravenous; mg, milligrams; PO, pe r os (orally, by mouth)  
Note:  Doses may be adjusted based on s tandard institutional practice.  In the event of a Grade 2 IRR, glucocorticoid therapy 
equivalent to a minimum of 25 mg IV hydrocortisone approximately 0.5 to 2 hours prior to the start of the next infusion 
may be considered . 
 
8.4.4 Premedication for o ther Study Drug -Related Toxicities  
Followin g the first dose, should a patient experience symptoms suggestive of other mild -to-
moderate study drug- related reactions (e.g. nausea, vomiting, diarrhea , etc. ), the patient may be 
premedicated with standard therapies to  reduce the potential for such react ions in the future.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 87 of 163 
 
 Based on ongoing review of patient safety data, the Sponsor may implement m andatory 
premedication for all patients treated in this study should a  pattern  begin to emerge of  other mild -
to-moderate study drug- related reactions that are amenable to prophylaxis with standard agents. 
Such action will occur following discussions between the Investigator(s) and the Sponsor's 
Medical Representative(s). 
Any medications administered for either prophylaxis or therapy of signs/ symptoms conside red to 
be related to  study drug will be documented on the appropriate page of the CRF.   
8.5 Dose Modification Options  
8.5.1 Prolongation of Infusion Duration  
All IRRs that res ult in infusion prolongation must be reported promptly to the Sponsor (or 
designee).  
8.5.1.1 Instr uctions for Infusion Prolongation  for IRRs  
For IRRs , the following infusion prolongation instructions are provided:    
• For Grade 1 reactions , the infusion may  be slowe d to 50%  of the prior rate such that the 
remaining dose to be delivered is administered in 2 × longer than the amount of time that 
was initially scheduled .     
• For Grade 2 reactions , the infusion should be interrupted for a minimum of 30 minutes , 
and at least until there is either amelioration to ≤  Grade 1 severity  or return to ba seline 
status. Supportive care should be provided. The infusion should then be restarted and 
slowed to 50% of the prior rate , as described.  Subsequent infusions should be 
administered at the prolonged rate.  
• For Grade 3 rea ctions , the infusion will be STOPP ED and s upportive care will be 
provided. The occurrence will be considered a DLT and the patient will be either discontinued from treatment, or must receive subsequent doses at a prolonged infusion 
rate (slowed to 50% of t he prior rate or longer) . 
• For Grade 4 reactions , the infusion will be STOPPED and supportive care will be 
provided.  The occurrence will be considered a DLT and the patient will be discontinued from treatment.  
In all cases , the Investigator should use best  clinical judgme nt in managing such reactions. All 
infusion interruptions and subsequent prolongations, including modified infusion times, as well as the toxicity that necessitated them, will be clearly documented on the appropriate pag e of the 
patient’s C RF. 
Note: Any assessments to be performed or samples to be collected (e.g. vital signs, PK ) at the end of or following 
the EOI will still be performed or collected  beginning at the delayed EOI timepoint. In situations where 
collection o f late day samples, particular ly the 8 hours after EOI  sample, is logistically difficult due to 
clinic staff availability, an "end of day" sample may be obtained at the latest practical time on the day of the 
reaction.  
Guidelines for the grading and management of IRRs  of all severities are provided ( Appendix 9 ). 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 88 of 163 
 
 8.5.1.2 Treatment Following Infusion Prolongation  
To enhance patient safety following an infusion prolongation, subsequent infusions will be 
administered a t the prolonged rate. For Gra de 1 and 2 IRRs, r echallenge with a shorter duration 
of infusion (no less than 60 minutes ) may be attempted at the Investigator's discretion, after a 
minimum of 2 doses  with no evidence of infusion- related toxicity  at the prolo nged rate . For 
Grade 3 IRRs, continue administration at the prolonged rate.  
8.5.2 Dose Reduction  
There is no provision for dose reduction in this study. 
8.5.3 Dose Delay  
All delays of study drug must be reported promptly to the Sponsor (or designee) .  
Toxicities may be managed by delay  in dosing provided they do not meet the criteria for study 
discontinuation ( Section  9.1).   
If indicated , the period between any 2 scheduled doses may be extended to allow for 
amelioration of the toxicity.  However, if any observed Grade 3 or Grade 4 toxicity thought to be 
possibly- , probably- , or related to  study drug results in delay of dosing beyond 2 weeks  of the 
next scheduled dose, the event will be considered a DLT.   
For toxicities that are to be managed by dose delay , dosing may be restarted at the same dose;  
however , administration of study drug may only be restarted upon amelioration to ≤  Grade 1, 
return to baseline status, or resolution of the observed toxicity.  
8.5.4 Schedule Alterations  
Altered schedules of study drug (i.e. reduc ed number of treatment days , longer interval between 
treatment days ) may be explored, only after discussion with t he Sponsor (or designee) , and only 
during subsequent cycles of treatment (Cycle 2 and beyond).   
Patients requiring such schedule alterations during Cycle 1  of the study will be considered to 
have met the criteria for DLT due to the inability to complete C ycle 1 of study drug treatment.    
Note: Any modification of study drug administration, and the reason for such action, must be clearly noted i n the 
patient’s CRF. If such a modification impacts a PK sampling interval, the details of such action must also 
be documented on the appropriate page of the CRF (to aid in the interpretation of PK findings).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 89 of 163 
 
 9 DISCONTINUING PATIENTS FROM STUDY TREATMENT  
Every reasonable effort will be made to keep patient s in the study; however, if  a patient is 
discontinued from study treatment , every effort will be made by the Investigator to complete and 
report the reasons for treatment discontinuation as thoroughly as possible. This includes  EOT  
observations, as required by the protocol at the time of treatment discontinuation , or before 
initiation of a new treatment, whichever comes first , as well as 1M FUP  evaluations  to follow  
(Section  7). The reason for treatment discontinuation must be clearly documented on the 
appropriate page of the CRF. A CRF must be completed for any patient who receives any 
amount of study drug.  
9.1 Criteria for Treatment Discontinuation  
Patients will be discontinued from further treatment with study drug in the event of any of the 
following:  
1. Adverse Event s, including:  
• ≥ Grade 3  evidence of any of the following immune -mediated toxicities:  
o Pneumonitis  
o Myocarditis  
o Adrenal insufficiency  
o Encephalitis  
o Nephriti s, renal dysfunction (serum creatinine elevation)  
o Episcleritis, uveitis, or iritis  
• > Grade 3  evidence of any of the following immune -mediated toxicities:  
o Colitis  
o Hypophysitis, hyperglycemia  
o Inflammatory arthritis  
o Myositis  
o Rash  
• Hepatotoxicity characterized by:   
o AST and/or ALT elevation > 3 × ULN  (or > 3 × baseline if elevated at study entry  
due to hepatic involvement by tumor ), with  
o total bilirubin ≥  2 × ULN without initial findings of cholestasis (i.e. serum ALP  < 
2 × ULN ), and  
o No explanation for the above findings such as viral hepati c injury, preexisting or 
acute liver disease, or another drug or condition capable of causing the observed 
injury 
Adapted from:  Hy’s Law. Drug– induced liver injury: premarketing clinical evaluation. Guidance for 
Industry. U.S. Department of HHS, FDA, CDER, CBER, 2009  
• > Grade 3  IRR; Grade 3  IRR in a pati ent who has received premedication  
Note: The occurrence of a Grade 3 IRR in a patient who has not received premedication will be 
considered a DLT and the patient will be either discontinued from treatment, or must receive 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 90 of 163 
 
 subsequent treatments at a prolonged infusion rate;  premedication prior to subsequent 
infusions will be required.  
• A DLT considered by the Investigator to require treatment discontinuation ( Section 
6.8.3)  
Note: Patients experiencing a DLT not requiring permanent discontinuation may continue if there is 
evidenc e of an OR , SD, or other clinical benefit, provided protocol stipulated retreatment  
criteria have been met , and ONLY following discussion with the Sponsor’s Medical 
Monitor(s) .    
• Another AE  or SAE considered by the Investigator to require treatment 
discontinuation  
Note: AEs resulting in a patient’s permanent discontinuation from study treatment , regardless of 
seriousness or relationship to study drug, MUST be reported promptly  to the Sponsor (or 
designee) . 
2. Progressive Disease:  Confirmed radiographically  
Note: An exception may be made in the case of suspected PSPD.   Patients will be permitted to continue 
treatment beyond initial RECIST v1.1 (or RECIL  2017) defined PD while waiting for confirmation of 
PD, provided they are clinically stable (per i RECIST ).  
3. Clinical Progression : Treatment failure not meeting the criteria for PD , but considered by 
the Investigator to require treatment discontinuation  
4. Physician Decision , including:  
• Use of or requirement for a non- permitted concomitant medication  
• Requirement for  a significant surgic al procedure  
Note: Patients requiring a minor surgical procedure (e.g. port placement, skin abscess drainage) may 
continue at the Investigator’s discretion following discussion with the Sponsor's Medical 
Monitor (s). A brief interruption in therapy may be considered.  
• Intercu rrent illness which  would prevent completi on of study- related evaluations  
• Any other reason in the opinion of the Investigator that would justify treatment 
discontinuation  
5. Withdrawal by Patient:  Withdrawal of consent and election to discont inue treatment 
(patients may leave the study at any time for any reason if they wish to do so, without 
consequence)  
6. Protocol Deviation:  Significant deviation /violation  from the protocol or eligibility criteria 
(discontinuation cons idered only following discussi on with the Medical Monitor(s))  
7. Noncompliance with study procedures  
8. Pregnancy  
9. Lost to Follow -up 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 91 of 163 
 
 10. Death  
11. Study Terminated by the Sponsor  
12. Site Terminat ed by the Sponsor  
9.2 Replacements  
Should a patient discontinue treatment with stud y drug for reasons other than the occurrence of a 
DLT  prior to completing Cycle 1, a replacement patient will be obtained using the original 
eligibility criteria. Patients discontinued due to DLTs  will not be replaced.  
Note:  Patients must receive their full planned dose s of study drug during Cycle 1  to be considered evaluable for 
tolerability, unless dose delay  or discontinuation is the result of a DLT. Patients receiving < 2 full planned 
study drug dose s plus 2 weeks of follow -up during Cycle 1 for reasons other than toxicity will be replaced.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 92 of 163 
 
 10 ADVERSE EVENTS  
10.1 Definitions  of Adverse Events  
10.1.1 Adverse Event  
An AE is any untoward medical occurrence in a patient or a clinical investigation subject 
administered a pharmaceutical product and which does not necessaril y have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and uninte nded sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP , 
whether or not considered related to the IMP. 
Causality for an AE will be assessed as  related, possibly -related, probably -related, unlik ely-
related, or not -related to IMP. Any AE, regardless of causality, that also meets the seriousness 
criteria, will be reported as an SAE.  
10.1.2 Events Not to be C onsidered as Adverse Events  
A pre-existing condition (i.e. a disorder  that is  present before the AE recording period starts and 
is noted on the medical history/physical examination form) should not be recorded as an AE 
unless the condition worsens or episodes increase in frequency during the AE recording period.  
PD will not be capt ured as an AE  as this will be recorded as part of the patient’s efficacy 
evaluation.  PD should be reported as an AE if the nature of the PD is different than expected (i.e. signs /symptoms are not typical of PD).   
Note: PD may be reported as an AE  in the case of patient death, with death being the outcome of the event.  
An abnormal  laboratory value  or an abnormal physiological test  finding ( e.g. ECG) need not be 
reported as an AE u nless one of the following applies:  
• The Investigator considers the abnormality CS   
• The event meets the definition of an SAE  
• The event requires an intervention  
• The event results in an action taken with study drug ( e.g. dose -delay  and/or 
discontinuation)  
Diagnostic and therapeutic non- invasive and invasive procedures , such as surgery, should not be 
recorded as AEs. A medical condition for which an unscheduled procedure was performed, 
should however be recorded if it meets the definition of an AE. For example, acute appendicitis should be recorded as the AE and not the appendectomy. 
Procedures to support the treatment regimens , such as insertion of central venous catheters , etc. , 
should not be recorded as AEs, unless the procedures result in complications.  
10.1.3 Adve rse Events of Medical Interest  
Not applicable  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 93 of 163 
 
 10.1.4 Serious Adverse Events  
An S AE is an AE that meets one or more of the following regulatory outcome criteria:      
• Results in d eath    
In the case of deaths, the event(s) lea ding to the death should be recorded and reported as 
SAE(s) with the outcome “Fatal”. The death itself will not be reported as an SAE, unless 
the cause of the death is unknown (e.g. in case of unexplained or sudden death)   
• Is life -threatening     
The term "life -threatening" refers to an event  in which the patient is at immediate risk of 
death at the time of the event; it does not refer to an event which hypothetically might cause death if it was more severe  
• Requires i npatient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability/incapacity    
A disability is defined as any substantial disruption of a person’s ability to conduct normal life functions.   
• Is a congenital anomaly /birth defect  
• Is medically important  
Medical and scientific judgment  must be exercised in deciding whether an AE is believed 
to be “medically important”. Medically important events may not be immediately life -
threatening or result in death or hospitalizati on but may jeopardize the patient or may 
require intervention to pre vent one of the other outcomes listed in this  definition .  
10.1.5 Events T hat Do Not Meet the Definition of Serious Adverse Events  
PD will not be captured as an SAE  unless the nature of the PD is  different than expected (i.e. 
signs/symptoms that are not typical o f PD).    
Note: PD may be reported as an SAE  in the case of patient death, with death being the outcome of the event . 
Elective surgery or other scheduled hospitalization periods  that were p lanned before the patient 
was included in this trial are not to be r ecorded as SAEs, unless an outcome of the 
surgery/hospitalization was considered serious.  
Hospitalization for observation or convenience  prior to or following study drug infusions without  
an SAE occurring should not be recorded as an SAE, e.g. if a patient is hospitalized merely for observation, or if a patient begins or finalizes the infusion at a time of day requiring a convenience overnight stay in the hospital.  
Procedures to support t he treatment regimen  that require hospitalization  should not be reco rded 
as SAEs ; however, in cases where a procedure results in complications requiring/prolonging 
hospitalization , this must be recorded and reported as an SAE.  
    
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 94 of 163 
 
 10.2 Adverse Event  Recording and Reporting   
All AE s will be  recorded from signing of informed cons ent for participation in the trial.  The 
recording period ends 30 days after receiving the final dose of study drug ( at the time of the 1M 
FUP Visit), unless extended FUP is  indicated , per the clinical trial protocol .   
Note:  Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for 
the occurrence of SAEs/AEs until it is determined that they will not be participating in th e trial. 
10.2.1 Information to be Provided for each AE  
The Investigator must record all directl y observed AEs and all AEs spontaneously reported by 
the patient.  Information regarding the occurrence of AEs s hould be elicited through open- ended 
questioning of the patient, review of physical examination findings, and review of laboratory 
results  or ot her safety information, e.g., ECGs .  
All AEs that occur in patients during the AE recording period must be recorded/entered to the 
AE section of the CRF, whether or not the event is assessed as related to study drug.  If the AE is 
serious, the SAE report f orms must also be completed and submi tted. The following information 
will be provided for each AE  term reported:  
• Diagnosis  
A diagnosis should be recorded, if possible. If no diagnosis is available, signs and symptoms should be recorded instead. For fatal A Es, death is  an outcome of the AE. The 
cause of death (rather than the term “death”) should be recorded.   
• Severity  
The Investigator will use the CTCAE version 5.0* to describe the severity of an AE.  If 
the severity of an AE is not specifically graded by the CTCAE gu idance document, the 
Investigator should use the general definitions of Grades 1 to 5 as per the following, and 
use his/her best medical judgment to describe the severity of the AE (Appendix 3 ): 
o Grade 1 : Mild  
o Grade 2: Moderate  
o Grade 3: Severe  
o Grade 4: Life- threatening or disabling 
o Grade 5: Death caused by the event  
Changes in severity of AEs will be recorded.  
Generally, an AE of CTCAE Grade 4 or 5 qual ifies for SAE reporting to the Sponsor (or 
designee) . However , a laboratory abnormality of Grade 4 does not  need to be reported as 
an SAE, unless it meets one of the SAE  criteria.  
*See <https://ctep.cancer.gov/protoc olDevelopment/electronic_applications/ctc.htm > 
• Relationship to IMP/ Causality  
The Investigator will attempt to assess causal relationship of the event to the study drug.  Relatedness must be assessed and recorded within the initial report (CRF and SAE report form).   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 95 of 163 
 
 The causal relationship is an assessment of whether the event is related to the use of the 
IMP.  It is not an evaluation of w hether the event could hypothetically occur in the 
investigational patient population. 
The causal relationship of an AE  to the IMP will be rated  using a 5 -point  causality scale 
(Appendix 4 ): 
o Not-related  
o Unlikely -related  
o Possibly- related  
o Probably- related  
o Related    
• Outcome 
The outcome of the AE must be assessed by the Investigat or utilizing one of the 
following options:  
o Recovered /resolved   
o Recovered /resolved  with sequelae  
o Recovering /resolving  
o Ongoing  
o Fatal  
o Unknown  
Instructions for reporting changes in an ongoing AE during a patient's participation in the trial 
will be provide d. 
10.2.2 Required Follow -up for AEs  
Appropriate consultation and foll ow-up evaluations should be carried out until the event either 
resolves, returns to baseline status, or has been adequately explained and assessed by the 
Investigator as chronic and/or stable, and that no long- term deleterious effects have become 
evident.   
This follow -up may extend beyond the 1M FUP Visit, to up to 4 months  after the end of 
treatment  if indicated, if the event has not resolved or been adequately explained.   
Any patient who develops an immune -mediated event during study or after the end of  treatment 
will be followed for up to 2 years  to assess the course of the condition and evaluate potential 
reversibility of the finding. 
Note:  Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for 
the occurrence of SAEs/AEs until it is determined that they will not be participating in the trial.  
10.3 Serious Adverse Event Recording and Reporting  
10.3.1 Timeframes  for Reporting to the Sponsor  
All SAE s occu rring at any time from signing of informed consent  for partic ipation in the trial 
and until  30 days after receiving the final dose of study drug ( at the time of the 1M FUP  Visit) 
must be recorded on the SAE R eport F orm and recorded as an SAE in the CRF. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 96 of 163 
 
 Note:  Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for 
the occurrence of SAEs/AEs until it is determined that they will not be participating in the trial.  
In case of an SAE, the Investigator must, wit hin 24 hours  of awareness  of the event , report the 
SAE  to the Sponsor (or designee) by telefax or e- mail transmission . Fax number(s) and e -mail 
address(es) will be stated on the SAE R eport F orm and the SAE R eport F orm Completion 
Instructions . SAE follow -up information must also be  reported to the Sponsor (or designee) 
within 24 hours of awareness . 
SAEs , still ongoing after the 1M FUP Visit, should be followed on a regular basis according to 
the Investigator’s clinical judgment, until the event resolve s or until the Investigator ass esses it 
as chronic or stable. The Sponsor (or designee)  will pursue sufficient information and will return 
to the trial sites for such information as deemed required. 
If the Investigator becomes aware of an SAE that occurred after  the 1M FUP Visit and fin ds it to 
be related to the IMP ( possibly- , probably- , or related to the study drug)  or trial conduct, it must 
be recorded and reported to the Sponsor (or designee)  as an SAE.  
The Investigator should be aware of local reporting regulations  to the  IRB/EC. The Sponsor (or 
designee) will either supply the Investigator with the reports, which should be forwarded to the 
IRB/EC, or report directly to the IRB /EC depending on local regulations.    
10.3.2 Safety Reporting to Health Authorities, Ins titutional Review Bo ards/Ethics 
Committees, and Investigators   
Reportability of an SAE as a “S uspected U nexpected S erious A dverse R eaction ” (SUSAR) will 
be determined solely by the Sponsor, based on seriousness, causality, and expectedness  criteria .   
In addition to SUSARs, t he Sponsor or designee is responsible for reporting all relevant safety 
information regarding SUSARs, or other safety developments, to appropriate Health Authorities  
and central IRBs/ECs, as well as participating I nvestigators. Reporting of SUSARs to local  
IRBs/ECs will be handled either by the Sponsor or designee, or the Investigator depending on local regulations.  
The timeline for notification of SUSARs is within 7 calendar days  for fatal/life -threatening 
events and within 15 calendar  days  for all other SUSARs.    
10.4 Pregnancy  
If any trial patient becomes pregnant during the trial, the patient must be discontinued from study drug immediately and the pregnancy must be reported to the Sponsor or designee according to 
the same timelines as an  SAE.  While pregnan cy is not considered an AE, all pregnancies are 
tracked as SAEs within the safety database to follow -up on exposure to the fetus/infant. 
Pregnancies reported in female partners of male trial patients must also be included in the safety database; therefore,  a female partner of a male patient on the trial who becomes pregnant will be 
approached for consent to have the pregnancy followed until term and reported upon to the 
Sponsor (or designee).  
All pregnancies must be followed up every thi rd month and 1- month post -delivery to determine 
outcome and status of mother and child . Pregnancy complications and elective terminations for 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 97 of 163 
 
 medical reasons must be reported as AEs or SAEs as appropriate. Elective terminations for non-
medical reasons should be reported as follow -up, but not as a separate AE/SAE unless 
complications meet AE/SAE criteria . Spontaneous abortion must be reported as an SAE.  
Any SAE occurring in association with a pregnancy brought to the Investigator’s attention after the patien t has completed the trial and considered by the Investigator as possibly- , probably- , or 
related to the study drug, must be promptly reported to the Sponsor (or designee).  
All pregnancy information including follow -up information must be reported on a desi gnated  
pregnancy form provided by the Sponsor (or designee).  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 98 of 163 
 
 11 PRECAUTIONS WHEN DOSING WITH STUDY DRUG  
11.1 Precautions Regarding Procreation  
Studies have not been performed to determine whether this study drug affects reproductive 
function in males  or can caus e fetal harm .  For this reason, men with partners of childbearing 
potential must use a highly effective method of contraception while receiving study drug. “A 
highly effective method of contraception” is defined as non -hormonal contraception 
equivalent to a doub le-barrier method ( includes a single -barrier method in combination 
with a spermicide)  or intrauterine device.  
There have been no studies in pregnant females ; therefore , it is not known whether study drug 
can cause fetal harm when administered to a pr egnant woman, or whether it  can affect 
reproductive capacity. For this reason, WOCBP should only be administered study drug when highly effective contraceptive measures have been taken and when pregnancy tests  are negative.   
WOCBP includes any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy), or is not postmenopausal. Post -menopause is defined as : 
• Amenorrhea  for ≥  12 months with no other cause  
• Irregular menstrual periods, on HRT, with documented FSH  level > 35 mIU/mL  
Note:  Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, transdermal 
patches, or implanted or injectable products), or mechanical products such as an intrauterine device or 
barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence, or 
where their partner is sterile (e.g. vasectomy), should be considered of childbear ing potential.  
 
Women and men of childbearing potential will be informed as to the unknown risk to procreation 
while participating in this trial and will be advised that they must use highly effective 
contraception within 2 weeks  prior to the first dose an d continuing until 6 months  after final 
administration of study drug. A pregnancy test will be performed on each premenopausal female 
of childbearing potential  within ≤  2 working days  prior to first study drug administration, and 
again at the end of the fi nal treatment cycle.   
11.2 Additional Precautions  
There are no known contraindications to the administration of study drug, however the following additional precautions are provided:   
• Lactating women and children:  Use in lactating women or in children has not bee n 
evaluated. These patients will be excluded from study entry.   
• Drug interactions : No formal drug interaction studies have been performed, therefore no 
specific guidance can be provided about use of conc omitant medications.   
• Overdose : There is no experience with clinical overdose. If severe reactions occur in 
patients , study drug should be discontinued and all appropriate supportive medical care 
should be instituted to ameliorate these potential AEs. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 99 of 163 
 
 • Nonclinical toxicology studies : No adverse events have been observed at the highest dose 
level of Sym 022 tested, which was weekly administration of 100 mg/kg. The highest 
dose to be administered in this trial is 10 mg/kg administered Q2W.  
• Studies of other mAb s: IRR s have been observed, therefore safety in pati ents with a 
history of IRRs to mAbs or similar products  should be carefully evaluated prior to 
administration of study drug. It is recommended that p remedication to prevent infusion 
reactions be administe red to all patients  with a history of such reactions , and facilities and 
personnel to treat such reactions, if they occur, should be available. In the event of an 
IRR, the infusion should be slowed /interrupted  so that appropriate measures may be 
taken  (Section 8.5.1, Appendix 9 ).  
• Studies of other anti -LAG -3 antibodies : For a listing of AEs observed with an other LAG -
3 antibody, see Section  2.3.1.2. 
• Studies of other antibodies to immune checkpoint s: For a listing of AEs observed with 
anti-PD-1/PDL1 antibodies , see Appendix 8 . For information on grading and 
management of immune -mediated toxicities, see Appendix 10 . 
 
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 100 of 163 
 
 12 SAFETY SURVEILLANCE DURING STUDY 
12.1 Safety Review  
The Investigator(s) and Sponsor's Medical Representatives will comprise a Study Safety Team . 
The team will review clinical and laboratory safety data on an ongoing basis throughout the 
study and make decisions regarding the advisability of continuing accrual to a dose cohort, and/or escalating the dose and allowing accrual to a higher dose cohor t. To  do so:   
• The following will be promptly reported to the Sponsor (or designee) : 
o SAEs within 24 hours  of Investigator awareness  
o Any immune -related AE of significance, even if not meeting the SAE or DLT 
definition  
o AEs resulting in permanent discontinuat ion from study, regardless of seriousness 
or relationship to study drug  
o DLTs  
o IRRs  
o Dose delays  
• AEs will be recorded i n the CRF in a timely manner following a patient completing (or 
being discontinued from) each dosing cycle. Each event will be assessed as to grade and 
causality.  
• The Investigator will make critical laboratory safety data available in a timely manner.    
• Patients will be carefully evaluated for evidence of all AEs, including potential cumulative and/or delayed toxicities, throughout the durat ion of their time on study.  
• Biweekly Safety Team Teleconferences will be held between the Investi gator(s) and the 
Sponsor’s Representative (s) to discuss ongoing patient status and any emerging safety 
concerns; frequency may fluctuate based on accrual and study activity, as indicated.  
Availability of these data also will enable the Sponsor (or designe e) to act promptly in response 
to safety signals and ensure that governing Health A uthorities, as well as Investigators who may 
be participating at other site s or in other clinical trials of the study drug, are informed of events 
occurring during the trial .  
12.2 Other Safety Surveillance Activities  
At least one Medical Monitor will be assigned to review and evaluate relevant clinical/safety 
information concerning the clinical trial. The responsibilities of the Medical Monitor include, but 
are not limited to: 
• Consultation with Investigator(s) regarding evaluation of patients to be enrolled to the 
study, treatment delays, restarts, and/or discontinuations   
• Ongoing safety monitoring of all patients being treated in the study  
• Evaluation of coding and trending of AE s in conjunction with the Drug Safety physician 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 101 of 163 
 
 • Performing surveillance on potential safety signals in conjunction with the Drug Safety 
physician 
• Evaluating abnormal laboratory values  and other relevant safety data, e.g., ECGs  
• Providing medical support to the Sponsor in answering questions related to the study protocol  
• Updating the Safety Team on trial status  
A Drug Safety physician will be assigne d to review, assess, and approve all SAE cases and 
associated reports. This physician will also perform the following:  
• Assess for safety signals and trends in conjunction with the Medical Monitor  
• Assist with questions regarding medical coding of SAEs  
• Discu ss with the Sponsor’s Chief Medical Officer any cases which may present a concern 
regarding a signal or safety  issue.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 102 of 163 
 
 13 REGULATORY AND ETHICAL CONSIDERATIONS  
13.1 Conditions of Testing  
In sponsoring this study, it is the intention of the Sponsor  to obtain patient  safety data for 
submission to governing Health A uthorities. In agreeing to conduct this investigation, the 
investigative facility agrees to follow all requirements stipulated in this protocol as well as 
regulations described in the U.S. CFR and /or by governing Health  Authorities concerning:  
• Responsibilities of Investigators ( in the U.S. Title 21  CFR Part 312)  
• Informed Consent of Human Subjects ( in the U.S. Title 21 CFR Part 50)  
• Institutional Review Boards ( in the U.S. Title 21 CFR Part 56)  
In addition, the Investigator agrees to perform the study in accordance with the principles of the 
Declaration of Helsinki, and ICH E6(R2) GCP . 
13.2 Institutional Review  
The Investigator will submit this protocol, any protocol modifications, and the patient ICF to be 
utilized in this study to the appropriate IRB/EC for review and approval. This committee must 
operate in accordance wit h ICH E6 (R2) GCP , the U.S. Title 21 CFR Part 56, and/ or governing 
Health  Authorities, as appropriate .  A letter confirming approval of the protocol and the ICF 
must be forwarded to the Sponsor (or designee)  prior to initiation of this study. The Investigat or 
will not start the study, nor will study drug be shipped to the investigational site, before providing the Sponsor (or designee)  with evide nce of this approval.  
The Investigator is responsible for assuring continuing review and approval of the clinical  study.  
The Investigator must also promptly report all changes in the research activity and all 
unanticipated problems involving risk to the patients or others to t he IRB/EC. The Investigator 
will not make any changes in the protocol without IRB /EC approval, except where necessary to 
eliminate apparent immediate hazards to the patients. The Investigator will provide progress reports to the IRB /EC as required by the I RB/EC. If the study remains in progress for more than 
the IRB/EC -specified approval period, the Investigator must obtain renewal and re -approval 
from the IRB /EC where appropriate. Documentation of renewal must be submitted to the 
Sponsor (or designee) . The Investigator will provide notice to the IRB /EC of completion of 
participation in the study.  
13.3 Informed Consent  
The Investigator agrees to protect the rights, safety, and welfare of the patients entered into the 
study, including obtaining written  informed consent prior to performing any study- related 
procedures , and informing each patient that th e study drug is  being used for investigational 
purposes.   
Prior to  study start, the Sponsor will provide a sample ICF for modification, as appr opriate, by 
each Investigator. The sample ICF must include all elements required by ICH E6 (R2) GCP  and 
must adhe re to the IRB/EC requirements and ethical principles that have their origin in the 
Declaration of Helsinki.   
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 103 of 163 
 
 The Investigator's revision to the Sponsor's sample ICF, along with any other written study 
information to be provided to the patient , must be reviewed and approved by the IRB /EC. A 
copy of the IRB /EC-approved ICF to be utilized during the study must be submitted to the 
Sponsor (or designee) prior to study initiation.  
Prior to each patient's entry to the study, the Investigator or his/her staff will  explain the nature 
of the study, its purpose and associated procedures, its expected duration, and the potential risks  
associated with participation.  All questions about the trial will be answered to the satisfaction of 
the patient or the patient’s legal representative.  The patient will be informed of the right to 
withdr aw from the study at any time without consequence, and without having to provide a 
reason for this decisio n. Following the discussion, the patient will be asked if they are willing to 
perso nally sign and date the ICF. Only if the patient voluntarily agrees  to sign the ICF  and has 
done so, may he/she enter the study.   
It is the responsibility of the Investigator to obtain written informed consent from each patient, 
thereby attesting that con sent was given freely in accordance with ICH E6 (R2) GCP , the U.S. 
Title 21 CFR Part 50, or governing Health  Authorities, as appropriate. An Investigator listed on 
the Form FDA 1572 will then co- sign the ICF. A copy of the signed and dated ICF will be 
provi ded to the patient. The original executed version must remain in the Investigator's file, per 
local requirements, and must be available for verification by a representative of the Sponsor (or 
designee) . 
13.4 Conditions for Modifying or Terminating the Study  
13.4.1 Mod ification of the Study Protocol  
The study is to be conducted as d escribed in this protocol. Departures from either the protocol 
eligibility criteria or the experimental plan, as outlin ed herein, will not be allowed. No protocol 
waivers will be granted.   
If modifications in the experimental design, dosages, assessments, patient selection, etc., of the 
protocol are indicated or required, such changes will only be instituted following consultation 
between the Sponsor (or designee)  and Investigator and will be  accomplished through formal 
amendment(s) to this protocol and approval by the appropriate regulatory authority (as indicated) 
and review committees, except where necessary to immediately eliminate apparent hazards to patients.   
A modification to the prot ocol will not be made without the express written approval of the  
Sponsor (or designee) . Any amendment prepared by the Sponsor (or designee)  will be 
implemented according to the Sponsor ’s (or designee ’s) standard operating procedures (SOPs) 
and will be rep orted to the appropriate regulatory authority, the appropriate IR B/EC, and made a 
formal component of the protocol document.  
Protocol changes to eliminate an apparent hazard to a trial patient may be implemented by the 
Investigator immediately. The Investigator must then, without delay, inform the local IRB /EC, 
and the Sponsor (or designee) will immediately notify local governing Health Authorities.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 104 of 163 
 
 13.4.2 Modification of the Informed Consent Form  
If modifications to the experimental design, dosages, assessments, patient selection, etc. of the 
protocol are indicated or require d, and if such modifications substantially alter the study design 
or increase the potential risk to patients, the Sponsor (or designee) will prepare a revision to the 
existing sample ICF  for modification, as appropriate, by each Investigator.  Any revision to the 
sample ICF prepared by the Sponsor (or designee) will be implemented according to the Sponsor’s (or designee’s) SOPs. Such a revision will be reviewed and approved by the appropriate regulatory authority (as indicated) and IRB /EC.  
In addition, all current patients , as well as subsequent study candidates, will be informed of the 
study design modification or increase in potential risk, and written informed consent for the modification/r isk will be obtained as outlined ( Section  13.3).  
13.4.3 Conditions for Termination of the Study  or a Study Site  
The Sponsor reserves the right to terminate the study, or terminate a clinical trial site's  
participat ion in the study, at any time. Should the Sponsor , the Sponsor’s designee, and/or the 
Investigator(s) discover conditions that indicate the study or a study site  should be discontinued, 
an appropriate procedure for termination will be instituted. Reasons for t ermination may include, 
but are not limited to, the following:  
• Termination of the Study 
o Safety concerns; incidence and/or severity of AEs in the study that indicate a 
potential health hazard or unexpected, serious, or unacceptable risk cause d by the 
study treatment  
o Discovery of lack of efficacy  
o Unsatisfactory enrollment across the entirety  of the trial 
o Drug supply or manufacturing issues  
o The Sponsor’s decision to modify or discontinue development of the study drug 
o A request to discontinue the study by a regulatory authority or H ealth A uthority  
• Termination of a Study Site  
o Investigator non- compliance with the protocol, ICH E6 (R2) GCP, or regulatory 
requirements  
o Unsatisfactory enrollment at the site with respect to quantity or quality  
o Incomplete data collection ; inaccurate or knowingly false data submission 
If terminating the  study, the Sponsor and Investigator(s) will ensure that adequate consideration 
is given to the protection of patients' interests. Further, the governing Health Authority and 
IRB/EC will be notified in writing and the reason for termination will be stated.  
13.5 Trial Registration  
The trial will be registered in one or more public trial registries (e.g. ClinicalTrials.gov) . The 
trial results will be posted in the same clinical trial registries as the initial registration in 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 105 of 163 
 
 accordance with the latest International Committee of Medical Journal Editors (ICMJE) 
recommendations (URL: www.icmje.org ). 
13.6 Insurance and Liability  
The Sponsor will obtain Human Clinical Trial s Insurance for its legal liability in accordance with 
laws and regulations, and with limits customary or required by law in the territory in question. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 106 of 163 
 
 14 INVESTIGATOR RESPONSIBILITIES  
14.1 Medical Supervision  
An Investigator conducting a clinical study with an investigational agent is required to comply 
with regulations described in U.S. Title 21 CFR Part s 50, 56, and 312 and/or by governing 
Health Authorities, as well as  ICH E6 (R2) GCP . 
Medical supervision for the conduct of this protocol is the responsibility of  the Principal 
Investigator. The Principal Investigator must name all Sub -Investigators and may delegate 
certain day -to-day activities to such Sub- Investigators, but retains overall responsibility for 
ensuring that the study is conducted properly and in ac cordance with the design and intent 
herein. A document outlining the specifics of the delegation will be maintained at the 
investigational site, in the study files, and will be updated as appropriate.   
The Principal Investigator is responsible for ensuring that drugs and devices are available for 
treating  possible medical emergencies. The Principal Investigator is required to ensure 
compliance with r espect to the study drug schedule, visit schedule , and procedures required by 
the protocol. The Principal Investigator is responsible for ensuring that the study is conducted 
according to sound medical practices.  
14.2 Confidentiality  
All goods, materials, infor mation (oral or written) and unpublished documentation provided to 
the Investigator (or any company acting on their behalf), inclusive of this protocol, the patient 
CRFs,  and the IB , are the exclusive property of the Sponsor. Documents and information 
provided to the Investigator by the Sponsor may not be given or disclosed by the Investigator or 
by any person w ithin his /her authority either in part or in totality to any unauthorized person 
without the prior written formal consent of the Sponsor. 
The submis sion of this protocol and other necessary documentation to the IRB /EC is expressly 
permitted ; the IRB /EC mem bers hav e the same obligation of confidentiality.  
The Investigator shall consider as confidential , and shall take all necessary measures to ensure 
that there is no breach of confidentiality, all information accumulated, acquired or deduced 
during the trial, other than that information to be disclosed to a third party mandated by applicable law.  
Note: Any language relating to these issues appearing in the clinical trial agreement will supersede that which is 
outlined in this section.  
14.3 Use of Information  
All u npublished information relating to this trial and the study drug is considered confidential by 
the Sponsor and shall remain the sole property of the Sponsor. The Investigator must accept that 
the Sponsor may use information from this trial relating to  the development of the study drug, 
and therefore, may disclose it as  required to Investigators, government -licensing authorities, 
Health Authorities  of other governments, investors, and commercial partners as indicated.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 107 of 163 
 
 14.4 Publication s 
The Sponsor acknowledges the Investigators’ rights to publish the full results of the trial , 
regardless of the outcome, in accordance with the latest ICMJE recommendations. Publication of 
a summary of the results of the study is permissible according to the Sponsor and is not incons istent with the preceding affirmation  regarding confidentiality . Scientific dissemination of 
the results of this s tudy is encouraged. Any formal publication of data collected from  the study 
will be considered a joint publication by the Investigator and the  appropriate personnel of the 
Sponsor  or their designees. Author ship will be determined by agreement .   
The Sponsor retains the right to designate one of the authors or someone else involved to be 
named as the Coordinating Investigator . The Coordinating Investigator and the Sponsor will 
decide on the publication strategy. The Coordinating Investigator will have the right to publish 
and present the results and methods as first or last author of multicenter publications. Co-
authorship will be decided by the S ponsor and the Coordinating Investigator and will be limited 
to persons who have contributed substantially to the trial . The Sponsor will have representation 
in the list of authors. 
Publication is subject to the following conditions:   
• No publication befor e the completion of the trial at all participating trial sites without 
preceding written approval from the Sponsor  
• Publications shall not disclose any Sponsor confidential information and property (not 
including the trial results)  
• The Sp onsor reserves the right to review results communications prior to public release 
and can embargo communications regarding trial results for a period that is less than or 
equal to 60 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.  
Note:   Any language relating to these issues appearing in the C linical Trial Agreement will supersede that which 
is outlined in this section.  
14.5 Patient Screening Log  
A record listing all patients entered into the study, as well as those considered for entr y into the 
study and subsequently excluded, must be maintained by the Investigator. Patients excluded from the study will have the reason for exclusion recorded on the Patient Screening Log (or similar document).  
14.6 Drug Dispensing Invento ry 
Study site perso nnel will maintain adequate records of the receipt, dispensing, and disposition of 
all study drug that the Sponsor ships to the site. Records will be maintained either on a form to be provided by the Sponsor or another similar document  authorized for use by the Sponsor, and 
should include appropriate dates, quantities received, quantities dispensed, lot number (or kit 
number), disposition details, and the identification code of the patient who received the study drug. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 108 of 163 
 
 The Investigator agr ees to administer s tudy drug only to patients under his/her personal 
supervision.  The Investigator will not supply study drug to any person not authorized to receive 
it. 
14.7 Handling and Disposal of Study Drug  
Study drug should be stored in a secure location, under the indicate d conditions ( Section  5.2).  
Information regarding the number of vials utilized for each patient, as well as the dose of study drug administered to the patient, will be recorded on the appropriate drug inventory form.  
Periodically throughout and at the conclusion of the study, vials of study drug will be inventoried 
by a representative of the Sponsor (or designee). At the completion of the study, all unused study 
materials MUST be returned to the Sponsor (or designee), unless otherwise authorized in writing.   
Information regarding the storage, handling, inventory, and disposition of study drug will be provided by the Sponsor  (or designee) .   
14.8 Recording of Data  
Clinical trial data for this study will be cap tured in a n electronic format. Electronic data capture 
(EDC) services will be provided by a vendor to be determined by the Sponsor. The Investigator agrees to pro vide all information requested in the CRF in an accurate manner accor ding to 
instructions provided. CRFs  are d esigned for co mputer processing and analysis. All data must be 
carefully entered to per mit meaningful interpretation. Corrections to entered data will be 
identified and tracked by audit trails within the EDC system. Data must be entered i nto CRFs in 
a time ly fashion. 
A CRF is required to be submitted for every patient who receives any amount of study drug.  
This includes submission of retrievable data on patients who withdraw before completion of the study. Prior to submission, CRFs must be reviewed f or com pleteness and accuracy, and signed 
and dated where indicated, by either the Principal Investigator or a physician Sub- Investigator 
whose name is listed on the  Form FDA 1572 for this study.  
All collected data will be entered into a validated database.  
14.9 Sourc e Document Requirements  
The Investigator will maintain adequate and accurate records for each patient treated with study drug. Source documents including but not limited to hospital, clinic or office charts, laboratory reports, radiology and pathology reports, pharmacy records, study worksheets, anonymized 
photographs aimed at documenting study- associated clinical findings, and signed ICFs , must 
completely reflect the nature and extent of the patient’s medical care, must be included in the 
Investigato r’s files along with patient study records, and must be available for source document 
verification against entries in the CRF.    
Each trial site will permit authorized representatives of the Sponsor and relevant Health 
Authorities direct access to (and wh en required by applicable law, to copy) clinical records for 
the purposes of quality assurance reviews, audits , and evaluation of the trial safety and progress. 
The Sponsor (or designee) will check CRF entries against source documents according to the 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 109 of 163 
 
 guidelines of ICH E6 (R2) GCP . Data not requiring a separate written record, i.e. data which may 
be recorded directly in the CRF, will be determined before trial start.  
The ICF will include a statement by which patients allow the Sponsor (or designee), as well as 
authorized regulatory agencies, to have direct access to  source data that support data i n the CRF 
(e.g. patient medical files, appointment books, original laboratory records, etc.). The Sponsor (or 
designee), bound by confidentiality and privacy regulat ions, will not disclose patient identities or 
personal medical information. 
14.10 Laboratory Reports  
Prior to initiation of this study, the Investigator must supply the Sponsor (or designee)  with the 
normal laboratory values for the laboratories to be utilized; specifically, the normal laboratory 
values for analytes required to be measured, per protoc ol, are to be supplied .   
Laboratory safety evaluations must be performed at the intervals specified.  If unexplained laboratory abnormalities occur, corroborative t ests will be performed until the laboratory 
abnormality has  resolved, returned to baseline status , and/or adequate explanation of the 
abnormality has been provided. 
Copies of any additional records pertinent to the study (e.g. laboratory data, radiological  reports, 
patient chart summaries, autopsy reports) must be made available to the Sponsor ( or designee)  or 
governing Health A uthorities, if requested, with due precaution taken to ensure patient 
confidentiality.  
14.11 Record Retention  
Regulatory authorities requ ire that the Investigator retain copies of all files pertaining to the 
study according to l ocal requirements . In addition, the Investigator is responsible for archiving 
all relevant source documents so that trial data may be compared against source data af ter 
completion of the trial, e.g. in case of inspection from authorities. Study records mus t be stored 
in a safe and secure location permitting timely retrieval, if necessary. The Investigator must 
obtain written permission from the Sponsor prior to dispos ing of any records. 
If the Investigator relocates, retires, or withdraws for any reason from the study, trial records 
may be transferred to an acceptable designee, such as another Inves tigator within the institution.  
The Sponsor (or designee) , as well as t he responsible IRB /EC, must be notified of the identity of 
the individual assuming responsi bility for maintaining the study records and the location of their 
storage.   
14.12 Monitoring of the Study  
The Sponsor has responsibility to governing Health Authorities  to take all reasonable steps to 
ensure the proper conduct of the study with respect to tria l ethics, protocol adherence, and data 
integrity and validity. 
This study will be closely monitored by representatives of the Sponsor (and/or designee) 
throughout it s duration. Monitoring will be in the form of periodic personal visits with the 
Investigato r and his/her staff as well as any appropriate communications by telephone, telefax, 
mail, or e -mail transmission. The purpose of these contacts is to review study progress, 
Investigator and patient adherence to protocol requirements , and any emergent problems 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 110 of 163 
 
 associated with the conduct of the study. The following usually will be assessed during 
monitoring visits at the site: 
• Required regulatory documentation 
• Signed ICFs  
• Patient accrual and follow -up 
• Study drug inventory records  
• Investigator and patient compliance to the study protocol  
• Concomitant therapy us age 
• AE documentation  
• Data is accurate, complete, and verifiable when compared to source documents  
The Investiga tor and study staff are expected to cooperate with monitors during such visits and 
provide them with all relevant study documents. The Investigator must give the Sponsor ( and/or 
designee)  direct access to all relevant source documents to confirm con sistenc y with the CRF 
entries. It is important that the Investigator and relevant personnel are available during 
monitoring visits and possible audits and that sufficient time is devoted to the process . 
In addition, the study may be evaluated by Sponsor  auditors (and/or designees) and government 
inspectors who must be allowed access to CRFs, source documents , and other study files. 
Sponsor  reports will be kept confidential. The Investigator should promptly notify the Sponsor of 
any audits scheduled by any regulatory authorities, and promptly forward copies of audit reports. 
As applicable, in a ccordance with the Health Insurance Portability and Accountability Act 
(HIPAA) and associated privacy regulations, patient authorization to use personally identifiable health information may be required from each patient before research activities. This 
authorization document must clearly specify what parties will have access to a patient’s personal 
health information, for what purpose , and for how long. 
14.13 Patient Confidentiality  
Every effort will be made to maintain the anonymity and confidentiality of patients during this clinical study. Each participating site will maintain appropriate medical and research records for 
this trial, in compliance with ICH E6 (R2) GCP , regulatory, a nd institutional requirements for the 
protection of confidentiality of patients.   
Coded patient identifiers will be utilized always  (including in any publications) when referring to 
a patient . However, because of the experimental nature of this treatment,  the Investigator agrees 
to allow representatives of the Sponsor  (and/ or designee ), as well as authorized representatives of 
the governing Health Authority , to inspect the facilities used in this study and to inspect, for 
purposes of verification, the hospi tal or clinic records of all patients enrolled into this study. A 
statement to this effect should be included in the ICF. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 111 of 163 
 
 14.14   Financing and Insurance  
The study will be supported by the Sponsor . Specifics of the financing and insurance coverage 
will be addre ssed in the clinical study agreement between the Sponsor  and the Investigator or 
Institution.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 112 of 163 
 
 15 HANDLING AND PROCESSING OF DATA  
15.1 Data Handling  
Study data collection, processing, transfer, and re porting, as well as handling of study personnel 
information , will be in compliance with ICH E6(R2) GCP and all applicable data protection 
regulations , including Regulation (EU) 2016/679 of the European Parliament and of the Council 
of 27 April 2016 on the protection of natural persons with regard to the processing of pe rsonal 
data and on the free movement of such data (General Data Protection Regulation) . 
15.2 Data Review During this Study  
Data obtained from  the study will be reviewed in a timely manner througho ut by the Sponsor (or 
designee) and Sponsor's Medical Representat ive(s) to  assess safety and the progress of the 
project.  
15.3 Data Processing 
A Data Management Plan (DMP) will be prepared for this trial. The Sponsor ( or designee ) will 
be responsible for data processing in accordance with applicable D ata M anagement SOPs  and 
the trial DMP .  
Once recorded within the electronic CRF, study data will pass through a set of pre -programmed 
data validation checks designed to identify inconsistencies and other data errors , and also will 
undergo an additional study- specific data review process, as stated above in Section 15.2.  Data 
issues will be queried via the EDC system and query resolutions will be documented.  
Entry and processing of data other than those directly recorded on electronic CRFs by trial sites 
(e.g. imports of laboratory results) will follow vendor (s) SOPs. Transfer of such data from 
vendor (s) to Sponsor (or designee) will be handled according to vendor (s) data transfer SOPs and 
the Sponsor data transfer requirements , with fu ll compliance to applicable regulations.  
Database Lock will occur upon reaching the pre -defined data cut -off for primary analysis and 
completion of Sponsor’s (or designee ’s) quality control and quality assurance procedures. 
Portable Document Format (PDF) f iles of the electronic CRFs will be provided to the 
Investigator upon removal of acce ss to the electronic CRFs . 
15.4 Clinical Trial Report  
Following study completion, a final integrated clinical/statistical Clinical Trial Report (CTR) 
will be prepared.  
15.5 Compliance with the General Data Protection Regulation  
The applicable data protection l egislation requires that parties enter into a written contract if one 
party (data processor) processes personal data on behalf of the other party (data controller). This written contract must regulate the subject- matter and duration of the processing, the nature and 
purpose of the processing, the types of personal data and categories of data subjects, as well as the obligations and rights of the data controller. Accordingly, the parties must enter into a data processing agreement. To the extent the processi ng of personal data involves transfers of 
personal data to third countries (e.g., jurisdictions outside of the European Economic Area [EEA]), the parties will enter into the European Commission's standard contractual clauses 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 113 of 163 
 
 between the data controller, th e data processor, and all sub -processors, if any. The European 
Commission's standard contractual clauses ensure an adequate level of protection in relation to 
transfers of personal data to third countries. 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 114 of 163 
 
 16 STATISTICAL ANALYSIS   
16.1 Statistical Considerations  
A Statistical Analysis Plan (SAP) that includes a more technical and detailed description 
(including templates for Tables, Listings, and Figures) of the planned statistic al summaries 
analyses will be prepared and finalized prior to database lock.  
Further data- driven and exploratory analyses may be defined and performed and presented in the 
CTR  as appropriate.    
16.2 Sample Size Considerations  
Approximately 15- 30 male and female patients will be enrolled and treated , based on a standard 
3+3 design, to allow determination of the MTD and /or RP2D. It is assumed that approximately 4 
cohorts will be required during the dose -escalation. However, the protocol allows for enrollment 
of > 4 cohorts, should this be necessary to identify the MTD and/or RP2D . Expansion of the 
MTD/MAD cohort to treat up to 12 patients may be considered for further evaluation of 
tolerability.   
16.3 Analysis Populations  
Two analysis sets will be defined in accordance with the consolidated guidelines, ICH E9 
Statistical Principles for Clinical Trials.  
The Full Analysis Set (FAS) will comprise all enrolled patients who have received at least a 
fraction of one dose of study drug. The FAS will be used for evaluation of a ll endpoints except 
evaluation of DLTs. The patients in the FAS will contribute to the analyses as allocated to 
treatment.  For the evaluation of PK endpoints, patients, full profiles, or single measurements can 
be excluded from the analyses. The decision of excluding patients, full profiles, or  part of 
profiles will be described in the CTR . 
The DLT Analysis Set will comprise all patients in the FAS enrolled in the dose -escalation , 
except patients who did not complete Cycle 1 for reasons other than drug toxi city. The DLT 
Analysis Set will be used  for evaluation of DLTs.   
16.4 Trial Endpoint s 
16.4.1 Primary Endpoints  
DLTs to establish MTD as defined in Section 6.9, and/or  the RP2D as defined in Section 6.6.3, 
will be the primary study endpoint .  RP2D will be determined by:  
• Incidence, severity, and relationship of treatment emergent AEs measured from 
administration of the first dose of study drug or worsening after taking study drug, to the last dose of study drug plus 30 days  
• AEs leading to dose interruption, dose delays, dose reduction, and permanent treatment cessation  
• Changes in safety laboratory values from baseline to end of safety follow up 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 115 of 163 
 
 16.4.2 Secondary Endpoints  
• Additional safety  endpoints , including:  
o Exposure to study medication, including duration, dose reduction and/or delay 
o Changes in vital signs, body weight, and physical examination findings from 
baseline to end of trial participation  
o ECG Findings  
• Occurrence of ADA measured in serum at selected timepoints from baseline to end of trial participation  
• Antineoplastic Activity, measured by tumor response to study treatment and tumor 
shrinkage, time to progression (TTP) based on radiological evident as per RECIST v1.1 
and relevan t lymphomas assessment criteria.  
• PK profile of study drug, derived based on the concentration- time curves after the first 
infusion 
16.5 Statistical Analysis  
16.5.1 General Specifications  
Statistical analyses will be carried out using Statistical Analysis System (SAS
®) Version 9.4 or 
higher. 
All data summaries and statistical analyses will be performed based on the FAS population, 
unless otherwise specified. 
In general, continuous variables, including baseline characteristics, will be summarized using 
descriptive  statis tics by reporting the number of observations, mean, standard deviation, median, 
minimum, and maximum. Categorical/discrete variables will be summarized using frequency 
distributions showing the number and percentage of patients within a category.  T ime-to-event 
data will be summarized using the Kaplan -Meier method, as appropriate.  
Unless indicated otherwise, summary statistics will be presented using observed data onl y. 
Missing data will not be imputed. If a baseline value is missing, no change fr om baselin e will be 
calculated.  Baseline is defined as the last available observation prior to the first administration of 
study drug on C1/D1. 
16.5.2 Patient Disposition, Baseline and Treatment Characteristics  
Patient disposition, including withdrawals of patients from st udy drug and reason, will be 
summarized using frequency distributions.  
Patient demographics, baseline and disease characteristics such as age, sex, race, cancer type, 
prior anti -cancer therapies, and ECOG PS, will be presented using descriptive sta tistics  or 
Frequency distributions, as appropriate.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 116 of 163 
 
 16.5.3 Study Treatment  
Exposure to study drug and the administration profile will be summarized descriptively for each 
cohort with respect to number of cycles taken, the cumulative dose, the dose intensity, the relativ e dose intensity, and dose modifications. 
16.5.4 Maximum Tolerated Dose  
All DLT events will be listed by dose cohort and patient. A summary table of DLTs across dose 
cohorts by System Organ Class (SOC) and preferred term will be presented, if applicable. T he 
summ aries will include number of DLTs, and number and percentages of patients experiencing a 
DLT.  
A table will be presented showing the MTD, if identified, as well as a summary of the dose -
escalation.  
16.5.5 Adverse Events  
AEs will be coded by SOC  and preferred term using the most current version of MedDRA. AEs 
including SAEs  will be recorded starting at signing of informed consent * through 30 days 
following the last dose of study drug (1M FUP Visit) , and will be tabulated by maximum 
severity according to the CTCAE v5.0.   
*Patients who sign informed consent and are subsequently deemed to be screen failures will be followed for the 
occurrence of SAEs/AEs until it is determined that they will not be participating in  the trial  
AEs will be regarded as TEAEs  if they occur after first treatment. Non -treatment emergent AEs 
(non- TEAEs) are defined as AEs collected before administration of the first dose . If non- TEAEs 
increase in frequency or severity after treatment , these will be considered TEAEs. TEAEs will be 
presented by S OC and preferred term unless stated otherwise. The frequencies of TEAEs will be 
presented including number and percentages of patients having experienced an event and the 
total number of events.  
The calculation of AE incidence will be based on the number of patients per AE category. For 
each patient who has multiple AEs classified to the same category, that patient will be tabulated under the highest  toxicity  grade for that AE category. Summary tables w ill be presented by:  
1. AEs, in total and sorted by freque ncy  
2. AEs by relationship 
3. AEs by grade and maximum grade  
4. SAEs, in total, and by relationship 
5. AEs leading to dose interruption, dose delays, dose reduction, and permanent treatment cessation  
6. AEs leading to trial drug delay  
7. Fatal AEs  
During dose -escalation , first-cycle DLTs, AEs leading to death or to discontinuation of study 
treatment, and SAEs will be evaluated with special attention.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 117 of 163 
 
 16.5.6 Laboratory Determinations  
Biochemistry, hematology, and coagulation parameters will be presented using box plots , if 
appropr iate.  In addition, individual patient biochemistry, hematology, and coagulation 
parameters during the trial will be presented graphically using longitudinal plots. U rinalysis 
parameters w ill be summarized using descriptive statistics.    
Laboratory measurements will be graded according to CTCAE  v5.0, when applicable. T he 
frequencies of the highest  CTCAE  v5.0 grade observed will be displayed for each AE and for 
each starting dose level.   
Laboratory values outside normal range will be flagged, and laboratory values will be listed 
including grading of abnormal values. Laboratory determinations categorized as in or out of 
normal range may be summarized in some cases using worst -case shift tables. CS or not 
clinically significant (NCS) criteria may be applied fo r out-of-range values.  
16.5.7 Vital Signs, Body Weight, Physical Exam Findings  
Actual values and change- from -baseline values for VS , body weights, PS, as well as physical 
examination findings, wi ll be summarized descriptively. Normal and abnormal findings in 
phys ical examination will be presented in shift tables by visit, if appropriate . 
16.5.8 ECG Findings  
Descriptive statistics of ECG observa tions will be presented. The frequency and percentage of 
ECG results will be summarized for the following ECG measurements:  HR , PR interval, QRS 
duration, QT interval , and QTc interval. The QTc  interval , indicating repolarization time, will be 
calculated . T-wave and ST -segment ECG abnormalities will be graded based on definitions in 
the Common Toxicity Criteria (CTC).   
Normal and abnormal findings will be presented in shift tables by visit. Additional details regarding the ECG analyses will be provided in the S AP. 
16.5.9 Other Safety Data  
Concomitant medications and findings in ophthalmology examinations, PFTs , thyroid function 
tests, and  ADA analyses  will be summarized in text as  recorded in the CRF , and as made 
available from an independent central assay laboratory, in the case of ADA data.  
16.5.10 Antineoplastic Activity   
All antineoplastic activity analyses will be descriptive and exploratory in nature. Disease status 
will be summarized by cycle and dose group, including changes from baseline. As a secondary objective, OR , duration of OR , SD, and TTP  will be assessed and calculated, wherever possible, 
according to standard response criteria.    
Response Calculations  
In the event of an OR (CR or PR) the duration of the OR  will be determined from the day the 
initial response is observed (using screening/baseline images for comparison) to the day that 
progression is observed. Number and percentages  of patients with documented OR will be 
presented.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 118 of 163 
 
 Duration of SD (minimum duration of not less than 16 weeks) will also be assessed  using the 
time from the first dose of study drug to the day that PD is confirmed  based on radiological 
evidence or censored at the last on -study tumor assessment without PD . The number and 
percentages  of patients with SD for more than 16 weeks will be presented.  
Best overall response will be summarized by cohort using frequency distribution. 
Waterfall plots will be presented  for patients with measurable disease.  
TTP calculated as from the first dose of study drug to the day that PD is confirmed based on 
radiological evidence or censored at the last on -study tumor assessment without PD will be 
presented in a Kaplan -Meier plot , as appropriate.   
Other Antineoplastic Assessments  
Tumor markers will b e listed and summarized, as appropriate  
16.5.11 Pharmacokinetic Analysi s 
PK analyses will be performed in dose -escalation c ohorts on patients who receive any amount of 
their assigned dose of st udy drug and have an adequate number of concentration determinations 
to allow for PK calculation . 
The PK profile of study drug will be derived based on the concentration- time cu rves after the 
first infusion. C max, CEOI, Ctrough and T max will be derived fro m observed data while AUC inf, 
AUC τ, AUC norm, τ , CL, V d, and T ½ will be estimated using non -compartmental methods and 
actual timepoints.   For repeated dosing, C EOI and C trough (equivalent to the concentration at EOI 
and SOI, respectively) will be assessed.  
Individual curves of serum concentration of total study drug versus time after the first infusion 
will be presented on log-  and linear scale for all patients in the PK population. Furthermore, 
maximum and trough serum concentrations for the period from first dose to EOT will be 
presented on linear scale individual pl ots. In addition, mean concentration- time curves will be 
presented on linear scale using nominal timepoint by cohort and trial part. All PK endpoints will 
be listed and summarized by trial part and cohort  (Table 5 ). 
 
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 119 of 163 
 
  
Table  5:  PK Endpoint, Definitions, and Derivations  
Symbol  Definition and Derivation  
Ctrough Trough concentration (i.e. concentration of study drug  measured pre -infusion)  
AUC inf Area under the concentration -time curve from start of infusion to infinity  
AUC τ Area under the concentration -time curve from start of infusion up to 336 hours.  
AUC norm,  τ 
 Dose -normalized area under the concentration -time curve in a dosing interval, calculated as AUC  τ divided by the 
dose infused  
Cmax Maximum concentration  
Tmax Time to maximum concentration  
CEOI Concentration at  the end of infusion  
λz Terminal rate constant (negative of the slope of an ln -linear regression of the un -weighted data considering the 
terminal phase of the concentration -time curve ≥ limit of quantifi cation). λ z is not an endpoint, but is used for 
derivation of endpoints  
T½ Terminal elimination half -life, calculated as ln(2)/ λ z 
CL  Clearance after first dose, calculated as Dose/AUC inf for C1/D1, where AUC inf will be calculated as the sum of 
the area from time zero to time of last quantifiable concentration, t z, and the area from t z to infinity. The second 
area will be estimated using the observed concentration at t z and the terminal ra te constant  
Vd Volume of distribution during the terminal phase a fter first dose (CL S/ λz) 
 
16.6 Additional Endpoints and Analyses  
16.6.1 Pharmacodynamic and other Biomarker Analyses  
Pharmacodynamic and other biomarker assessments , to include collection of peripheral blood, 
will be conducted in all patients . Tumor biopsies are optional and biomarker analysis of biopsied 
tumors may be performed on material collected.    
Exploratory analysis may  be performed.  Endpoints may include genes and/or proteins that are 
unknown or have not been included in the scientific hypotheses at the time of the trial, but that, 
during the collection of data from this trial, may evolve as new candidate genes and markers related to safety, efficacy, or mech anism of action of the study drug.  
Pharmacodynamic and other biomarker  analyses will be performed according to standard 
methodologies and will examine relationships between the pharmacodynamic /biomarker  
assessments and clinical toxicities observed during t he study.  
16.7 Modeling of Pharmacokinetic and P harmacodynamic /Biomarker Data  
PK samples will be analyzed on an on -going basi s during the trial. All data collected in this trial 
may be used for modeling of PK , pharmacodynamic  and other biomarker  assessment  to support 
the planning and dose setting within the current trial as well as for future trials. Preliminary data generated d uring the trial may be used for exploratory modelling. The final data  (i.e. after 
Database Lock) will be used for the final model and potentially for cross -trial modelling. These 
modelling activities will be reported separately from the current trial.  
16.8 Devi ations from the Statistical Plan  
Any deviation(s) from the original analysis plan will be descri bed in a protocol amendment 
and/or in the SAP  and/or in the final CTR , as appropriate.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 120 of 163 
 
 16.9 Interim Analysis  
Safety evaluation will be performed prior to each dose -escalation. No other interim analyses are 
planned.  
All relevant safety, PK , and toxicity data wil l be reviewed on an ongoing basis throughout the 
trial.  Based on an overall evaluation of data collected, the RP2D will be chosen. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 121 of 163 
 
 17 REFERENCES 
1. WHO World Cancer Report 2014. Edited by Bernard W. Stewart and Christopher P. 
Wild.   
2. Le Mercier I, Lines JL, Noel le RJ. Beyond CTLA -4 and PD -1, the g eneration Z of  
negative c heckpoint r egulators. Front Immunol. 2015; 6: 418. 
 
3. Anderson AC, Joller N, Kuchroo VK. Lag- 3, Tim -3, and TIGIT: Co- inhibitory 
receptors with s pecialized f unctions in i mmune r egulation. Immunity 2016; 44(5): 989-
1004.  
4. Donia M, Andersen R, Kjeldsen JW, et al. Aberrant e xpression of MHC c lass II in 
melanoma a ttracts i nflammatory t umor -specific CD4+ T -Cells, which dampen CD8+ T -
cell antitumor r eactivity. Cancer Res. 2015; 75(18): 3747- 3759. 
 
5. Huang R -Y, Eppolito C, Lele S, et al. LAG3 and PD1 co- inhibitory molecules 
collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 2015; 6: 27359 –27377. 
 
6. Woo S -R, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG -3 and PD -
1 synergistically regulate T -cell function to promote tumoral immune escape. Cancer 
Res. 2012; 72: 917–927.  
7. Lipson, E, Gopal A , Neelapu SS, et al. Abstract P232: Initial experience administering 
BMS -986016, a monoclonal antibody that targets lymphocyte activation gene (LAG) -3, 
alone and in combination with nivolumab to patients with hematologic and solid malignancies. J Immunothe r. Cancer 2016:  4 (Suppl 1):73: 129- 130. 
 
8. Ascierto PA, Melero I, Bhat ia S, et al. Initial efficacy of anti- lymphocyte activation gene -
3 (anti –LAG- 3; BMS -986016) in combination with nivolumab (nivo) in pts with 
melanoma  (MEL) previously treated with anti- PD-1/PD -L1 therapy. J Clin Oncol . 2017; 
35 (Suppl; Abstract 9520) . 
 
9. Hezareh M, Hessell AJ, Jensen RC, et al. Effector function activities of a panel of 
mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. 2001; 75( 24): 12161- 12168. 
 
10. Hessell AJ, Hangartner L, Hunter M, et al. Fc rece ptor but not complement binding is 
important in antibody protection against HIV. Nature 2007; 449(7158): 101- 104. 
 
11. Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol -Myers Squibb Company; 
2017. 
 
12. Keytruda (pembrolizumab) [package inset]. Whitehouse  Station, NJ: Merck & Co., Inc; 
2017. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 122 of 163 
 
  
13. Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genent ech, Inc.; 
2017. 
 
14. Bavencio (avelumab) [package insert]. Rockland, MA; EMD Serono, Inc.; 2017.  
15. Imfinzi (durvalumab) [package insert]. Wilmingto n, DE : AstraZeneca Pharmaceuticals 
LP; 2017.  
16. He Y, Rivard CJ, Rozeboon L, et al. Lymphocyte -activation gene -3, an important 
immune checkpoint in cancer. Cancer Sci. 2016; 107(9): 1193- 1197.  
 
17. Postow M and Wolchok J. Toxicities associated with checkpoint inhibitor immunotherapy. UpToDate 2017; 13.57: 1- 21. 
 
18. Adbel -Wahab N, Shah M, and Suarez -Almazor ME. Adverse events associated with 
immune checkpoint blockade in patients with cancer: a sys tematic review of case reports.  
PLoS ONE 2016; 11(7):  e0160221. 
 
19. Heinzerling L and Goldinger SM. A review of serious adverse effects under treatment with checkpoint inhibitors. Current Opinion- Oncol. 2017; 29:  1-9. 
 
20. Kumar V, Chaudhary N, Garg M, et al. Cu rrent diagnosis and management of immune 
related adverse events (irAEs) induced by immune checkpoint inhibit or therapy. Frontiers 
in Pharmacol. 2017; 8: 1- 14. 
 
21. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in tr ials testing immunotherapeutics. Lancet Oncol. 2017; 18:  e143-e152. 
 
22. Litiè re S, Collette S, de Vries EGE, et  al. RECIST -learning from the past to build the 
future. Nature Reviews -Clinical Oncol. 2017; 14:  187- 192. 
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 123 of 163 
 
 18 APPENDICES  
Appendix 1  Performance Status Evaluation  
 
 
Measures of Performance Status  
 
 
Percent   
KARNOFSKY  
Performance Status Description1 
   
Level   
Eastern Cooperative Oncology Group 
(ECOG )  
Performance Status Description2 
 
 
100  
Normal; no complaints, no evidence o f 
disease  
  
0 
 
  
Normal activity  
 
90  
Able to carry on normal activity; minor signs or 
symptoms of disease  
 
 
80  
Normal activity with effort; some signs or 
symptoms of disease  
  
1 
 
  
Symptoms but ambulatory  
 
70  
Cares for self; unable to carry on n ormal activity or 
do active work  
 
 
60  
Requires occasional assistance but is able to care 
for most needs  
  
2 
 
  
In bed < 50% of time  
 
50  
Requires considerable assistance and frequent 
medical care  
 
 
40  
Disabled; requires special care and assista nce 
  
3 
 
  
In bed > 50 % of time  
 
30  
Severely disabled; hospitalization is indicated 
although death is not imminent  
 
 
20  
Very sick; hospitalization is necessary  
 
  
4 
 
  
100 % bedridden  
 
10  
Moribund; fatal processes progressing rapidly 
 
 
0  
Death 
 
  
5  
Death  
 
1Karnofsky DA, Abelman WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma.  Cancer . 
1948 ;1:634 -656. 
2Oken M, Creech RH, Tormey DC, Horton J, Davis TE, McFadden E, Carbone PP. Toxicity and response criteria of the eastern cooperative 
oncology group.  Am J Clin Oncol . (CCT) 1982 ; 5:649 -655. 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 124 of 163 
 
 Appendix 2  New York Heart Association Functional Criteria  
 
 
New York Heart Association Functional Criteria  
 
 
Class I   
No li mitation of physical activity.  Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea, or anginal pain.  
 
 
Class II   
Slight limitation of physical activity.  Comfortable at rest, but ordinary physical activity results in 
fatigue, pa lpitation, dyspnea, or anginal pain.  
 
 
Class III   
Marked limitation of physical activity.  Comfortable at rest, but less than ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal pain.  
 
 
Class IV  
  
Unable to carry on any physic al activity without discomfort.  Symptoms of cardiac insufficiency or 
anginal syndrome may be present even at rest.  If any physical act ivity is undertaken discomfort 
increases.  
 
 
The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great 
Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253 -256 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 125 of 163 
 
 Appendix 3  Clinical Adverse Event s: Grading Scale  
 
Severity  CTCAE*  
Grade  Definition  
Mild  1 Awareness of symptom, but easily tolerated.  Event is usually transient requiring 
no special treatment; does not interfere with usual status or activities  
 
Moderate  2 Event may be ameliorated by simple therapeutic measures; may interfere with usual activities  
 
Severe 3 Event results in temporary disability or incapacity; inability to perform usual activities; requires intervention  
 
Life-threatening  4 Event requires immediate intervention; need for emergency treatment; patient is at 
risk of death at the time of the ev ent 
 
Fatal  5 Event resulting in the subsequent death of the patient  
 
 
Note:  In those cases where further definition of an event is provided by the Common Terminology Criteria for Adverse Events 
(CTCAE v 5.0), please refer to that document for grading and severity information.  
*<https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm > 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 126 of 163 
 
 Appendix 4  Clinical Adverse Events:  Determining Relationship to Study Drug  
 
NOT-RELATED  
This category applies to those AEs which, after careful medical consideration, are clearly felt to be due to extraneous causes 
(disease, environment, etc. ) that are not-related  to the administration of study drug.  
UNLIKELY -RELATED  (must have first 2)  
This category applies to those AEs which, after careful medical consideration, are felt unlikely to be related to the administration 
of the study drug.  The relationship of an AE  to the study drug can be c onsidered unlikely  if: 
• It does not follow a reasona ble temporal sequence from administration of the drug.  
• It could readily have been a result of the patient’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to the pat ient. 
• It does not follow a known response pattern t o the suspected drug.  
• It does not reappear or worsen when the drug is re -administered.  
 
POSSIBLY -RELATE D (must have first 2)  
This category applies to those AEs which, after careful medical consideration,  are felt unlikely to be related to the administration 
of the study drug, but the possibility cannot be ruled out with certainty.  The relationship of an AE  to the study drug can be 
considered possible  if: 
• It follows a reasonable temporal sequence from adm inistration of the drug.  
• It could readily have been a result of the patient’s clinical state, environmental or toxic factors, or other modes of 
therapy administered to the patient.  
• It follows a known response pattern to the suspected drug.  
 
PROBABLY -RELAT ED (must have first 3)  
This category applies to those AEs which, after careful medical consideration, are felt with a high degree of certainty to be 
related to the administration of the study drug.  The relationship of an AE  to the study drug can be consi dered probable  if: 
• It follows a reasonable temporal sequence from administration of the drug.  
• It could not be reasonably explained by the known characteristics of the patient’s clinical state, environmental or toxic 
factors , or other modes of therapy admi nistered to the patient.  
• It disappears or decreases upon cessation of drug or reduction in dose  (if applicable) .* 
• It follows a known response pattern to the suspected drug.  
 
RELATED  (must have first 3)  
This category applies to those AEs, which, after car eful medical consideration, are felt to be related to the administration of the 
study drug.  The relationship of an AE  to the study drug can be considered related  if: 
• It follows a reasonable temporal sequence from administration of the d rug or drug levels have been established in body 
fluids or tissues.  
• It could not be reasonably explained by the known characteristics of the patient’s clinical state, environmental or toxic factors , or other modes of therapy administered to the patient.  
• It disappears or decr eases upon cessation of drug or reduction on dose (if applicable) and appears upon rechallenge.*  
• It follows a known response pattern to the suspected drug.  
 
Adapted from:  Karch FE and Lasagna L. Adverse drug reactions: a critical review. JAMA . 1975 Dec 2 2; 234 (12):1236 -1241.  
 
*There are exceptions when an AE  does not disappear upon discontinuation of the drug, yet drug-relatedness clearly exists, e.g. 
1) ta rdive dyskinesia, 2) fixed drug eruptions.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 127 of 163 
 
 Appendix 5  Response Evalu ation Criteria in Solid Tumors ( RECIST  v1.1)  
 
Summary of RECIST v1.1 Guidelines  
 
For the purposes of this study, patients should be re -evaluated for response every 8 weeks .  In addition to a baseline scan, 
confirmatory scans should also be obtained >  4 we eks following initial documentation of objective response  (OR).  
 
Response and progression will be evaluated in this study using the new international criteria proposed by the revised 
Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) [ Eur J Ca  45:228 -247, 2009].  Changes in 
the largest diameter (unidimensional  measurement) of the tumor lesions and the shortest diameter in the case of malignant 
lymph nodes are used in the RECIST v1.1 criteria.  
 
A. DEFINITIONS  
 
Evaluable for Toxic ity:  All patients will be evaluable for toxicity from the time of their first treatment with study drug.   
 
Evaluable for Objective Response:  Only those patients who have measurable disease present at baseline, have received at 
least one cycle of therapy , and have had their disease re-evaluated will be considered evaluable for response.  These patients 
will have their response classified accor ding to the definitions stated below.   
 
Note:        Patients who exhibit objective disease progression prior to the end of cycle 1 will also be considered evaluable.  
 
Evaluable Non -Target Disease Response :  Patients who have lesions present at baseline t hat are evaluable but do not meet 
the definitions of measurable disease, have received at least one cycle of therapy, and have had their disease re-evaluated 
will be considered evaluable for non-target disease.  The response assessment is based on the pres ence, absence, or 
unequivocal progression of the lesions.  
 
B. DISEASE PARAMETERS  
 
Measurable Disease:  Measurab le lesions are defined as those that can be accurately measured in at least one dimension 
(longest diameter to be recorded) as ≥  20 mm by chest x -ray, as ≥ 10 mm with CT scan, or as ≥10 mm with calipers by 
clinical exam.  All tumor measurements mu st be recorded in millimeters  (or decimal fractions of centimeters).  
 
Note:  Tumor lesions that are situated in a previously irradiated a rea might or might not be considered measurable.   
If the investigator thinks it appropriate to include them, the conditions under which such lesions should be considered must be 
defined in the pr otocol . 
 
Malignant Lymph Nodes :  To be considered pathologic ally enlarged and measurable, a lymph node must be ≥  15 mm in 
short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) .  At baseline and at  
follow -up, only the short axis will be measured and followed.  
 
Non-Measurable Disease:  All other lesions (or sites of dise ase), including small lesions (longest diameter < 10 mm or 
pathological lymph nodes with ≥ 10 to < 15 mm short axis), are considered non-measurable disease.  Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/p ulmonitis, inflammatory breast disease, 
and abdominal masses (not followed by CT or MRI) are considered as non-measurable.  
 
Note:  Cystic lesions that meet the criteria for radiographically defined simple cysts should not be considered as malignant lesions  
(neither measurable nor non -measurable) since they are, by definition, simple cysts.  
 
Cystic lesions  thought to represent cystic metastases can be considered as measurable lesions, if they meet the definition of 
measurability described above.  However, if  non-cystic lesions are present in the same patient, these are preferred for selection as 
target lesi ons. 
 
Target Lesions :  All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total, representative of all 
involved organs, should be identified as target lesions  and recorded and measured at baseline.  Target lesions should be 
selected based on their size (lesions with the longest diameter), be representative of all involved organs, but in addition 
should be those that lend themselve s to reproducible repeated measurements.  It may be the case that, on occasion, the 
largest lesion do es not lend itself to reproducible measurement in which circumstance the next largest lesion which can be 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 128 of 163 
 
 measured reproducibly should be selected.  A sum of the diameters (longest for non -nodal lesions, short axis for nodal 
lesions) for all target lesions  will be calculated and reported as the baseline sum diameters.  If lymph nodes are to be 
included in the sum, then only the short axis is added into the s um.  The baseline sum diameters will be used as reference to 
further characterize any objective tumor  regression in the measurable dimension of the disease.  
 
Non-Target Lesions :  All other lesions (or sites of disease) including any measurable lesions over  and above the 5 target 
lesions should be identified as non -target lesions and should also be recorde d at baseline.  Measurements of these lesions 
are not required, but the presence, absence, or in rare cases unequivocal progression of each should be noted  throughout 
follow -up. 
 
C. METHODS FOR EVALUATION OF MEASURABLE DISEASE  
 
All measurements should be taken and recorded in metric notation using a ruler or calipers.  All baseline evaluations should 
be performed as closely as possible to the beginning of treatment and never more than 4 weeks  before the beginning of the 
treatment . 
 
Note:  The same method of assessment and the same technique should be used to characterize each identified and reported lesion at 
baseline and during follow -up.  Imaging -based eva luation is preferred to evaluation by clinical examination unless the lesion(s) 
being followed cannot be imaged but are assessable by clinical exam.  
 
Clinical Lesions :  Clinical lesions will only be considered measurable when they are sup erficial (e.g. ski n nodules and 
palpable lymph nodes) and ≥  10 mm diameter as assessed using calipers (e.g. skin nodules).  In the case of skin lesions, 
documentation by color photography, including a ruler to estimate the size of the lesion, is recommende d.  
 
Chest X-ray :  Lesions on chest x -ray are acceptable as measurable lesions when they are clearly defined and surrounded by 
aerated lung.  However, CT is preferable.  
 
Conventional CT and MRI :  This guideline define s measurability of lesions on CT scan based on the assu mption that CT 
slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the minimum size for a measurable 
lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (e.g. for body scans).   
 
Use o f MRI remains a complex issue.  MRI has excellent contrast, spatial, and temporal resolution; however, there are many 
image acquisition variables involved in MRI, which greatly impact image quality, lesion conspicuity, and measurement.  
Furthermore, the av ailability of MRI is variable globally.  As with CT, if an MRI is performed, the technical specifications 
of the scanning sequences used should be optimized for the evaluation of the type and site of disease.  Furthermore, as with CT, the modality used at follow -up should be the same as was used at baseline and the lesions should be measured/assessed 
on the same pulse sequence.  It is beyond the scope of the RECIST v1.1 guidelines to prescribe specific MRI pulse sequence 
parameters for all scanners, body parts, and diseases.  Ideally, the same type of scanner should be used and the image acquisition protocol should be followed as closely as possible to prior scans.  Body scans should be performed with breath-hold scanning techniques, if possible.  
 
PET-CT :  At present, the low dose or attenuation correction CT portion of a combined PET -CT is not always of optimal 
diagnostic CT quality for use with RECIST v1.1 measurements.  However, if the site can document that the CT performed 
as part of a PET -CT i s of identi cal diagnostic quality to a diagnostic CT (with IV and oral contrast), then the CT portion of 
the PET -CT can be used for RECIST v1.1 measurements and can be used interchangeably with conventional CT in 
accurately measuring cancer lesions over ti me.  Note, however, that the PET portion of the CT introduces additional data 
which may bias an Investigator if it is not routinely or serially performed.   
Ultrasound :  Ultrasound is not useful in assessment of lesion size and should not be used as a meth od of measu rement.  
Ultrasound examinations cannot be reproduced in their entirety for independent review later,  and, because they are operator 
dependent, it cannot be guaranteed that the same technique and measurements will be taken from one assessment to  the next.  
If new lesions are identified by ultrasound during the study, confirmation by CT or MRI is advised.  If there is concern about 
radiation exposure using CT, MRI may be used instead of CT in selected instances.  
 
Endoscopy, Laparoscopy:  The utilization of t hese techniques for objective tumor evaluation is not advised.  However, 
such techniques may be useful to confirm complete pathological response when biopsies are obtained or to determine relapse in trials where recurrence following complete response (CR) or surgical resection is an endpoint.  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 129 of 163 
 
 Tumor Markers :  Tumor markers alone cannot be used to assess response.  If markers are initially above the upper normal 
limit, they must normalize for a patient to be considered in complete clini cal response.  Specifi c guidelines for both CA -125 
response (in recurrent ovarian cancer) and prostate specific antigen ( PSA) response (in recurrent prostate cancer) have been 
published [ JNCI 96:487 -488, 2004; J Clin Oncol  17, 3461- 3467, 1999; J Clin Oncol  26:1148 -1159, 2008].  In addition, the 
Gynecologic Cancer Intergroup has developed CA -125 progression criteria which are to be integrated with objective tumor 
assessment for use in first -line trials in ovarian cancer [ JNCI 92:1534 -1535, 2000].  
 
Cytology, Histology:  These tech niques can be used to differentiate between partial responses (PR) and complete responses 
(CR) in rare cases (e.g. residual lesions in tumor types, such as germ cell tumors, where known residual benign tumors can 
remain).  
 
The cytolog ical confirmation of t he neoplastic origin of any effusion that appears or worsens during treatment when the 
measurable tumor has met criteria for response or stable disease is mandatory to differentiate between response or stable 
disease (an effusion may be a side effect of th e treatment) and progressive disease.  
 
FDG -PET:  While FDG -PET response assessments need additional study, it is sometimes reasonable to incorporate the use 
of FDG -PET scanning to complement CT scanning in assessment of progression (particularly possible ' new' disease).  New 
lesions based on  FDG -PET ima ging can be identified according to the following algorithm:  
a. Negative FDG -PET at baseline, with a positive FDG -PET at follow -up is a sign of PD based on a new lesion.  
b. No FDG-PET at baseline and a positive FD G-PET at follow -up:   
• If the positive FDG -PET at follow -up corresponds to a new site of disease confirmed by CT, this is PD.   
• If the positive FDG -PET at follow -up is not confirmed as a new site of disease on CT, additional follow -up 
CT scans are needed to determine if there is truly progression occurri ng at that site (if so, the date of PD will 
be the date of the initial abnormal FDG -PET scan).   
• If the positive FDG -PET at follow -up corresponds to a pre -existing site of disease on CT that is not 
progressin g based on the anatomic images, this is not PD.  
c. FDG-PET may be used to upgrade a response to a CR in a manner similar to a biopsy in cases where a residual 
radiographic abnormality is thought to represent fibrosis or scarring.  The use of FDG -PET in this c ircumstance 
should be prospectively described in the protocol and supported by disease -specific medical literature for the 
indication.  However, it must be acknowledged that both approaches may lead to false positive CR due to limitations 
of FDG-PET and bi opsy resolution/sensitivity.  
 
Note:  A ‘positive’  FDG- PET scan lesion means one which is FDG avid with an uptake greater than twice that of the surrounding 
tissue on the attenuation corrected image.  
D. RESPONSE CRITERIA  
 
1. Evaluation of Target Lesions  
 
 Complete Response (CR) :  Disappearance of all target lesions.  Any pathological lymph nodes (whether target or non-
target) must have reduction in short axis to <  10 mm.  
 
 Partial Response (PR) :  At least a 30% decrease in the sum of the diameters of target  lesions, taking as ref erence the 
baseline sum diameters.  
 
 Progressive Disease (PD) :  At least a 20% increase in the sum of the diameters of target lesions, taking as reference 
the smallest sum on study (this includes the baseline sum if that is the small est on study).  In addi tion to the relative 
increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.   
 
Note:       The appearance of one or more new lesions is also considered progressions . 
 
 Stable Disease (SD) :  Neither suff icient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as 
reference the smallest sum diameters while on study.  
 
2.  Evaluation of Non -Target Lesions  
 
Complete Response (CR) :  Disappearance of all non -target lesions and normali zation of tumor marker level.  All 
lymph nodes must be non -pathological in size (< 10 mm short axis).  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 130 of 163 
 
  
Note:   If tumor markers are initially above the upper normal limit, they must normalize for a patient to be considered in complete 
clinical response.  
 
Non-CR/Non -PD:  Persistence of one or more non -target lesion(s) and/or maintenance of tumor marker level above 
the normal limits.  
 
Progressive Disease (PD) :  Appearance of one or more new lesions and/or unequivocal progression of existing non-
target lesions .  Unequivocal progression should not normally trump target lesion status.  It must be representative of 
overall disease status change, not a single lesion increase.     
 
Although a clear progression of “non -target” lesions only is exceptional, the opinion of the treating physician should 
prevail in such circumstances, and the progression status should be confirmed later  by the review panel (or Principal 
Investigator).  
 
3.  Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the 
treatment started).  The patient's best response assignment will depend on the achievement of both measurement and 
confirmation criteria.  
 
For Patients with Measurable Disease (i.e. Target Disease)  
Target 
Lesions  Non-Target Lesions  New 
Lesions  Overall 
Response  Best Overall Response when 
Confirmation is Required*  
CR CR No CR ≥ 4 wks. Confirm ation**  
CR Non-CR/Non -PD No PR  
≥ 4 wks. Confirmation**  CR Not evaluated  No PR 
PR Non-CR/Non -PD/Not evaluated  No PR 
SD Non-CR/Non -PD/Not evaluated  No SD Documented at least once  
≥ 4 wks. from baseline**  
PD Any Yes or No  PD  
no prior SD, PR or CR  Any PD***  Yes or No  PD 
Any Any Yes PD 
*      See RECIST v1.1 manuscript for further details on what is evidence of a new lesion.  
**    Only for non -randomized trials with response as primary endpoint.  
***  In exceptional circumstances, unequivocal progr ession in non -target lesions may be accepted as disease 
progression.  
 
Note:    Patients with a global deterioration of he alth status requiring discontinuation of treatment without objective 
evidence of disease progression at that time should be reported as “symptomatic deterioration.”   Every effort 
should be made to document the objective progression even after discontinuati on of treatment.  
 
Abbreviations (in alphabetical order):  CR, complete response; PD, progressive disease; PR, partial response; SD, sta ble disease 
 
For Patients with Non -Measurable Disease (i.e. Non -Target Disease)  
Non-Target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/non -PD No Non-CR/Non -PD* 
Not all evaluated  No Not evaluated  
Unequivocal PD  Yes or No  PD 
Any Yes PD 
*   No n-CR/non -PD is preferred over ‘stable disease’ for non -target disease since SD is increasingly used as an 
endpoint for assessment of efficacy in some trials , so to assign this category when no lesions can be measured is not 
advised.  
 
Abbreviations (in alp habetical order):  CR, complete response; PD, progressive disease; PR, partial response; SD, stable diseas e 
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 131 of 163 
 
 E. DURATION OF RESPONSE  
 
Duration of Overall Response:  The duration of overall response is measured from the time measurement criteria are met  
for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively document ed 
(taking as reference for progressive disease the smallest measurements r ecorded since the treatment started).  
 
The duration of overall CR  is measured from the time measurement criteria are first met for CR until the first date that 
progressive disease is objectively documented.   
 
Duration of Stable Disease :  Stable disease is measured from the start of the treatment until the crit eria for progression are 
met, taking as reference the smallest measurements recorded since the treatment started, including the baseline 
measurements.  
 
F. PROGRESSION  FREE SURVIVA L 
 
Progression Free Survival  is defined as the duration of time from start  of treatment to time of progression or death, 
whichever occurs first.  
 
Adapted from:  Eisenhauer EA, Therasse P, Bogaerts J, et. al.  New response evaluation criteria in solid tumours: revised 
RECIST guideline (version 1.1). Eur. J. Cancer.  2009; 45:229-2 47. 
  <http://www.eortc.be/recist/documents/RECISTGuidelines.pdf >  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 132 of 163 
 
 Appendix 6  Immunotherapeutics RECIST ( iRECIST )  
 
1. DEFINITIONS  
 
1.1 Evaluable for adverse events .  All patients will be evaluable for adverse event evaluation for t he tim e of their 
first treatment.   
 
1.2 Evaluable for response .  All patients who have received at least one cycle of therapy and have their disease re-
evaluated will be considered evaluable for response (exceptions will be those who exhibit objective disease  
progr ession prior to the end of cycle 1 who will also be considered evaluable).  Patients on therapy for at least 
this period and who meet the other listed criteria will have their response classified according to the definitions 
set out below.  
 
Response and progression will be evaluated in this study using the revised international criteria proposed by the 
Response Evaluation Criteria in Solid Tumors  (Version 1.1 ) (RECIST v1.1) committee as well as the modified 
iRECIST guidelines.  Investigators should note the different requirements for confirmatory scans as well as 
follow -up for the two criteria.  
 
See below  for criteria for continuing treatment past RECIST v 1.1 disease progression.  
 
2 RECIST v1.1 RESPONSE AND EVALUATION ENDPOINTS  
 
2.1 Measurable  Disease .  Meas urable tumor lesions (nodal, subcutaneous, lung parenchyma, solid organ 
metastases) are defined as those that can be accurately measured in at least one dimension (longest diameter to 
be recorded) as ≥ 20 mm with chest x- ray and as ≥  10 mm with CT scan or clinical examination.  Bone lesions 
are considered measurable only if assessed by CT scan and have an identifiable soft tissue component that 
meets these requirements (soft tissue component ≥ 10 mm by CT scan).  Malignant lymph nodes  must be ≥ 15 
mm in the  short axis to be consi dered measurable; only the short axis will be measured and followed.  All tumor 
measurements must be recorded in millimeters (or decimal fractions of centimeters).  Previously irradiated 
lesions are not conside red measurable unless progression has been documented in the lesion.  
 
2.2 Non-measurable Disease .  All other lesions (or sites of disease), including small lesions are considered non -
measurable disease.  Bone lesions without a measurable soft tissue component,  leptomeningeal disease , ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory breast disease, lymphangitic involvement of lung or skin and abdominal masses followed by clinical examination are all non- measurable.  
Lesions in previously irradiated are as are non -measurable, unless progression has been demonstrated.   
 
2.3 Target Lesions .  When more than one measurable tumor lesion is present at baseline , all lesions up to a 
maximum of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs should be identified as target lesions and will be recorded and measured at baseline.  Target lesions should be selected 
based on their size (lesions with the longest diameter), be representative o f all involved organs, and  should be 
those that lend themselves to reproducible repeated measurements.  Note that pathological nodes must meet the 
criterion of a short axis of ≥ 15 mm by CT scan and only the short axis of these nodes will contribute to the  
baseline sum.  All other pathological nodes (those with short axis ≥ 10 mm but < 15 mm) should be considered 
non-target lesions.  Nodes that have a short axis < 10 mm are considered non -pathological and should not be 
recorded or followed.  At baseline, the sum of the target lesions (longest di ameter of tumor lesions plus short 
axis of lymph nodes: overall maximum of 5) is to be recorded.   
 
After baseline, a value should be provided on the CRF for all identified target lesions for each assessment, even 
if very small.  If extremely small and fai nt lesions cannot be accurately measured but are deemed to be present, 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 133 of 163 
 
 a default value of 5 mm may be used.  If lesions are too small to measure and indeed are believed to be absent, a 
default value of 0 mm may be use d.   
 
2.4 Non-target Lesions .  All non -meas urable lesions (or sites of disease) plus any measurable lesions over and 
above those listed as target lesions are considered non- target lesions.  Measurements are not required but these 
lesions should be noted at bas eline and should be followed as “present” or “absent”.  
 
2.5 Response .  All patients will have their BEST RESPONSE from the start of study treatment until the end of 
treatment classified as outlined below:  
 
Complete Response  (CR):  disappearance of target and non -target lesions and normalization of tumor markers.  
Pathological lymph nodes must have short axis measures < 10 mm (Note:  continue to record the measurement 
even if < 10 mm and considered CR).  Residual lesions (other than nodes < 10 mm) thought to be non-
malignant should be further investi gated by cytology specialized imaging or other techniques as appropriate for 
individual cases before CR can be accepted.  Confirmation of response is only required in non- randomized 
studies.  
 
Partial Response  (PR):  at least a 30% decrease in the sum of measures (longest diameter for tumor lesions and 
short axis measure for nodes) of target lesions, taking as reference the baseline sum of diameter.  Non -target 
lesions must be non- PD.  Confirmation of response is only required in non- randomized studies.   
 
Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD , 
taking as reference the smallest sum of diameters on study.   
 
Progre ssive Disease  (PD): at least 20% increase in the sum of diameters of measured lesions taking as reference 
the smallest sum of diameters recorded on study (including baseline) AND an absolute increase of ≥ 5 mm.  
Appearance of new lesions will also constitute progressive disease (including lesions in previously unassessed 
areas).  In exceptional circumstances, unequivocal progression of non- target disease may be accepted as 
evidence of disease progression, where the overall tumor burden has increased by at l east 73% in volume.  
Modest increases in the size of one or more non -target lesions are NOT considered unequivocal progression.  If 
the evidence of PD is equivocal (target or non -target), treatment may continue until the next assessment, but if 
confirmed, the earlier date must be used.   
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 134 of 163 
 
 Integration of Target, Non -Target and Ne w Lesions into Response Assessment  
Target Lesions  Non-Target Lesions  New  
Lesio ns Overall  
Response  Best Response for this Category Also  Requires  
Target lesions +  non- target lesions  
CR CR No CR Normalization of tumor markers, tumor nodes < 10 mm  
CR Non-CR/Non -PD No PR  
CR Not all evaluated  No PR  
PR Non-PD/not all evaluated  No PR  
SD Non-PD/not all evaluated  No SD Documented at least once ≥ 4 weeks from baseline  
Not all evaluated  Non-PD No NE  
PD Any Any PD  
Any PD Any PD  
Any Any Yes PD  
Non-target lesions ONLY  
No Target  CR No CR Normalization of tumor markers, tumor nodes < 10 mm  
No Target  Non-CR/non -PD No Non-CR/non -PD  
No Target  Not all evaluated  No NE  
No Target  Unequivocal PD  Any PD  
No Target  Any Yes*  PD  
Note:  Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidenc e of disease 
progress ion at that time should be reported as “symptomatic deterioration”.  This is a reason for stopping therapy, bu t is NOT objective PD.  
Every effort should be made to document the objective progression even after discontinuation of treatment.   
*Investigator s should record all new lesions; if the new lesion is felt to be equivocal, treatment may be continued pending  further 
assessments.  
Abbreviations (in alphabetical order):  CR, complete response; NE, not evaluable; PD, progressive disease; SD, stable disease  
 
3 iRECIST RESPONSE ASSESSMENT  
Overall response will also be assessed using iRECIST.  Immunotherapeutics may result in infiltration of 
immune cells leading to transient increase in the size in malignant lesions, or undetectable lesions becoming 
detectable for instance where an increase in tumor burden, or the appearance of new lesions, does not reflect 
true tumor progression.  
 
Key differences are described below.  All responses defined using iRECIST criteria are designated with a prefix  
“i”.  iRECIST time -point and best overall response s will be recorded separately.   
 
3.1 Confirming Progression  
Unlike RECIST v 1.1, iRECIST requires the confirmation of progression and uses the terms iUPD (unconfirmed 
progression) and iCPD (confirmed progression).  Confirmatory scans should be performed at least 4 weeks , but 
no longer than 8 weeks , after iUPD.  
 
iCPD is confirmed if further increase in tumor burden, compared to the last assessment, is  evidenced by one or 
more of the following:  
• Continued increase in tumor burden (f rom iUPD) where RECIST v 1.1 definitions of progression had 
been met (from nadir) in target, non- target disease or new lesions.  
o Progression in target disease worsens  with an increase of at least 5 mm in the absolute val ue 
of the sum  
o Continued unequivocal progression in non- target disease with an increase in tumor burden  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 135 of 163 
 
 o Increase in size of previously identified new lesion(s) (an increase of at least 5 mm in the 
absolute value of the sum of those considered to be target n ew lesions) or additional new 
lesions .  
• RECIST v1.1 criteria are met in lesion types (target or non -target or new lesions) where progression was 
not previously identified, including the appearance of additional new lesion.  
 
If iUPD is not confirmed at the  next assessment, then the appropriat e response will be assigned (iUPD if the 
criteria are still met, but no worsening, or iSD, iPR, or iCR if those criteria are met compared to baseline).  As 
can be seen in  the table below , the prior documentation of iUPD  does not preclude assigning iCR, iPR , or iSD 
in subsequent time -point assessments or as best overall response providing that iCPD is not documented at the 
next assessment after iUPD.  
 
3.2 New Lesions  
New lesions should be assessed and measured as they appear using RECIST v 1.1 criteria (maximum o f 5 
lesions, no more than 2 per site, at least 10 mm in long axis [or 15 mm in short axis for nodal lesions]), and 
recorded as New Lesion -Target (NLT) and New Lesion -Non-Target (NLNT) to allow clear differentiation from  
baseline target and non -target lesio ns.   
 New lesions may either meet the criteria of NLT or NLNT to drive iUPD (or iCPD).  However, the 
measurements of target lesions should NOT be included in the sum of measures of original lesions identified at 
baseline.  Rather, these measurements will be coll ected on a separate table in the CRF .    
 
PD is confirmed in the New Lesion category if the next imaging assessment, conducted at least 4 weeks (but not 
more than 8 weeks) after iUPD confirms further progression from iUPD with either an increase of at leas t 5 mm 
in the absolute value of the sum of NLT or an increase (but not necessarily unequivocal increase) in the size of 
NLNT lesions or  the appearance of additional new lesions.  
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 136 of 163 
 
 iRECIST Timepoint Response  
Target 
Lesions*  Non-Target 
Lesions*  New 
Lesions*  Time point Response  
No 
Prior 
iUPD**  Prior iUPD**, ***  
iCR iCR No iCR iCR 
iCR Non-iCR/Non -
iUPD No iPR iPR 
iPR Non-iCR/Non -
iUPD  No iPR iPR 
iSD Non-iCR/Non -
iUPD No iSD iSD 
iUPD with no 
change or 
decrease from 
last TP  iUPD with no 
change or 
decrease from 
last TP  Yes NA NLs confirms iCPD if NLs were previously identified and increase in 
size (≥ 5 mm in SOM for NLT or any increase for NLNT) or number.  
If no change in NLs (size or number) from last TP, remains iUPD  
iSD iUPD  No iUPD  Remains iUPD unless iCPD confirmed based  on further increase in size 
of NT  lesion  (need not meet RECIST v 1.1 criteria for unequivocal PD)  
iUPD  Non-iCR/Non -
iUPD No iUPD  Remains iUPD unless iCPD confirmed based on:  
• Further increase in SOM of at least 5 mm, otherwise remains iUPD  
iUPD  iUPD  No iUPD Remains iUPD unless iCPD confirmed based on further increase in:  
• Previously identified T lesion iUPD SOM ≥ 5 mm and/or  
• NT lesion iUPD (prior assessment –  need not be unequivocal PD)  
iUPD  iUPD  Yes iUPD  Remains iUPD unless iCPD confirmed based on further increase in:  
• Previously identified T lesion iUPD ≥ 5 mm and/or  
• Previously identified NT lesion iUPD (need not be unequivocal) 
and/or  
• Size or number of NLs previously identified  
Non-iUPD/PD  Non-iUPD/PD  Yes iUPD  Remains iUPD unless iCPD confirmed based on  
• Increase in size or number of NLs previously identified  
*Using RE CIST v1.1 principles.  If no PSPD occurs, RECIST v 1.1 and iRECIST categories for CR, PR, and SD would be the same  
**in any lesion category 
***previously identified in assessment immediately prior to this TP  
Abbreviations (in alphabetical order):  CPD, con firmed progressive disease; CR, complete response; NE, not evaluable; NL, new lesion;  
NLNT, new lesion -non-target; NLT, new lesion -target;  NT, non -target; PD, progressive disease; PR, partial response; PSPD, 
pseudoprogression; SD, stable disease; SOM, sum of measure ment s; T, target; TP, timepoint; UPD, unconfirmed progressive disease  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 137 of 163 
 
 All patients will have their iRECIST best overall response (i BOR)  from the start of study treatment until the end 
of treatment classified as outline d below.  
 
iRECIST Best Ove rall Response  
TPR1  TPR2  TPR3  TPR4  TPR5  iBOR  
iCR iCR, iPR, iUPD, NE  iCR, iPR, iUPD, NE  iUPD  iCPD  iCR 
iUPD  iPR, iSD, NE  iCR iCR, iPR, iSD, iUPD, NE  iCR, iPR, iSD, iUPD, iCPD, NE  iCR 
iUPD  iPR iPR, iSD, iUPD, NE  iPR, iSD, iUPD, NE, iCPD  iPR, iSD, iUPD, iCP D, NE  iPR 
iUPD  iSD, NE  PR iPR, iSD, iUPD, NE  iPR, iSD, iUPD, iCPD, NE  iPR 
iUPD  iSD iSD, iUPD, NE  iSD, iUPD, iCPD, NE  iSD, iUPD, iCPD, NE  iSD 
iUPD  iCPD  Anything  Anything  Anything  iCPD  
iUPD  iUPD  iCPD  Anything  Anything  iCPD  
iUPD  NE NE NE NE iUPD  
• Table a ssumes a randomized study where confirmation of CR or PR is not required  
• NE=not evaluable that cycle 
• Designation “i” for BOR can be used to indicate prior iUPD to aid in data interpretation  
• For patients with non -target disease only at baseline, only CR or non -CR/non -PD can be assigned at each TPR but is not shown in 
the table for ease of presentation.  
Abbreviations (in alphabetical order):  BOR, best overall response; CPD, confirmed progressive disease; CR, complete response ; NE, not 
evaluable; NL, new les ion; PD, progressive disease; PR, partial response; PSPD, pseu doprogression; SD, stable disease; SOM, sum of 
measurement s; TP, timepoint; TPR, timepoint response; UPD, unconfirmed progressive disease  
 
 
4 RESPONSE AND STABLE DISEASE DURATION (RECIST v 1.1 AND iRECIST)  
Response duration will be measured from the time measurement criteria for CR/PR or iCR/iPR (whichever is 
first recorded) are first met until the first date that recurrent or progressive disease is objectively documented, 
taking as reference the sm allest measurements recorded on study (including baseline) . 
 
Stable disease duration will be measured from the time of start of treatment until the criteria for progression are 
met, taking as reference the smallest sum on study (including baseline).  
 
5 METHO DS OF MEASUREMENT  
The same method of assessment and the same technique should be used to characterize each identified and 
reported lesion at baseline and during follow -up.  Assessments should be identified on a calendar schedule and 
should not be affected by delays in therapy.  While on study, all lesions recorde d at baseline should have their 
actual measurements recorded at each subsequent evaluation, even when very small (e.g. 2 mm).  If it is the 
opinion of the radiologist that the lesion has likely disa ppeared, the measurement should be recorded as 0 mm.  
If the lesion is believed to be present and is faintly seen but too small to measure, a default value of 5 mm 
should be assigned.  For lesions which fragment/split , add together the longest diameters of  the fragmented 
portions; for lesions which coalesce, measure the maximal longest diameter for the “merged lesion”.  
 
5.1 Clinical Lesions .  Clinical lesions will only be considered measurable when they are superficial and ≥ 10 mm as 
assessed using calipers (e. g. skin nodules).  For the case of skin lesions, documentation by color photography 
including a ruler to estimate the size of the lesion is recommended.  If feasible, imaging is preferred.   
 
5.2 Chest X -Ray.  Chest CT is preferred over chest X -ray, particular ly when progression is an important endpoint, 
since CT is more sensitive than X -ray, particularly in identifying new lesions.  However, lesions ≥ 20 mm on 
chest X -ray may be considered measurable if they are clearly defined and surrounded by aerated lung.  
 
5.3 CT, MRI .  CT is the best currently available and reproducible method to measure lesions selected for response 
assessment.  This guideline has defined measurability of lesions on CT scan based on the assumption that CT  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 138 of 163 
 
 slice thickness is 5 mm or less.  If CT scans have slice thickness greater than 5 mm, the minimum size for a 
measurable lesion should be twice the slice thickness.  MRI is also acceptable in certain situations (e.g. for body 
scans).  Other specialized ima ging or other techniques may also be a ppropriate for individual cases.  For 
example, while PET scans are not considered adequate to measure lesions, PET -CT scans may be used 
providing that the measures are obtained from the CT scan and the CT scan is of identical diagnostic quality to a 
diagnostic CT (with IV and oral contrast).    
 
5.4 Ultrasound.   Ultrasound is not useful in assessment of lesion size and should not be used as a method of 
measurement.  If new lesions are identified by ultrasound during the stu dy, confirmation by CT is advised.  
 
5.5 Endoscopy, Laparoscopy .  The utilization of these techniques for objective tumor evaluation is not advised.  
However, they can be useful to confirm complete pathological response when biopsies are obtained or to 
determi ne relapse in trials where recurrence following complete response or surgical resection is an endpoint.   
 
5.6 Tumor Markers .  Tumor markers alone  cannot be used to assess objective tumor response.  If markers are 
initially above the upper normal limit, howeve r, they must normalize for a patient to be considered in complete 
response.   
 
5.7 Cytology, Histology .  These techniques can be used to differentiate between PR and CR in rare cases if required 
by protocol (for example, residual lesions in tumor types such as  germ cell tumors, where known residua l 
benign tumors can remain).  When effusions are known to be a potential adverse effect of treatment (e.g. with 
certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the neoplastic origi n of 
any effusion that appears or wors ens during treatment when the measurable tumor has met criteria for response 
or stable disease is advised to differentiate between response or stable disease and progressive disease.   
 
Adapted from:  Seymour L, Bogaerts J, Perrrone A, et. al.  iRECIST: gui delines for response criteria for use in trials 
testing immunotherapeutics. Lancet . 2017; 18:143 -152. (supplemental materials)  
     <http://www.eortc.org/recist/irecist/>  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 139 of 163 
 
 Appendix 7  Response Evaluation Criteria in Lymphoma ( RECIL  2017)  
 
Response Evaluation Criteria in Lymphoma  
International Working Group: Response Criteria Based on Assessment of Target 
Lesions  
Response  % Change from Baseline  FDG -PET Bone Marrow 
Involvement  New 
Lesions  
CR Complete disappearance of all target  lesions and 
all nodes with long axis < 10 mm  
 
≥ 30% decrease in the sum of longest diameter 
of target lesions (PR) with normalization of 
FDG -PET Normalization of FDG -
PET (Deauville score 1 -3)* Not involved  No 
PR ≥ 30% decrease in the sum of longest diameters 
of target lesions but not a CR  Positive  
(Deauville score 4 -5)* Any No 
MRa ≥ 10% decrease in the sum of longest diameters 
of target lesions but not a PR (< 30%)  Any Any No 
SD < 10% decrease or  ≤ increase in the sum of 
longest diameters of target lesions  Any Any No 
PD 20% increase in the sum of longest diameters of 
target lesions  
 For small lymph nodes measuring < 15 mm post therapy, a minimum absolute increase of 5 mm 
and the long diameter should exceed 15 mm  
 
Appearance of a new lesion  Any Any Yes or No  
a A provisional category  
 
*Deauville Sco ring (for FDG avidity in Hodgkin’s or Non -Hodgkin’s Lymphoma ) (as seen by FDG -PET)  
Score 1:  No uptake above the background  
Score 2:  Uptake ≤ mediastinum  
Score 3:  Uptake > mediastinum but ≤ liver  
Score 4:  Uptake moderately increase compared to the liver at any site  
Score 5:  Uptake markedly increased compared to the liver at any site  
Score X:  New areas of update unlikely to be relate d to lymphoma  
 
Abbreviations (in alphabetical order):   CR, complete response ; FDG, fluorodeoxyglucose ; mm, millimeter; MR, minor response; PD, progressive 
disease; PET, positron emission tomography; PR, partial response ; SD, stable disease  
 
Adapted from:  Younes A, Hilden P, Coiffier B , et. al.  International Working Group consensus response evaluation criteria in 
lymphoma  (RECIL 2017). Annals  Oncol . 201 7 Apr 3. doi: 10.1093/annonc/mdx097.  
Barrrington  SF, Qian W, Somer EJ,  et al., Concordance between four European centres of PET reporting criteria 
designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010 . 37: 1824- 1833.  
 Fellows  GA, Ardeshna KM, Barrington ST,  et al. Guidelines for the first line management of classical Ho dgkin 
lymphoma.  British J Haemotology, 2014 . 166: 34-49. 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 140 of 163 
 
 Appendix 8  Adverse Events Observed with Antibodies to PD -1 and PD -L1 
 
Although the mechanism of action is distinct, inhibitors of LAG -3 have many similarities to 
blockers of immune checkpoint pathways. Because of these similarities, data on the potential AEs seen after treatment with antibodies to PD -1 and PD -L1 are being in cluded in this CTP.  
Immune -mediated and non- immune -mediated AEs  reported in the literature and/or pr escribing 
information for  PD-1 and PD -L1 pathway inhibitors are listed below, organized by System 
Organ Class.  These data have been collated from the pres cribing information of approved 
products as well as applicable literature and are listed below . 
 
Adve rse Events Observed with Antibodies to PD -1 and PD -L1 
Blood and lymphatic 
system disorders  
 Anaemia  
Lymphopenia  
Haemolytic anaemia  
Neutropenia  
Thrombocytopenia  
Pure red cell aplasia 
Pancytopenia  
Eosinophilia  
Acquired haemophilia A  
Cryoglobulinemia  
Dissem inated intravascular coagulopathy  
Cardiac disorders  Myocarditis  
Ventricular arrhythmias  
Hypotension  
Cardiomyopathy  
Pericarditis  
Ear and labyrinth 
disorders  Autoimmune inner ear disease (listed below under Immunologic Disorders)  
Endocrine disorders  Autoi mmune inflammation of pituitary, thyroid, adrenal glands  
Hypophysitis, hypopituitarism, panypopituitarism  
Autoimmune thyroid disease (thyr oiditis, hypothyroidism, hyperthyroidism)  
Thyroid disorders  
Adrenal insufficiency (central or primary)  
Diabetes mellit us (type 1)  
Syndrom e of inappr opriate antidiuretic hormone secretion  
Eye disorders (Intraocular 
inflammation is rare ~1% in 
patients treated)  Uveitis  
Iridocylitis  
Retinal detachment  
Decreased visual acuity  
Ocular inflammatory toxicity  
Iritis  
Episcleritis  
Conjunctivitis  
Orbital inflammation (symptoms include photophobia, dryness of the eye, pain, 
blurred vision)  
Gastrointestinal disorders  Diarrheal colitis (common, presents ~ 6 -8 weeks into treatment; G rade 3-4 in 1 -2%) 
Diarrhea 
Colitis, enterocolitis, gas troenteritis  
Nausea  
Vomiting  
Abdominal pain (abdominal discomfort, upper and lower abdominal pain)  
Decreased appetite  
Intestinal perforation  
Intestinal obstruction  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 141 of 163 
 
 Adve rse Events Observed with Antibodies to PD -1 and PD -L1 
Constipation  
Pancreatitis (increased amylase and lipase)  
Stomatitis  
Dysphagia  
Hypogeusia  
Ulcer haemorrhage  
General disorders and 
administration site 
conditions  Fatigue -includes asthenia and fatigue, decreased activity, malaise  
Pyrexia  
IRR (Mild up to 25%, Severe < 2%; composite term includes chills, fever, back pain, 
flushing, dyspnea, hypotens ion) 
Oedema (includes periorbital, face oedema, generalized oedema, localized oedema, 
gravitational oedema, peripheral oedema, pulmonary oedema, and lymph 
oedema 
Weight loss (also listed under investigations)  
Cachexia secondary to dysphagia  
Hepatobiliary disorders  Hepatitis  
Immune system disorders 
(See also endocrine and 
other classes)  Pneumonitis  
Inflammatory myositis  
Myositis  
Myocarditis  
Colitis  
Hepatitis  
Autoimmune inflammation of pituitary, thyroid, adrenal glands  
Pancreatitis  
Myasthenia gravis and ot her autoimmune neurologic disorders  
Inflammatory arthritis  
Bullous pemphigoid  
Complications after allogeneic HSCT (veno -occlusive disease, graft versus host 
disease)  
Vasculitis  
Arthritis  
Psoriasis 
Histiocytic necrotizing lymphadeni tis 
Systemic inflammator y response  
Polymyositis  
Pericarditis  
Dry eye (sicca syndrome)  
 Defined systemic disease  
Sarcoidosis (cutaneous, pulmonary, muscle, neurological)  
Polymyalgia rheumatica-giant cell arteritis  
Celiac disease  
Lupus nephritis  
Dermatomyositis  
Autoimmune inflammat ory myopathy  
Psoriasis 
Polymyositis  
Myasthenia gravis  
Sjogren’s syndrome  
Bullous skin diseases (pemphigoid, bullous pemphigus)  
Autoimmune endocrinopathies (pituitary, thyroid, adrenals)  
Autoimmune hepatitis  
Autoimmune pa ncreatitis  
Autoimmune haemolytic ana emia 
Pure red cell aplasia 
Cryoglobulinemia  
Acquired Haemophilia A  
Autoimmune hepatitis  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 142 of 163 
 
 Adve rse Events Observed with Antibodies to PD -1 and PD -L1 
Systemic inflammatory response syndrome  
Autoimmune colitis  
Autoimmune pneumonitis  
Infections and infestations  Upper respiratory tract infection (rhinitis, viral rhinit is, pharyngitis, nasopharyngitis)  
Respiratory tract infection  
Pneumonia/bronchopneumonia (bacterial, mycoplasma, Pneumocystis jiroveccii  
pneumonia)  
Nasal congestion  
Urinary tract infection (bacterial, fungal)  
Severe infections including sepsis, herpes encephalitis, mycobacterial infection 
leading to retroperitoneal haemorrhage  
Sepsis  
Investigations  Increased ALT  
Increased AST  
Increased bilirubin  
Increased alkaline phosphate  
Increased GGT  
Increased creatinine 
Hyponatremia 
Hyperkalaemia Hypocalcemia 
Hypercal cemia  
Hypomagnesemia  
Hypermagnes emia 
Hypophosphatemia  
Decreased bicarbonate 
Increased amylase  
Increased lipase Increased thyroid stimulating hormone ( TSH ) 
Decreased weight  
Anaemia  
Lymphopenia  
Leukopenia  
Thrombocytopenia  
Increased triglycerides  
Increased cholesterol  
Hyperglycaemia  
Hypoalbuminemia  
Glomerular filtration rate decreased  
Musculoskeletal and 
connective tissue 
disorders  Arthralgia  
Sjogren’s syndrome  
Spondyloarthropathy 
Myositis  
Myopathy 
Rhabdomyolysis  
Musculoskeletal pain (includes back pain, bone pain, musculoskeletal chest pain, 
musculoskeletal discomfort, myalgia, pain in jaw, pain in extremities, neck pain, 
and spinal pain)  
Inflammatory arthritis -polyarthritis  
Myalgi a 
Sarcoidosis  
Dry eye (sicca syndrome)  
Nervous system disorders 
(neurologic s yndromes in 
~1-3% of patients)  Guillain -Barre syndrome  
Myasthenia gravis  
Non-infectious meningitis  
Transverse myelitis  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 143 of 163 
 
 Adve rse Events Observed with Antibodies to PD -1 and PD -L1 
Peripheral neuropathy and sensory neuropathy (hyperesthesia, hypoesthesia, 
paraesthesia, dysesthesia, peripheral motor neuropathy, peripheral sensory 
neuropathy, polyneuropathy); motor and sensory neuropathy  
Autoimmune encephalitis  
Encephalitis  
Dizziness  
Peroneal nerve palsy  
Neuritis  
Headache/migrain e headache 
Partial seizures associated with focal inflammatory foci in brain  
Dizziness  
Dysge usia  
Confusional state  
Meningitis/encephalitis  
Demyelination  
Encephalopathy  
Paralysis  
Polymyositis  
Insomnia  
Hypersomnia  
Recurrent seizures -bradykinesia (Parkinsonism)  
Polyradiculopathy  
Necrotizing myelopathy  
Symmetrical multifocal neuropathy  
Phrenic nerv e palsy  
Meningoradiculoneuritis  
Posterior reversible encephalopathy syndrome (PRES)  
Aseptic Meningitis -Immune related meningitis  
Enteric neuropathy  
Autoimmune inner ear disease 
Multiple sclerosis  
Pregnancy, puerperium 
and perinatal conditions  Embryo -foetal toxicity  
 
Psychiatric disorders  Insomnia  
Renal and urinary 
disorders  Nephritis and renal dysfunction  
Renal failure  
Acute kidney injury (rare ~ 1- 2% of any grade; G rade 3-4 < 1%; Onset median 91 
days; range 21 -245 days)  
Glomerular filtration rate decreased  
Hematuria   
Urinary obstruction  
Tubulointerstitial nephritis -acute granulomatous interstitial nephritis  
Acute tubular necrosis  
Immune complex glomerulonephritis  
Thrombotic microangiopathy  
Creatinine elevation  
Reproductive system and 
breast disorders  Lymphocytic vasculitis of the uterus  
 
Respiratory, thoracic, and 
mediastinal disorders  Pneumonitis (uncommon~3%,  but potentially severe or life -threatening; median 
onset 2.8 months)  
Cough, productive cough  
Dyspnea, exertional dyspnea  
Pleural effusion  
Respiratory failure  
Respiratory distress  
Pneumonia  
Pulmonary embolism  
Pneumothorax  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 144 of 163 
 
 Adve rse Events Observed with Antibodies to PD -1 and PD -L1 
Hypoxia  
Acute respiratory distress syndrome  
Radiation recall pneumonitis  
Skin and subcutaneous 
tissue disorders -
Dermatologic (Overall 30 -
40%; average onset 3.6 
weeks  Rash (inc ludes maculopapular rash, erythematous rash, macular rash, popular rash, 
reticular rash, pustu lar rash, vesicular rash, acneiform rash, follicular rash, 
pruritic rash, drug eruption, generalized rash, seborrheic keratosis, lichenoid keratosis, genital rash ) 
Palmar plantar erythrodyses thesia  
Erythema 
Vitiligo  
Pruritus  
Exfoliative dermatitis  
Erythema multiforme  
Pemphigoid  
Bullous dermatitis  
Erythema multiforme 
Toxic epidermal necrolysis  
Stevens -Johnson syndrome  
Alopecia Dermatitis  
Sweet syndrome (neutrophil i nfiltration of skin)  
Oral mucositis  
Xerostomia  
Vascular disorders  Venous thromboembolism  
Hypertension/hypertensive crisis  
Angiopathy  
Adapted from:  Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol -Myers Squibb Company; 2017.  
Keytruda (pembroliz umab) [package inset]. Whitehouse Station, NJ: Merck & Co., Inc; 2017.  
Tecentriq (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2017.  
Bavencio (avelumab) [package insert]. Rockland, MA; EMD Serono, Inc.; 2017.  
Imfinzi (durvalumab) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.  
 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 145 of 163 
 
 Appendix 9  Grading and Management of Infusion -Related  Reactions  
 
Grading of Infusion -Related  Reactions  
The CTCAE v 5.0* definition of IRRs  (General Diso rders and Administration Site Conditions) is shown below. 
Symptoms occurring during or following infusion of investigational therapy may also be defined according to AE 
categories such as allergic reaction, anaphylaxis, or cytokine release sy ndrome.  In the  setting of symptoms occurring 
during or following infusion of investigational therapy, investigators are encouraged to use the AE term “Infusion -
Related Reaction” and any additional terms (including those not listed here) that best describe the event. Those 
described should be graded as follows:  
 
Grading of Infusion- Related  Reactions  
Adverse 
Event  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Infusion -
related 
reaction  Mild transient 
reaction;  infusion 
interruption not  
indicated; 
intervention not  
indicated  Ther apy or infusion  
interruption indicated but  
responds promptly to 
symptomatic treatment 
(e.g. antihistamines, 
NSAIDS,  narcotics, IV 
fluids);  prophylactic 
medications  indicated for 
≤ 24 hours Prolonged (e.g. not rapidly  
responsi ve to symptomatic  
medication an d/or brief  
interruption of infusion);  
recurrence of symptoms  
following initial 
improvement;  hospitalization 
indicated for  clinical sequelae  Life-threatening  
consequences; urgent  intervention 
indicated  Death  
Definition: A disorder characterized by adverse reaction to the infusion of pharmacological or biological substances.  
Allergic 
reaction  Systemic  
intervention not 
indicated  Oral intervention indicated  Bronchospasm; 
hospitalization indicated for clinical se quelae; intravenous 
intervention indicated  Life-threatening  
consequences; urgent  intervention 
indicated  Death  
Definition: A disorder characterized by an adverse local or general response from exposure to an allergen.  
Anaphylaxis  - - Symptomatic bronchospasm,  
with or without urticaria; parenteral inter vention  
indicated; allergy -related  
edema/angioedema;  
hypotension  Life-threatening  
consequences; urgent  intervention 
indicated  Death  
Definition: A disorder characterized by an acute inflammatory reaction resulting from the release of histamine and histamin e-like substances 
from mast cells, causing a hypersensitivity immune response. Clinically, it presents with breathing difficulty, dizziness, hy potension, cyanosis 
and loss of conscio usness and may lead to death.  
Cytokine 
release syndrome  Fever with or 
without 
constitutional 
symptoms  Hypotension responding 
to fluids; hypoxia responding to < 40% O2  Hypotension managed with 
one pressor; hypoxia requiring ≥ 40% O2  Life-threatening  
consequences; urgent intervention  
indicated  Death  
Definition: A disorder characterized by fever, tachypnea , headache, tachycardia, hypotension, rash, and /or hypoxia caused b y the release of 
cytokines.  
*See < https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm > 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 146 of 163 
 
 Guidelines for Management of Infusion -Related  Reactions  
Consistent with usual medical practice, selected parenteral medications may be utilized for Grade > 2 
allergic/hypersensi tivity reactions. The Sponsor should be contacted immediately if questions arise concerning the 
grade of the reaction. The following are recommended management guidelines for IRRs  associated with study drug 
administration . In all cases the Investigator sho uld use best clinical judgment in managing such reactions.  
Management of Infusion -Related Reactions  
Grade 1  • Consider slowing the infusion to 50% of the prior rate  
• Monitor the patient for worsening condition  
• If the infusi on is extended, a dminister subsequent infusions at the prolonged rate  
• Consider premedication or adjustment to premedications for subsequent infusions  
Grade 2  
 • Interrupt  the infusion for a minimum of 30 minutes  
• Administer additional pharmacologic therapy ( e.g. diphenhydramine, acetaminophen) and appropriate 
supportive care (e.g. oxygen), as medically indicated  
• Resume the infusion at 50% of the prior rate once the infusion-related  reaction has resolved or decreased to 
Grade 1  
• Monitor the patient for worseni ng condition 
• Administer subsequent infusions at the prolonged rate  
• Consider premedication or adjustment to premedications for subsequent infusions  
≥ Grade 3  
 • Stop the infusion  
• Administer additional pharmacologic therapy (diphenhydramine, dexamethasone) and appropriate 
supportive care (e.g. oxygen), as medically indicated  
• Administer epinephrine or bronchodilators as medically indicated  
• Hospital admi ssion for observation may be i ndicated  
• Do not resume infusion after a ≥  Grade 3  reaction  
• Patients who have a Grade 3  infusion -related  reaction will be considered to have had a DLT and will be 
either discontinued from treatment , or must receive subsequent t reatments at a prolonged infusion rate 
(slowed to 50% of the prior rate or longer); premedication prior to subsequent infusions is required.  
• Patients who have a > Grade 3  infusion- related reaction will be considered to have had a DLT and will be 
discontinu ed from treatme nt 
 
In the Event of Infusion Prolongation  
Any assessments to be performed or samples to be collected (e.g. VS , PK) at the end of or following EOI will still 
be performed or collected beginning at the delayed EOI timepoint. In situations whe re collection o f late day 
samples, particular ly the 8 hours after EOI sample, is logistically difficult due to clinic staff availability, an "end of 
day" sample may be obtained at the latest practical time on the day of the reaction.  
 
For Grade 1 and 2 re actions, r echal lenge with a shorter  duration of infusion (no less than 60 minutes ) may be 
attempted at the Investigator's discretion, after a minimum of 2 doses  with no evidence of infusion- related toxicity  at 
the prolonged rate .  For Grade 3 reactions, su bsequent infusions must be administered at the prolonged rate.  
 
All infusion interruptions and subsequent prolongations, including modified infusion times, as well as the toxicity 
that necessitated them, will be clearly documented on the appropriate page o f the patient’s CRF.  
 
Modification of Infusion Duration for the Trial  
The duration of infusion will be prolonged for all subsequent patients entered to the trial in the following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds o f the patients entered to a cohort, the duration of infusion for 
subsequent patients entered to the trial will be extended by 30 minutes  (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in a ny patient within a cohort, the duration of inf usion for 
subsequent patients entered to the trial will be extended by 30 minutes  (or longer, if indicated). Such a case 
will also be considered to have met the protocol criteria for a DLT, thus requiring expa nsion of the cohort . 
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 147 of 163 
 
 These same criteria will be applied in the event IRRs occur on the extended infusion schedule. In such a case, the 
duration of infusion for subsequent patients entered to the trial will be further extended by 30 minutes  (or longer, if  
indicated).  See Section 6.5.3.5.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 148 of 163 
 
 Appendix 10  Management of Immune -Mediated Toxicities  
 
Adverse Reaction  Severity*  Dose Modification  
Pneumonitis  Grade 2 pneumonitis  Withhold dose^  
Grade 3 or 4 pneumonitis  Permanently discontinue  
Myocarditis** Grade 2 myocarditis  Withhold dose^  
Grade 3 or 4 myocarditis  Permanently discontinue  
Adrenal 
Insufficiency  Grade 2 adrenal insufficiency  Withhold dose^  
Grade 3 or 4 adrenal insufficiency  Permanently discontinue  
Encephalitis  New -onset moderate or severe neurologic signs or symptoms  Withhold dose^  
Immune -mediated encephalitis  Permanently discontinue  
Nephritis and 
Renal Dysfunction  Serum creatinine more than 1.5 and up to 6 × ULN  Withhol d dose^  
Serum creatinine more than 6 times the ULN  Permanently discontinue  
Episcleritis, 
Uveitis, or Iritis**  Grade 2  episcleritis, uveitis, or iritis     Withhold dose^  
Grade 3 or 4 episcleritis, uveitis, or iritis  Permanently discontinue  
Colitis/Diarrhea  Grade 2 or 3 diarrhea or colitis  Withhold dose^  
Grade 4 diarrhea or colitis  Permanently discontinue  
Hypophysitis  Grade 2 or 3 hypophysitis  Withhold dose^  
Grade 4 hypophysitis  Permanently discontinue  
Type 1 Diabetes 
Mellitus  Grade 2 or 3 hyperg lycemia  Withhold dose^  
Grade 4 hyperglycemia  Permanently discontinue  
Inflammatory 
arthritis  Grade 2 arthritis  Withhold dose^  
Grade 3 arthritis  Permanently discontinue  
Myositis**  Grade 2 myositis  Withhold dose^  
Grade 3 myositis  Permanently discontin ue 
Rash  Grade 2 or 3 rash  Withhold dose^  
Grade 4 rash  Permanently discontinue  
Hepatitis  AST or ALT > 3 - 5 × ULN or  
total bilirubin > 1.5 - 3 × ULN (Grade 2)  Withhold dose^  
AST or ALT > 5 × ULN or  
total bilirubin > 3 × ULN (≥ Grade 3)  Permanently d iscontinue  
Other  Other Grade 3 adverse reaction:    
 First occurrence  
 Recurrence of same event  Withhold dose^  
Permanently discontinue  
Life-threatening or Grade 4 adverse reaction  Permanently discontinue  
Requirement for 10 mg per day or greater p rednisone or 
equivalent for more than 12 weeks  Permanently discontinue  
Persistent Grade 2 or 3 adverse reactions lasting ≥ 12 weeks  Permanently discontinue  
Abbreviations (in alphabetical order):  ALT, alanine aminotransferase; AST, aspartate aminotrans ferase; mg, milligram; ULN, upper limit of 
normal  
* Toxicity graded per Common Terminology Criteria for Adverse Events (Version 5.0) (CTCAE v 5.0) 
**Adapted from product package inserts to include these reactions; there are no recommended dose modifications  for hypothyroidism or 
hyperthyroidism.  
^ May resu me treatment when adverse reaction returns to Grade 0 or Grade 1 and glucocorticoid therapy for reaction is discontinued  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidentia l  Page 149 of 163 
 
 Appendix 11  Maximum Total Blood Collection Volumes  
 
Maxi mum Total Blood Collection Volumes  
 
STUDY 
ASSESSMENTS  Vol./ 
sample 
(mL) Screening  Cycle 1  Cycle 2  EOT  1M FUP  
TOTAL 
VOLUME  # Vol.  
(mL)  # Vol.   
(mL)  # Vol.  
(mL)  # Vol.  
(mL)  # Vol.   
(mL)  
Hematology Panel  5 1 5 5 25 2 10 1 5 1 5 50 
Biochemistr y Panel 10 1 10 5 50 2 20 1 10 1 10 100 
Coagulation Panel  5 1 5 2 10 1 5 1 5 1 5 30 
Thyroid Function 
Tests  5 1 5 1 5 1 5 1 5 1 5 25 
Pregnancy Test  5 1 5 1 5   1 5   15 
Tumor Markers  5 1 5   1 5 1 5 1 5 20 
ADA Testing  5   2 10 1 5 1 5 1* 5 25 
PK Studies  5   11 55 4 20 1 5 1* 5 85 
Pharmacodynamic 
Studies ( Receptor 
Occupancy ) 10   3 30 3 30 1 10 1 10 80 
Biomarker Studies  30 1 30   1 30 1 30   90 
Total Volume   65  190  130  85  50 520 
Abbreviations (in alphabetical order): #, number of samples; 1M FUP, 1-month follow -up; ADA, anti -drug antibody; EOT, end of treatment; mL, 
milliliter; PK, pharmacokinetic; Vol, volume  
 
*additional samples to be obtained at 2, 4, and 6 months after EOT if patient is available for blood collection  
 
 
Along with Screening, day s with maximum blood volume requirements:  
• C1/D1:  100 mL  
• Cx/D1: 40 mL (+ 5 mL for odd number cycles)  
• EOT:  85 mL 
• 1M FUP:   50 mL 
 
Blood volumes for each additional cycle:    
• Additional odd number cycles:  ~70 mL  
• Additional even number cycles: ~ 70 mL  
If sites can perform hematology, serum chemistry, and coagulation studies with smaller volumes of blood per sample, they are encour aged to do 
so.  Required PK, ADA, and PD/biomarker volumes are fixed and should not be reduced.   
To estimat e a patient’s tot al blo od collection volume during study participation, maximum estimates are used. During a patient’s study 
participation, the maximum amounts of venous blood that will be collected are listed above.  Study duration is based on 8 weeks  estimated 
average pa tient participation, i.e. an average of Cycle 1 (4 weeks) plus Cycle 2 (4 weeks).   
An indwelling venous access device is required for PK blood sample collections on Day 1 of Cycle 1.  When an indwelling catheter (or 
equivalent venous access)  is utilized, a bloo d flush discard of up to 3  mL is to be done before drawing the first blood tube collected on the 
scheduled day/time for routine laboratory tests and PK samples. Blood flush discard volumes ARE NOT included in volume calculations in 
table above and sh ould b e considered when summarizing actual blood collection volumes.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 150 of 163 
 Appendix 12  Schedule of Assessments  
 
STUDY ASSESSMENTS  Screening  CYCLE 1  CYCLE 2  SUBSEQUENT CYCLES  
EOT     
within 10d after  
treatment  
discontinuation  1M FUP* 
30d (+7) 
after last 
dose Long -Term 
FUP *              
if OR/ SD at 
EOT , 
for new -onset 
or ongoing 
immune -
mediated AEs    As 
Clinically 
Indicated  D1 D2 D3 
(+1) D8 
(±2) D15 
(±2) D22 
(±2) D1 
(±2) D15 
(±2) End of 
Cycle 2 
(final 
week)  D1 
(±2) D15 
(±2) End of 
Even 
Num bered 
Cycles 
(final week)  
CONSENT AND MEDICAL HISTORY  
Informed Consent1/ Eligibility 
Assessment  x                 
Demography  x                 
Past Medical History2 x x                
History of Primary Malignancy3 x                 
SAFETY ASSESS MENTS (screening assessments within 14 days prior to first dose of study drug unless otherwise specified)  
Medication/Procedure Survey4 from 14 days prior to 1st dose through 30 days after last dose    
AE Reporting5 from signing of informed consent through  30 days after last dose; through 2 month s (or 4 months to 2 years) FUP if related critical AEs persist  Q2Mc x 
DLT Assessment6   C1/D1 through C1 /D28 (+/ - 2 days)          x 
ECOG PS Evaluation  x xa      x   x   x x  x 
Vital Signs7  x SOI; 
EOI;  
2h, 4 h, 8h 
after EOI  x x  SOI,  
EOI  x   x   x x  x 
Physical Exam  (to include weight, 
pulmonary and cardiac 
assessments )8 x xa      x   x   x x  x 
Hematology Panel9 x xa  x x x x x x  x x  x x  x 
Biochemistry Panel10 x xa  x x x x x x  x x  x x  x 
Coagulation Pan el11 x xa    x  x   x   x x  x 
Thyroid Function Tests12 x xa      x   x   x x  x 
Urinalysis13 x xa    x  x   x   x x  x 
Pregnancy Testing14 x x            x   x 
ECG (12 -lead)15 x SOI,  
EOI           
+15 min          SOI, 
EOI   
+15 
min      x   x 
SAFETY  ASSESSMENTS (results from assessments previously performed as standard of  care within 28 days [+2d] prior to 1st dose may be utilized provided no antineoplastic therapy has been delivered between assessment and 1st dose; 
otherwise within 14 days of 1st dose) 
MUGA Scan or ECHO16 x             x   x 
Ophthalmology Exam17 x         x   x x   x 
Pulmonary Function Tests18 x             x   x 
DISEASE ASSESSMENTS (screening assessments within 28 days [+2d] prior to first dose of study drug)  
Tumor Marker Measu rement19 x         x   x xb If no  
prior PD  Q2Md  
Imaging for Disease (and 
Pulmonary Status)20 x         x   x xb If no  
prior PD  Q2Md  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 151 of 163 
 STUDY ASSESSMENTS  Screening  CYCLE 1  CYCLE 2  SUBSEQUENT CYCLES  
EOT     
within 10d after  
treatment  
discontinuation  1M FUP* 
30d (+7) 
after last 
dose Long -Term 
FUP *              
if OR/ SD at 
EOT , 
for new -onset 
or ongoing 
immune -
mediated AEs    As 
Clinically 
Indicated  D1 D2 D3 
(+1) D8 
(±2) D15 
(±2) D22 
(±2) D1 
(±2) D15 
(±2) End of 
Cycle 2 
(final 
week)  D1 
(±2) D15 
(±2) End of 
Even 
Num bered 
Cycles 
(final week)  
Lymphoma patients :  FDG -PET, X -
ray, U/S, BM aspiration/Bx  As 
indicated          As 
indicated    As 
indicated  As indicated  As 
 indicated  Q2Md  
Response Assessment (in event of 
OR or SD)21          x   x xb If no  
prior PD  Q2Md  
ADDITIONAL ASSESSMENTS  
ADAAssessment22  x    x  x   Odd 
# Cs   x x Q2M for 6 
monthse x 
PK Assessment23  SOI; EOI;  
2h, 4h, 8h 
after EOI  24h 
after 
EOI -12h 
to 
+24h  x SOI, 
EOI x SOI, 
EOI SOI, 
EOI  SOI, 
EOI SOI, 
EOI  x x Q2M for 6 
monthse  
Peripheral Blood for 
Pharmacodynamic Studies ( receptor 
occupancy )24  x 24h   x  x D15 
(+7) EOC2 or 
C3/D1    Q4C (C6, 
C10, etc.)  x x   
Peripheral Blood for Biomarke r 
Studies25 upon 
eligibility         D15 
(+7)     x    
Tumor Biopsy for Biomarker Studies  (optional)
26 upon 
eligibility         D15 (+7)     Upon PD i f 
prior OR or 
SD > 16wks     
TRIAL TREATMENT  
Premedication Administration (if 
indicated)   x    x  x x  x x      
Study Drug Infusion (30 minutes ) 
(+10 min )  x    x  x x  x x      
Post-Infusion Monitoring   2h    1h  1h 1h  1h 1h      
Abbreviations (in alphabetical order):  1M FUP, 1-month follow -up; ADA, anti -drug antibody; AE, adverse event; BM, bone marrow;  Bx, biopsy; C, cycle: D /d, day; DLT, dose -limiting toxicity; h, hour; ECG, 
electrocardiogram; ECHO , echocard iogram; ECOG, Eastern Cooperative Oncology Group; EOC, end of cycle; EOI, end of infusion; EOT , end of treatment; FDG, fluorodeoxyglucose ; FUP, fol low-up; MUGA, 
multi -gated acquisition; OR, objective response; PET, positron emission tomography; PK, pharmac okinetic; PS, performance status; Q2M, every 2 months; Q4C, every 4 cycles; SD, stable disease; SOI, start of 
infusion ; U/S, ultrasound  
 
a Need not  be assessed prior to Cycle 1 if ≤ 7 days since screening  
b Conduct only if > 6 weeks since the previous assessment  
c To be conducted to assess for delayed onset of any post -therapy immune-mediated AE (up to 6 months following last dose), and in the even t of an immune -mediated toxicity 
ongoing at the 1M FUP or noted during the 6-month post -therapy FUP period (up to 2 years). Clinical events may be followed in writing or by telephone; an in- person visit will 
not be required.  
d To be conducted in t he event of ongoing OR or SD at the end of treatment; continue until confirmed PD or another therapeutic intervention is initiated , or until the end of trial.  
Documentation may be submitted in writing  or by e -mail ; an in -person visit will not be required.    
e Samp les to be obtained if patient is available for blood collection  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 152 of 163 
  
1. Informed Consent : To be signed prior to enrollment and prior to performing any protocol -related procedure, unless such testing was performed previously as part of the routine 
clinica l managem ent of the patient.   
2. Past Medical History : To include history of prior/ongoing diseases or conditions as well as prior surgical procedures not related to the underlyi ng malignancy . 
3. History of Primary Malignancy : To include details of the primary malignancy, including:  diagnosis and histological/cytological classification; date of initial diagnosis; stage of 
disease at diagnosis and at entry; current sites of metastases; prior surgical procedures for the malignancy and dates; prior  antineoplastic therapy, prior radiation therapy, as well as 
dates of treatments, numbers of cycles, and best response to each therapy; date of most recent disease progression.   
4. Medication/Procedure Survey :  To include period within 14 days  prior to first study drug dose and throu ghout study for a period of 30 days following last study drug dose.  
5. AE Reporting:  To detail symptoms that may be present prior to/at the time of first administration.  AEs to be assessed from signing of informed consent, throughout study,  and for 
the 1-mon th period (30 days) following last study drug dose; AEs to continue to be assessed for 2 months  (and if necessary 4 month s) following last study drug dose if events 
associated with study drug persist (to confirm that events have resolved, returned to basel ine status,  or been adequately explained. Investigator discretion may be used with respect 
to the method of contact for this AE assessment; clinical events may be followed in writing or by telephone, an in- person visit will not be required). Any patient wh o develops an 
immune-related toxicity (e.g. pulmonary fibrosis, myocarditis, ocular toxicity, drug-induced hepatotoxicity, etc.) will be followed at approximately 2-month intervals for up to 2 
years to assess the course of the condition an d evaluate potent ial reversibility of the finding.  
6. DLT Assessment : Beginning on C1/ D1 and ending at EOC1 (C1/ D28 ± 2 days).  To include evaluation for the occurrence of events meeting the trial DLT criteria.  Only DLTs 
occurring during Cycle 1 will be used to make decision s regarding dose -escalation and tolerability.  Events occurring after Cycle 1 will also be evaluated and taken into 
consideration when deciding upon further doses to be assessed as well as establishment of the RP2D.  
7. Vital Signs :  To includ e temperature, pu lse, respiratory rate, blood pressure, and pulse oximetry .   
8. Physical Examination : Complete at screening including height, weight, general appearance, skin, head, eyes, ears, nose, throat, neck/thyroid, chest  [includes pulmonary assessment , 
breasts], cardi ovascular [includes heart, peripheral pulses] abdomen, musculoskeletal system, lymph nodes, neurologic and mental status; dir ected thereafter, must include weight as 
well as pulmonary and cardiac assessments . Dose adjustments should be made in the event of  noted weight change (± 10% [less at the site’s discretion or if required by institution 
procedures]).  Pulmonary findings will be evaluated in detail at each visit by the Investigator (or physician designee). Evaluation to include review of pulmonary symptoms 
including but not limited to: cough, sputum production, hemoptysis, wheezing, dyspnea, dyspnea on exertion, chest pain, and/or chest pain associated with respirations, as well as review of cardiac symptoms including but not limited to chest pain, orth opnea, nocturia, edema, and palpitations.  
9. Hematology Panel :  To include CBC with hemoglobin, hematocrit, differential, ANC, and platelet count. Evaluation frequency should be increased in the event of hematologic 
toxicity.  
10. Biochemistry Pan el (fasting not r equired): To include Na, K, Cl, bicarbonate or carbon dioxide, BUN or equivalent, creatinine, glucose, bilirubin [total and direct], AST, ALT, ALP, 
Ca, Mg, phosphorous, albumin, total protein, uric acid, amylase, lipase, and CK (if abnorma l, perform isoenz yme analysis to include at minimum CK -MB ), serial trop onins, and 
measurement of BNP. Evaluation frequency should be increased in the event of significant serum chemistry abnormalities. Clinically significant el ectrolyte abnormalities shoul d be 
corrected pr ior to dosing.  
11. Coagulation Panel : To include PTT (or aPTT), PT  and/or INR. 
12. Thyroid Function T ests: To include measurement of TSH, fT3, and fT4 . 
13. Urinalysis : Multi- panel chemical test strips are acceptable and should include assessment of specific gravity, p H, protein, glucose, ketones, leukocyte s, nitrite, bilirubin, 
urobilinogen, and blood. Microscopic examination of sediment, if clinically indicated, to include assessment of cells (WBC and RBC per HPF, and casts ).   
14. Pregnan cy Testing :  β-hCG in WOCBP; seru m at Screening, serum or urine thereafter; negative test must be confirmed within 2 working days prior to first dose of study drug. 
15. ECG (12 -Lead) : To include measurement of PR interval, QRS duration, QT interval, and QTc in terval (msec), as well as HR  (BPM ); to be performed after patient has been supine 
for ≥ 10 minutes; repeat subsequent timepoints in triplicate separated by 5 minutes for 4 cycles (Day 1, SOI and EOI) in pati ents with a Cycle 1 or Cycle 2 QTc that is either:  a)  > 
500 msec; b), increased b y 60 msec over baseline; or c) decreased by 20 msec below baseline. If abnormit ies suggest new evidence of myocardial ischemia, perform isoenzyme 
analysis (to include at minimum CK -MB ), serial troponins, a nd measurement of BNP.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 153 of 163 
 16. MUGA Scan or ECHO: For measu rement of LVEF; to be performed ONLY in patients with a history of CHF, individual patients should be followed with the same testing 
procedure throughout the study.  
17. Ophthalmology Examination:  To include funduscopic and slit lamp evaluation s for assessment of retinal and corneal integrity , visual acuity , and any other noted ocular abnormality  
18. Pulmonary Function Tests : To include spirometry and diffusing capacity of carbon monoxide [DL CO] to assess for evidence of pulmonary fibrosis.  Spirometry assessments t o 
include at minimum:  FVC, FEV1, FRC, RV, and TLC.  To be repeated if evidence of interstitial pneumonitis, pulmonary fibrosis or other potential evidence of drug-related 
pulmonary t oxicity is documented on imaging studies or if pulmonary symptomatology i ndicates . 
19. Tumor Marker Measurement : As indicated by tumor type.  
20. Imaging for Assessment of Disease (and Pulmonary Status) : To include diagnostic imaging by CT or MRI of the chest with each evaluation  (for disease evaluation where indicated, 
and to assess fo r evidence of pulmonary fibrosis) plus abdomen and pelvis, and other sites as indicated based on tumor type and clinical  judgment to assess the status of the 
underlying malignancy. Use of contrast is preferred but is at the discretion of the Investigator, as medically indicated .  The same method(s) of disease evaluation and the same 
technique should be used throughout the s tudy. For all imaging timepoints, the following will be recorded as per RECIST v1.1 (or other response criteria, as indicated): target 
lesions including size, location, and type (nodal/non- nodal); sum of diameters of target lesions; any new lesions noted d uring trial, including size, location, and type (nodal/non-
nodal).  
21. Response Assessment : To be assessed by the Investigator or qualified designee as per RECIST v1.1 ( or other response criteria, as indicated ). 
22. ADA (Specialty Lab): To assess immunogenicity; w hole blood (~5 mL at each timepoint) will be collected for serum acquisition.  If sampling is on a dosing day, collect prior to 
infusion.  If a collected serum sample is inadequate or insufficient for ADA analysis, the analysis of ADA can be done using a PK  serum sample from the same timepoint, if available. 
A detailed laboratory manual specifying sample collection, handling, storage, and s hipment will be provided to the trial sites.   
23. PK Sampling  (Specialty Lab) : Whole blood (~5 mL at each timepoint) will be co llected for serum acquisition. If a collected serum sample is inadequate or insufficient for PK 
analysis, the analysis of PK can be done using an ADA serum sample from the same timepoint, if available.  A detailed laboratory manual specifying sample collection, handling, storage, and shipment will be provided to the trial sites.  PK sampling times may be adjusted  according to early tri al results to optimize evaluation.   
24. Peripheral Blood for Pharmacodynamic Studies ( Receptor Occupancy ) (Specialty Lab):  Whole blood (~ 10 mL at each timepoint) will be collected for assessment of receptor 
occupancy .  End of Cycle sampling may be combined wi th EOT if patient discontinues treatment. A detailed laboratory manual specifying sample collection, handling, storage, and 
shipment will be provided to the trial sites.   
25. Peripheral Blood for Biomarker Studies  (Specialty Lab):  To be obtained only after el igibility has been confirmed .  (May be collected C1D1 prior to dosing.)   Whole blood (~30 mL 
at each ti mepoint) to be collected.  C2D15 (+ 7 days) after dosing; to be collected on the day  of tumor biopsy, if performed. For those timepoints where both a blo od sample and a 
tumor biopsy are to be obtained,  the blood sample  is to be collected first. A detailed laboratory manual specifying sample collection, handling, storage, and shipment will be 
provided to the trial sites.  
26. Tumor Biopsy for Biomarker Studies  (optional) ( Specialty Lab ): To be obtained only after eligibility has been confirmed.  (May be collected C1D1 prior to dosing.)   Tissue for 
FFPE to be collected. C2D15 (+ 7 days) after dosing ; to be collected with paired periphera l blood for biomarker studies.  For those timepoints where both a blood sample and a 
tumor biopsy are to be obtained,  the blood sample is to  be collected first. EOT sample upon PD only in patients with a prior OR  or prolonged SD (> 16 weeks). A detailed 
laboratory manual specifying sample collection, handling, storage, and shipment will be provided to the trial sites  
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 154 of 163 
 19 SUMMARY OF CHANGES  
19.1 Protocol Amendment 1 dated 13- Mar- 2018  
• Clarified that IV solution containing Sym022 diluted with 5% dextrose to be stored refrigerated at 2°C to 8° C, and then 
allowed to reach room temperature before administration to the patient.  
• Patients with a history of organ transplantation (e.g. stem cell or solid organ transplant)  have been added as an exclusion 
criterion . 
• Clarified  that i mmune -mediated toxic ity that requires systemic use of glucocorticoids at a dose of 1 to 2 mg/kg/day 
prednisone equivalents for treatment of the toxicity will be considered a DLT . 
• Include d that a 2 -week delay in the initiation of Cycle 2 due to Grade 2 toxi city in Cycle 1 will be considered a DLT (i.e. 
treatment delays > 2 weeks from the scheduled next dose during Cycle 1 or the initiation of Cycle 2 due to Grade 2 toxicity 
that has occurred in Cycle 1)  
• Modif ied Sym022 infusion duration to require an initial infusion time of 60 minutes ( +10 minutes) . Both Cycle 1 doses (D1 
and D15) should be adm inistered over 60 minutes (+ 10 minutes) for all patients within a 3 to 6 patient dose -escalation 
cohort.  If no Grade 2 infusion reaction is observed in ≥ two thirds of the patients in a  cohort, the protocol  will allow a 
decrease of the infusion time to 30 minutes (+ 10 minutes), as patients are treated in Cycle 2.  
• Added a notation to the retreatment guidelines  to indicate that patients may receive standard doses of replacement hormonal 
therapy for adrenal insufficiency, hypothyroidism, or other endocrine end -organ failure, and may resume study drug once 
considered by the Investigator to be stable on such therapy. This was added to be consistent with eligibility criteri a. 
• Tables have been updated based on changes described, including correction to the recommended premedication dose of 
famotidine from 30mg to 20mg (Table 4).  
• Formatting adjustments, outline modifications, cross -reference links and link corrections, and other minor typographic al 
corrections and slight wording changes are included. 
Refer to  Table 6  for the  changes in Protocol Amendment 1. 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 155 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
1 Synopsi s: 
Investigational 
Medicinal Product  Storage  
Refrigerate (2ºC to 8ºC); store in an access -controlled, secure location; 
protect from direct light or sunlight  Storage  
Refrigerate (2ºC to 8ºC); store in an access -controlled, secure location; 
protect from dire ct sunlight  
1 Synopsis: Trial 
Objectives: Sym022 Dose -Escalation  Primary  
Evaluation of the safety, tolerability, and dose -limiting toxicities (DLTs) 
to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalat ing doses of Sym022 when 
administered once every 2 weeks (Q2W) by 30-minute IV infusion…  
Note:   Q2W  dosing; 4 weeks equals 1 dosing cycle.  Goal is identification of the 
MTD or determination of a RP2D based on clinical data, including safety, 
pharmacokine tic (PK), and pharmacodynamic (receptor occupancy or target 
engagement in peripheral blood) outcomes … 
 
Exploratory  
• Evaluation of potential pharmacodynamic markers using either 
receptor occupancy on peripheral blood mononuclear cells (PBMCs) or 
target eng agement (peripheral blood to be collected)…  
Note:…cytometric analysis of cells in blood and tumor, and 
immunohistochemistry (IHC) of tumor material when collected ( tumor sampling 
is optional ) Primary  
Evaluation of the safety, tolerability, and dose -limitin g toxicities (DLTs) 
to establish the maximum tolerated dose (MTD) and/or recommended 
Phase 2  dose (RP2D) of sequential escalating doses of Sym022 when 
administered once every 2 weeks (Q2W) by IV infusion…   
Note:   Q2W dosing; 4 weeks equals 1 dosing cycle .  Goal is identification of the 
MTD or determination of a RP2D based on clinical data, incl uding safety, 
pharmacokinetic (PK), and pharmacodynamic outcomes…  
 
Exploratory  
• Evaluation of potential pharmacodynamic markers, e.g. receptor 
occupancy in periphe ral blood mononuclear cells (PBMCs) (peripheral 
blood to be collected)…  
Note:…cytometric ana lysis of cells in blood, and immunohistochemistry (IHC) of 
tumor material when collected ( tumor sampling is optional ) 
1 Synopsis: Trial 
Design  This is a Phase 1, m ulticenter, open -label, dose -escalation study… of 
Sym022 (study drug) when administered Q2W (4 weeks equals 1 cycle) by 30-minute IV infusion...  This is a Phase 1, multicenter, open -label, dose -escalation study… of 
Sym022 (study drug) when administered Q2W  (4 weeks equals 1 cycle) 
by IV infusion...  
1 Synopsis: Patient 
Selection: Eligibility  
 4.3.1 Patients to be 
Excluded  Not applicable (new text added)  Patients to be Excluded  
12. Patients with a history of organ transplantation (e.g. stem cell or 
solid organ transplant)  
1 Synopsis: IMP 
Administration: 
Diluent and Deliv ery Commercially available sterile 5% dextrose in water (D5W) solution for 
IV infusion   
Once diluted for IV administration, study drug should be administered within 8 hours . Commercially ava ilable sterile 5% dextrose in water (D5W) solution for 
IV infusio n. Once diluted:  
• Store refrigerated between 2° C to 8° C (36º F to 46º F) and 
protected from direct sunlight  
• Allow to warm to room temperature before administration  
• Administer within 8 hours  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 156 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
1 Synopsis: IMP 
Administration: 
Infusion Duration  Approximately 30 minutes (+10 minutes)  Cycle 1: 60 minutes (+10 minutes)  
Cycle 2 and thereafter: If no Grade 2 IRR is observed in ≥ two thirds of the patients in a cohort, a decision may be made to decrease the infusion 
time to 30 minutes (+10 minutes) as patients within a cohort are treated 
in Cycle 2 and thereafter.  
1 Synopsis: AEs and 
DLTs: Dose -Limiting 
Toxicities Definition  
 
6.8.3 Definition of Dose -Limiting 
Toxicity  3. ≥ Grade 2:…  
Not applicab le (new text added)  
 
 
 
11. Treatment delays > 2 weeks from  the scheduled next dose during 
Cycle 1 due to ≥ Grade 3 toxicity  3. ≥ Grade 2:…  
• Immune-mediated toxicity that requires use of glucocorticoids at a 
dose of ≥ 1 mg/kg/day of prednisone equivalents for treatment of the 
toxicity  
 11. Treatment delays > 2 weeks from the scheduled next dose during 
Cycle 1 or the initiation of Cycle 2 due to Grade 2 toxicity that has 
occurred in Cycle 1  
1 Synopsis: Toxicity 
Safety Management and Safety Monitoring: IRR Management  
 8.5.1.2 Treatment Following Infusion Prolonga tion …For Grade 1 and 2 IRRs, rechallenge with a shorter duration of 
infusion (no less than 30 minutes) may be attempted at the Investigator’s discretion, after a minimum of 2 doses with no evidence o f infusion -
related toxicity…  …For Grade 1 and 2 IRRs, re challenge with a shorter duration of 
infusion (no less than 60 minutes) may be attempted at the Investigator’s discretion, after a minimum of 2 doses with no evidence of infusion-related toxicity at the prolonged rate…  
1 Synopsis: Study 
Assessments: Other  
Assessments (Specialty Lab)  Pharmacodynamic and other Biomarker Studies  
Peripheral blood sampling (pre - and post -dosing)  
• Evaluation of receptor occupancy/target engagement  
• Evaluation of DNA, RNA,  protein, and cellular biomarkers  Pharmacodynamic and ot her Biomarker Studies  
Peripheral blood sampling (pre - and post -dosing)  
• Pharmacodynamic evaluation (e.g. receptor occupancy)  
• Evaluation of DNA, RNA, proteins/cytokines, and cellular 
biomarkers  
3.1.1 Primary 
Objective  Evaluation of the safety, tolerability, and dose -limiting toxicities 
(DLTs)… of Sym022 (anti -LAG -3) when administered once every 2 
weeks (Q2W) by 30 -minute intravenous (IV) infusion…  
 
Note:  Q2W dosing; 4 weeks equals 1 dosing cycle.  Goal is the identification of 
the MTD or determ ination of a RP2D dose based on clinical data, including 
safety, PK, and pharmacodynamic (receptor occupancy or target engagement in 
peripheral blood) outcomes…  Evaluation of the safety, tolerability, and dose -limiting toxicities 
(DLTs)… of Sym022 (anti -LAG -3) when administered once every 2 
weeks (Q2W) by intravenous (IV) infusion…  
 
Note:  Q2W dosing; 4 weeks equals 1 dosing cycle.  Goal is the identification of 
the MTD or determination of a RP2D dose based on clinical data, including 
safety, PK, an d pharmacodynamic (e.g. receptor occupancy in peripheral blood) 
outcomes…  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 157 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
3.1.3 Exploratory 
Objectives  • Evaluation of potential pharmacodynamic markers using either 
receptor occupancy on peripheral blood mononuclear  cells (PBMCs) or 
target engagement (peripheral blood to be collected)…  
 
Note:…cytometric analysis of cells in blood and tumor; and 
immunohistochemistry (IHC) of tumor material when collected ( tumor sampling 
optional ). • Evaluation of potential pharmacodyn amic markers, e.g. receptor 
occupancy i n peripheral blood mononuclear cells (PBMCs) (peripheral 
blood to be collected)…  
 
Note:…cytometric analysis of cells in blood; and immunohistochemistry (IHC) of tumor material when collected ( tumor sampling optional ).
 
3.2 Trial Design 
Summary  Dosing Schedule and Treatment Duration  
• On Day 1 of study, patients will receive study drug administered by 
30-minute (+10 min) IV infusion… Determinations regarding cohort 
escalation, DLTs, and MTD will be based on the toxiciti es observed 
during this initial cycle…  
Doses to be Evaluated  
…These doses will be evaluated until the MTD is identified, a MAD is 
reached, or until a RP2D is determined based on clinical data, including 
safety, PK, and pharmacodynamic (e.g. receptor occupa ncy or target 
engagement in peripheral blood) outcomes…  Dosing Schedule and Treatment Duration  
• On Day 1 of study, patients will receive study drug administered by 
60-minute (+10 min) IV infusion… Determinations regarding infusion duration, cohort escalat ion, DLTs, and MTD will be based o n the 
toxicities observed during this initial cycle…  
Doses to be Evaluated  
…These doses will be evaluated until the MTD is identified, a MAD is 
reached, or until a RP2D is determined based on clinical data, including 
safet y, PK, and pharmacodynamic (e.g. r eceptor occupancy in peripheral 
blood) outcomes…  
5.3 Stability of IMP  When diluted for use, the study drug has been found to be stable at room 
temperature and should be administered within an 8-hour  time window 
(Section 5 .8) (please see the IB  and the IMP  Manual  for additional 
information ). When diluted for use, the study drug must be stored refrigerated at 2° C 
to 8° C (36º F to 46º F), protected from direct sunlight, and should be administered within an 8 -hour time window (Section 5.8).  
5.6 Administration of 
IMP …An appropriate dose, based on the patient’s cohort assignment, diluted 
to a total volume of 100 mL with 5% dextrose in water (D5W) solution 
for IV infusion will be administered initially over 30 minutes  (+10 
minutes), once every 2 we eks (Q2W; 4 weeks [28 days] equals 1 dosing 
cycle).   …An appropriate dose, based on the patient’s cohort assignment, diluted 
to a total volume of 100 mL with 5% dextrose in water (D5W) solution for IV infusion will be administered once every 2 weeks (Q2W;  4 weeks 
[28 days] equals 1 dosing cycle).   
• Cycle 1: Study drug will be administered over 60 minutes (+10 
minutes)  
• Cycle 2 and thereafter:  If no Grade 2 IRR is observed in ≥ two 
thirds of the patients in a cohort, a decision may be made to decrease t he 
infusion time to 30 minutes (+10 minutes) as patients within a cohort are 
treated in Cycle 2 and thereafter  
5.8 Dose Preparation  Not applicable (new text added)  • Once diluted, store refrigerated between 2° C to 8° C (36º F to 46º  
F) and protected from  direct sunlight.  Allow to warm to room 
temperature before administration.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 158 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
6.5.3.3 Diluent and 
Delivery  Not applicable (new text added)  The IV bag containing diluted study drug is to be stored refrigerated 
between 2° C to 8° C (36º F to 46º F) and protec ted from direct sunlight.  
Allow to warm to room temperature before administration to the patient.  
6.5.3.5 Duration of 
Infusion  Study drug will be administered over 30 minutes (+10 minutes)  
 
   
 
 
Note:   In the event of a Grade 2 IRR, the Investigator may prolong the infusion 
duration to extend longer than the initially assigned duration  (for further 
instructions see Section 8.5.1, Appendix 9).  
 
Study drug will be administered over a longer period for all patients 
entered to the trial in the following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients…will 
be extended to 1 hour (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient… will be 
extended  to 1 hour (or longer, if indicated)…  
These same criteria will be applied in the event IRRs occur on the extended 1 -hour infusion schedule.  In such a case, the duration of 
infusion… will be extended to 1.5 hours (or longer, if indicated).  • Cycle 1: Study  drug will be administered over 60 minutes (+10 
minutes)  
• Cycle 2 and thereafter: If no Grade 2 IRR is observed in ≥ two 
thirds of the patients in a cohort, a decision may be made to decrease the infusion time to 30 minutes (+10 minutes), as patients wit hin a cohort 
are treated in Cycle 2 and thereafter  
 
Note:   Any patient experiencing an infusion reaction will receive future doses at a 
prolonged rate, as instructed (Section 8.5.1, Appendix 9).  
 
 
Study drug will be administered over a longer period for al l patients 
entered to the trial in the following situations:  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients… will 
be extended by 30 minutes (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient… will be 
exten ded by 30 minutes (or longer, if indicated)…  
These same criteri a will be applied in the event IRRs occur on the 
extended infusion schedule.  In such a case, the duration of infusion… 
will be further extended by 30 minutes (or longer, if indicated).  
6.7.1 Retreatment 
Guidelines  Not applicable (new text added)  Note:  P atients may receive standard doses of replacement hormonal therapy for 
adrenal insufficiency, hypothyroidism, or other endocrine end -organ failure, and 
may resume study drug once consider ed by the Investigator to be stable on such 
therapy.   
7.7.1 
Pharmacodynamic 
Assessments (To include peripheral blood collection for evaluation of receptor 
occupancy/target engagement)  (To include peripheral blood collection for evaluation of receptor 
occupancy)  
7.7.2 Biomarker 
Assessments Not applicable (new text added)  The purpose of biomarker assessments is to develop…  
Analyses may include genes and/or proteins that are unknown…  
All analyses will be related to and used in connection with…  
Residuals fr om samples collected will be stored for up to 15 years…  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 159 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
7.7.2.1 Bloo d 
Samples for 
Biomarker 
Assessments  (To include tumor tissue collection for evaluation of potential 
biomarkers, including but not limited to DNA, protein, and cellular biomarkers)  (To include peripheral blood collection for evaluation of potential 
biomarke rs, including but not limited to ctDNA, RNA, relevant 
proteins/cytokines, and cellular biomarkers)  
7.7.2.2 Tumor 
Samples for Biomarker Assessment ( Biopsies 
Optional ) (To include tumor tissue collection for evaluation of potential 
biomarkers, including but  not limited to DNA, protein, and cellular 
biomarkers)…  
 
 
Note: Tumor tissue for formalin -fixed paraffin -embedded (FFPE) and 
fresh/frozen cells to be collected at each of the indicated timepoints; handling 
instructions will be provided.  
  
Not applicable (n ew text added)  
  
 (To include tumor tissue collection for evaluation of potential 
biomarkers, including but not limited to DNA, RNA, protein, and 
cellular biomarkers)…  
 
Note: Tumor tissue for formalin -fixed paraffin -embedding (FFPE) to be collected 
at each  of the indicated timepoints; handling instructions will be provided. For 
those timepoints where both a blood sample and a tumor biopsy are to be 
obtained, the blood sa mple is to be collected first.  
 
Tumor biopsies to include core samples of a locally recu rrent or 
metastatic lesion; to be performed with minimal morbidity to the patient 
by a percutaneous core needle biopsy either with or without the aid of an imaging moda lity chosen at the discretion of the physician performing 
the biopsy.  
10.1.2 Events Not  to 
be Considered as Adverse Events  PD may be reported as an AE/SAE  in the case of patient death, with 
death being the outcome of the event or if it results in hospital ization.  Note: PD may be reported as an AE  in the case of patient death, with death bein g 
the outcome of the event.  
10.1.5 Events That 
Do Not Meet the Definition of Serious 
Adverse Events  PD may be reported as an SAE  in the case of patient death, with death 
being the outcome of the event or if it results in hospitalization.  Note: PD may be r eported as an SAE  in the case of patient death, with death 
being the outcome of the event.  
10.3.1 Timeframes 
for Reporting to the 
Sponsor  In case of an SAE, the Investigator must, within 24 hours of awareness 
of the event, report the SAE to the Sponsor (or designee) by telefax or e -
mail transmission. Fax number(s) and e-mail address(es) will be stated 
on the SAE Report Form  and the SAE Report Form Completion 
Instructions . 
 Timelines for reporting of SAEs and SAE follow -up information are 
shown (Table 5).  In case of an SAE, the Investigator must, within 24 hours of awareness 
of the event , report the SAE to the Sponsor (or designee) by telefax or e -
mail transmission. Fax number(s) and e-mail address(es) will be stated on the SAE Report Form  and the SAE Report  Form Completion 
Instructions .  SAE follow -up information must also be reported to the 
Sponsor (or designee) within 24 hours of awareness . 
 Removed Table 5: Timelines for Submission of SAEs and SAE Follow -up
 
10.4 Pregnancy  Elective terminations for non -medical reasons should not be reported as 
AEs.  Elective terminations for non -medical reasons should be reported as 
follow -up, but not as a separate AE/SAE unless complications meet 
AE/SAE criteria.  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 160 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
11.1 Precautions 
Regarding 
Procreation  Studies have not bee n performed to determine whether this study drug 
affects reproductive function in males. For this reason, men with partners with childbearing potential must use a highly effective method 
of contraception while receiving study drug.  Studies have not been pe rformed to determine whether this study drug 
affects reproductive function in males or can cause f etal harm. For this 
reason, men with partners of childbearing potential must use a highly effective method of contraception while receiving study drug.  
13.4. 2 Modification 
of the Informed Consent Form  If modifications… the Investigator will prepare a revision to the existing 
ICF.  Such a revision will be reviewed and approved by the appropriate regulatory authority (as indicated) and IRB/EC, and documentation of 
this approval will be forwarded to the Sponsor (or designee) for 
submission to the appropri ate regulatory body.  If modifications… the Sponsor (or designee) will prepare a revision to 
the existing sample ICF for modification, as appropriate, by each 
Investigator.  Any revision to the sample ICF prepared by the Sponsor 
(or designee) will be implem ented according to the Sponsor’s (or 
designee’s) SOPs. Such a revision will be reviewed and approved by the 
appropriate regulatory authority (as indicated) and IR B/EC.  
14.1 Medical 
Supervision  An Investigator conducting a clinical study with an investigat ional agent 
is required to comply with regulations described in U.S. Title 21 CFR 
Part 312 and ICH E6(R2) GCP.  An Investigator conducting a clinical study with an  investigational agent 
is required to comply with regulations described in U.S. Title 21 CFR Parts 50, 56, and 312 and/or by governing Health Authorities, as well as 
ICH E6(R2) GCP.  
14.8 Recording of 
Data  Corrections to entered data will be tracked within  the EDC system.  Corrections to entered data will be identified and tracked by audit trails 
within the EDC system.  
15.1 Data Handling  Data will be handled according to good data management practices, all 
applicable data protection regulations, and will comply with ICH 
E6(R2) GCP.  Study data collection, processing, transfer, and reporting as well as 
handling of study personnel information will be in compliance with ICH E6(R2) GCP and all applicable data protection regulations.  
15.3 Data Processing  A Data M anagement Plan will be prepared for this trial. The Sponsor (or 
designee) w ill be responsible for data processing in accordance with 
applicable Data Management SOPs.  
 Database Lock will occur once quality control procedures and quality 
assurance procedures (if applicable) have been completed upon reaching 
the data cut -off for pr imary analysis.  
 Portable Document Format (PDF) files of the CRFs will be provided to 
the Investigator before access to the CRF system is revoked.  A Data Management Plan (DMP) will be prepared for this trial. The 
Sponsor (or designee) will be responsible f or data processing in 
accordance with applicable Data Management SOPs and the trial DMP.  
 
Database Lock will occur upon reaching the pre -defined data cut -off for 
primary analysis a nd completion of Sponsor’s (or designee’s) quality 
control and quality assu rance procedures.  
 Portable Document Format (PDF) files of the electronic CRFs will be 
provided to the Investigator upon removal of access to the electronic 
CRFs.  
 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 161 of 163 
 Table 6:  Protocol Amendment 1  
SECTION  ORIGINAL TEXT  NEW TEXT  
Appendix 9: Grad ing 
and Management of 
Infusion-Related 
Reactions  In the Event of Infusion Prolongation  
For Grade 1 and 2 reactions, rechallenge with a shorter duration of 
infusion (no less than 30 minutes) may be attempted at the Investigator's 
discretion, after a minimum  of 2 doses with no evidence of infusion-
related toxicity…  
 
Modif ication of Infusion Duration for the Trial  
• In the event of a Grade 2 IRR in ≥ two thirds of the patients… will 
be extended to 1 hour (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient… will be 
extended to 1 hour (or longer, if indicated)…  
 These same criteria wil l be applied in the event IRRs occur on the 
extended 1 -hour infusion schedule. In such a case, the duration of 
infusion… will be extended to 1.5 hours (or longer, if indicated).  In the Event of Infusion Prolongat ion 
For Grade 1 and 2 reactions, rechalleng e with a shorter duration of 
infusion (no less than 60 minutes) may be attempted at the Investigator's 
discretion, after a minimum of 2 doses with no evidence of infusion-
related toxicity at the prolonged rate…  
 Modification of Infusion Duration for the Tr ial 
• In the event of a Grade 2 IRR in ≥ two thirds of the patients… will 
be extended by 30 minutes (or longer, if indicated).  
• In the event of a Grade 3 or greater IRR in any patient… will be 
extended by 30 minutes (or longer, if indicated)…  
 These same criteria will be applied in the event IRRs occur on the extended infusion schedule. In such a case, the duration of infusion… 
will be further extended by 30 minutes (or longer, if indicated).  
 
19.2 Protocol Amendment 2 dated 04- Apr-2019  
• In order to apply more current adverse event grade descriptions and term definitions, the version of the Common 
Terminology Criteria for Adverse Events (CTCAE) used for this study has been updated from Version 4.03 to Version 5.0. 
All references to the CTCAE version throughout t his protocol have been updated accordingly.  
• Grading of infusion- related reactions specified in Appendix 9 have been updated to reflect the use of CTCAE Version 5.0. 
• The Study Safety Committee ha s been renamed to the Study Safety Team to better align with s cope.   
• Guidelines pertaining to the General Data Protection Regulation have been added.  
• Formatting adjustments, minor typographical corrections, and slight wording changes are included.  
• The synopsis and tables have been updated based on changes described, where applicable.  
Refer to Table 7  for the changes in Protocol Amendment 2. 
 
  
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 162 of 163 
 Table 7:  Protocol Amendment 2  
SECTION  ORIGINAL TEXT  NEW TEXT  
2.3.2  Clinical 
Experience with 
Sym022  No prior s tudies with Sym022 have been conducted.  The study described in this clinical trial protocol is ongoing. Sym022 is 
also being studied in a Phase 1 study in combination with Sym021 (anti -
PD-1 monoclonal antibody; ClinicalTrials.gov number [STUDY_ID_REMOVED]).  
4.3.1  Patients to be 
Excluded  6. Patients with any of the following coagulation parameter 
abnormalities at baseline (unless on a stable dose of anticoagulant 
therapy for a prior thrombotic event, as determined by the Investigator):  
• Prothrombin time (PT) (as assessed by international normalized 
ratio [INR]) > 1.5 × ULN for the institution (> 3× ULN for the 
institution if anticoagulated) … 6. Patients with any of the following coagulation parameter 
abnormalities at baseline (unless on a stable dose of antico agulant 
therapy for a prior thrombotic event, as determined by the Investigator):  
• Prothrombin time (PT) ( or international normalized ratio [INR]) > 
1.5 × ULN for the institution (> 3× ULN for the institution if 
anticoagulated) … 
6.8.3  Definition of 
Dose -Limiting 
Toxicity  5. Any other ≥ Grade 3 non -hematologic toxicity regardless of 
duration, with the exceptions of:  
• Grade 3 fatigue  
• Grade 3 nausea, vomiting, or diarrhea lasting ≤ 2 days with best 
supportive care  • ≥ Grade 3 asymptomatic electrolyte abnormalities lastin g ≤ 3 days 
that are not clinically complicated, and resol ve spontaneously or respond 
to conventional medical interventions  5. Any other ≥ Grade 3 non -hematologic toxicity regardless of 
duration, with the exceptions of:  
• Grade 3 fatigue  
• Grade 3 nausea, vomiting, or diarrhea lasting ≤ 2 days with best 
supportive care  • Grade 3 asymptomatic electrolyte abnormalities lasting ≤ 3 days 
that are not clinically complicated, and resolve spontaneously or respond to conventional medical interventions  
• Other Gra de 3 asymptomatic laboratory abnormalities that are 
clinically non -significant in the investigator’s opinion, and that resolve 
spontaneously or with conventional medical interventions  
7.2.7.3  Coagulation 
Panel  (To include PTT [or aPTT], PT, INR)  (To inclu de PTT [or aPTT], PT and/or INR)  
15.1 Data Handling  
  Study data co llection, processing, transfer, and reporting, as well as 
handling of study personnel information, will be in compliance with ICH E6(R2) GCP and all applicable data protection regulations,  
including Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with 
regard to the processing of personal data and on the free movement of 
such data (General Data Protection Regulation ). 
15.5 Compliance 
with the General Data Protection Regulation  
 Not applicable  The applicable data protection legislation requires that parties enter into 
a written contract if one party (data processor) processes personal data on behalf of the other part y (data controller). This written contract must 
regul ate the subject -matter and duration of the processing, the nature 
and purpose of the processing, the types of personal data and categories 
of data subjects, as well as the obligations and rights of the data 
controller. Accordingly, the parties must enter i nto a data processing 
Symphogen Clinical Trial Protocol 
Trial ID: Sym022- 01 Version 3.0  
 
Confidential   Page 163 of 163 
 Table 7:  Protocol Amendment 2  
SECTION  ORIGINAL TEXT  NEW TEXT  
agreement. To the extent the processing of personal data involves 
transfers of personal data to third countries (e.g., jurisdictions outside of 
the European Economic Area [EEA]), the parties will enter into the European Commission's s tandard contractual clauses between the data 
controller, the data processor, and all sub -processors, if any. The 
European Commission's standard contractual clauses ensure an adequate level of protection in relation to transfers of personal data to third 
countries.  
16.5.11  
Pharmacokinetic 
Analysis Individual curves of serum concentration of total study drug versus time 
after the first and fourth infusion will be presented on log-  and linear 
scale for all patients in the PK population.  Individual curves of s erum concentration of total study drug versus time 
after the first infusion will be presented on log- and linear scale for all 
patients in the PK population.  
 
 